

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolyethynyl-octahydro-indole-1-carboxylic acid methyl ester	n/a	10/12/2011	Treatment of Fragile X syndrome	Novartis Pharmaceuticals Corp.
2	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate	n/a	6/5/2013	Treatment of pancreatic cancer	EMD Serono
3	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate	n/a	3/9/2012	Treatment of soft tissue sarcoma	Threshold Pharmaceuticals, Inc.
4	(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15 oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclote tradecine-3-carbonitrile	n/a	6/23/2015	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer	Pfizer, Inc.
5	(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-	n/a	2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Pfizer, Inc.
6	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/13/2004	Treatment of acute lymphoblastic leukemia	Mundipharma Research Limited
7	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	1/29/2004	Treatment of T-cell non-Hodgkin's lymphoma	Mundipharma Research Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
8	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/10/2004	Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia	Mundipharma Research Ltd.
9	(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride	n/a	9/15/2010	Treatment of infantile spasms.	Catalyst Pharmaceuticals, Inc.
10	(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c]pyridine-3,6(2h,5h)-dione)	n/a	10/14/2015	Treatment of systemic sclerosis.	Genkyotex Innovation SAS
11	(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl) nona-2,4,6,8-tetraen-1-yl acetate	n/a	12/2/2010	Treatment of retinitis pigmentosa	QLT Inc.
12	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)	n/a	12/2/2010	Treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	QLT, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
13	(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1"S)-7,9-acrolein acetal-11(15-1)-abeotaxane	n/a	6/23/2014	Treatment of progressive supranuclear palsy	Cortice Biosciences, Inc.
14	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of primary biliary cirrhosis	Albireo AB
15	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of progressive familial intrahepatic cholestatis	Albireo AB
16	(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-hepten-6-ynamide	Fk778	1/10/2005	Prevention of acute rejection following kidney, heart, and liver transplantation	Fujisawa Healthcare, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
17	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of chronic myelogenous leukemia.	NATCO Pharma Limited
18	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of pancreatic cancer	NATCO Pharma Limited
19	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019	n/a	3/18/2011	Treatment of Glioma	NATCO Pharma Limited
20	(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-One	n/a	4/30/2014	Treatment of multiple myeloma	VivoLux AB
21	(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	n/a	12/9/2015	Treatment of Fragile X Syndrome.	Centre National de la Recherche Scientifique (CNRS)
22	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate	n/a	9/11/2014	Treatment of Gaucher disease	Genzyme
23	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate	n/a	8/26/2014	Treatment of Fabry's disease	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
24	(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine	n/a	7/5/2007	Treatment of tuberculosis	Global Alliance for TB Drug Development
25	(3S)-3-[(2S)-2-({N-[2-tert-butyl]phenyl}carbamoyl)carboxylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoic acid	n/a	8/19/2003	Treatment of patients undergoing solid organ transplantation.	Pfizer Global Research and Development
26	(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate	n/a	9/18/2015	Treatment of pediatric (0 through 16 years of age) juvenile idiopathic arthritis (JIA) categories excluding systemic JIA	AbbVie, Inc.
27	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of alagille syndrome	Shire Human Genetic Therapies, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
28	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary sclerosing cholangitis	Shire Human Genetic Therapies, Inc.
29	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Shire Human Genetic Therapies, Inc.
30	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary biliary cirrhosis	Shire Human Genetic Therapies, Inc.
31	(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride	n/a	7/24/2013	Treatment of trigeminal neuralgia	Convergence Pharmaceuticals Ltd.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
32	(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)	n/a	2/21/2014	Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics	DARA BioSciences, Inc.
33	(6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid	n/a	10/13/2015	Treatment of cystic fibrosis.	Corbus Pharmaceuticals, Inc.
34	(6aR, 10aR)-3-(1,1'-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid	n/a	6/10/2015	Treatment of systemic sclerosis	Corbus Pharmaceuticals, Inc.
35	(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/2011	Treatment of soft tissue sarcoma	CytRx Corporation
36	(6R,S)5,10-methylene-tetrahydrofolic acid	Cofactor	8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Adventrx Pharmaceuticals, Inc.
37	(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid	n/a	12/8/2004	Prevention of post-operative complications of aortic aneurysm surgical repair	Inotek Pharmaceuticals Corporation
38	(monomethoxypolyethylene glycol) recombinant adenosine deaminase	n/a	3/19/2015	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency	Sigma-Tau Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
39	(N-[2,6-bis(1-methylethyl)-phey-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	3/9/2012	Treatment of adrenocortical carcinoma	Atterocor, Inc.
40	(R)-1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide	n/a	4/24/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
41	(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/2011	Treatment of idiopathic pulmonary fibrosis	Bristol-Myers Squibb Company
42	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)pipe ridin-1-yl]phenoxy)methyl}-2,3-dihydroimidazo[2,1-b]oxazole	n/a	7/12/2007	Treatment of pulmonary tuberculosis.	Otsuka Pharmaceutical Company, Ltd

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
43	(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride	n/a	12/19/2007	Treatment of small cell lung cancer.	AbbVie, Inc
44	(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride	n/a	11/19/2015	Treatment of cholangiocarcinoma.	ArQule, Inc.
45	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc.
46	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	n/a	7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc.
47	(RS)-baclofen, naltrexone and D-sorbitol	n/a	3/17/2014	Treatment of Charcot-Marie-Tooth disease type 1A	Pharnext SAS
48	(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine	n/a	11/5/2014	Treatment of acute myeloid leukemia	BerGenBio AS

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
49	(S)-10- [[dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2",4",5",7"-tetranitro-9"-fluorenylideneaminooxy)propionyl]-1H-pyrano[3',4',6',7',]indolizino [1,2-B]-quinoline-3,14-(4H, 12H)-dione, hydrochloride	Lipotecan	10/6/2010	Treatment of hepatocellular carcinoma	TLC Biopharmaceuticals, Inc.
50	(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile	n/a	1/26/2015	Treatment of pemphigus vulgaris	Almirall S.A.
51	(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)carbonyl)-5-methylpyridin-1-ium	n/a	11/17/2014	Treatment of pulmonary arterial hypertension	Pulmokine, Inc.
52	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/2013	Treatment of follicular lymphoma	Infinity Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
53	(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	BioMed Valley Discoveries, Inc.
54	(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide	n/a	10/22/2015	Treatment of Waldenstrom macroglobulinemia.	Acerta Pharma BV
55	(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazine-1-yl)-N-(pyridine-2-yl)-benzamide	n/a	9/21/2015	Treatment of mantle cell lymphoma.	Acerta Pharma BV
56	(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thioxolecarboxylic acid	n/a	2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Ferrokin BioSciences, Inc.
57	(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride	n/a	11/17/2014	Treatment of inherited mitochondrial respiratory chain diseases	Khondrion BV
58	(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	n/a	4/29/2015	Treatment of Hodgkin lymphoma	Incyte Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
59	(S)-8-{2-Amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester	n/a	10/6/2015	Treatment of pulmonary arterial hypertension (PAH).	KAROS Pharmaceuticals, Inc.
60	(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	n/a	8/31/2015	Treatment of soft tissue sarcoma.	Loxo Oncology, Inc.
61	(S)-perillyl alcohol temozolomide	n/a	11/12/2014	Treatment of glioma	NeOnc Technologies, Inc.
62	(UDU-stereoisomer of c-UJUun UNU-terminal UkJUnhibitor)	n/a	3/28/2006	Treatment of acute sensorineural hearing loss	Auris Medical, Inc.
63	(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of diffuse large B-cell lymphoma	Karyopharm Therapeutics, Inc.
64	[131I]-N-(2-(diethylamino)ethyl-4-(4-fluorobenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/2008	Treatment of metastatic melanoma, stages IIB, IIC, III and IV	Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
65	[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt	n/a	2/14/2014	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Daiichi Sankyo, Inc.
66	[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride	n/a	11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Aeolus Pharmaceuticals, Inc.
67	[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone	n/a	10/20/2014	Treatment of pancreatic cancer	Synovo GmbH
68	[AC3-γCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/2011	Treatment of glioblastoma multiforme	Tocagen, Inc.
69	[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	5/14/2014	Treatment of glioblastoma multiforme	Angiochem, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
70	[1±â€Ž€N-(2â€Ž€succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[1µâ€Ž€N-(2â€Ž€succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[1µâ€Ž€N-(2â€Ž€succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	4/15/2015	Treatment of breast cancer patients with brain metastases	Angiochem, Inc.
71	[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Advanced Accelerator Applications
72	[met5]-enkephalin	Opioid Growth Factor	1/24/2013	Treatment of pancreatic cancer	TNI BioTech, Inc.
73	{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]}(3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide	n/a	4/10/2014	Treatment of ovarian cancer	VentiRx Pharmaceuticals, Inc.
74	1 8-(p[131I]-iodophenyl)octadecyl phosphocholine	n/a	12/3/2014	Treatment of multiple myeloma	Cellectar Biosciences, Inc.
75	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of acute myelogenous leukemia	Cyclacel Limited
76	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of myelodysplastic syndrome	Cyclacel Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
77	1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole	n/a	1/6/2016	As a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma.	Advanced Imaging Projects, LLC
78	1-(3-chloro-5-{{4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl}carbamoyl}-2-pyridyl) piperidine-4-carboxylic acid Monomaleate	n/a	9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Eisai, Inc.
79	1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide	n/a	7/8/2015	Treatment of multiple myeloma	Cleave Biosciences, Inc.
80	1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid	n/a	3/31/2015	Treatment of systemic sclerosis	Inventiva Pharma
81	1,2:5,6-Dianhydrogalactitol, NSC-132313	n/a	1/31/2012	Treatment of malignant gliomas	DelMar Pharmaceuticals, Inc.
82	1,5-(Butylimino)-1,5 dideoxy,D-glucitol	n/a	5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences
83	1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene	n/a	1/9/2012	Treatment of poliovirus infection.	ViroDefense, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
84	1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	n/a	11/19/2012	Treatment of erythromelalgia	Teva Pharmaceuticals
85	10 synthetic peptides targeting 5 tumor associated antigens	n/a	1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Orphan Synergy Europe Pharma (OSE Pharma)
86	111Indium pentetretotide	Somatother	6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation
87	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/2011	Treatment of pancreatic cancer	Oncos Therapeutics
88	17 amino acid peptide	n/a	1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung transplantation	Apeptico Forschung und Entwicklung GmbH
89	177-LU-DOTA-GlyGlyNle-CycMSHhex	n/a	4/16/2015	Treatment of Stage IIB through IV malignant melanoma	SolaranRx, Inc.
90	177Lu-tetraxetan-tetulumab	Betalutin	5/14/2014	Treatment of Follicular Lymphoma	Nordic Nanovector AS
91	17-a-hydroxyprogesterone caporate (oral formulation)	n/a	6/1/2015	Prevention of preterm birth in women with a singleton pregnancy	Lipocine, Inc.
92	17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/2004	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
93	18-(p-[124I]-iodophenyl)octadecyl phosphocholine	n/a	4/30/2014	Diagnostic for the management of glioma	Cellectar Biosciences, Inc.
94	18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane	n/a	1/26/2015	Diagnostic to be used in the management of multiple system atrophy (MSA)	Advanced Imaging Projects, LLC
95	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/2009	Treatment of acute myeloid leukemia	Astex Therapeutics Ltd
96	1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]	n/a	2/17/2016	Treatment of spinal and bulbar muscular atrophy	Allianz Pharmascience Ltd.
97	2 dimethylbutyrate	n/a	6/18/2008	Treatment of beta thalassemia	HemaQuest Pharmaceuticals, Inc.
98	2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate	n/a	9/10/2015	Treatment of Charcot-Marie Tooth disease.	InFlectis BioScience
99	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione	n/a	9/21/2010	Treatment of idiopathic pulmonary fibrosis.	GenKyoTex S.A.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
100	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	7/1/2014	Treatment of hepatocellular carcinoma	CASI Pharmaceuticals, Inc.
101	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	3/18/2009	Treatment of ovarian carcinoma	EntreMed, Inc.
102	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/2008	Treatment of multiple myeloma.	EntreMed, Inc.
103	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/2010	Treatment of acute myeloid leukemia.	EntreMed, Inc.
104	2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate	n/a	1/26/2015	Treatment of pancreatic cancer	Incyte Corporation
105	2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate	Atiprimod	12/2/2003	Treatment of multiple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
106	2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5]decane dimaleate	Atiprimod	9/18/2006	Treatment of carcinoid tumors	Callisto Pharmaceuticals, Inc.
107	2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline	n/a	6/1/2015	Treatment of acute myeloid leukemia	Aptose Biosciences, Inc.
108	2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide	n/a	5/13/2015	Treatment of cystic fibrosis	Flatley Discovery Lab
109	2,2'-(2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid (ixazomib citrate)	n/a	3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Millennium Pharmaceuticals, Inc.
110	2,5-dimethyl-3-[2-methyl-4-(methoxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-	n/a	1/15/2015	Treatment of congenital adrenal hyperplasia (CAH)	Neurocrine Biosciences, Inc.
111	2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl]-1H-benzimidazole	Prevonco (Tm)	8/27/2008	Treatment of hepatocellular carcinoma.	BioQuant, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
112	2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide	n/a	9/29/2015	Treatment of nuclear protein in testis (NUT) midline carcinoma.	Tensha Therapeutics, Inc.
113	2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate	n/a	7/16/2014	Treatment of acute myeloid leukemia	OncoEthix SA
114	2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide	n/a	12/18/2007	Treatment of malignant melanoma stages IIb through IV.	AbbVie, Inc.
115	2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl)(ethyl)amino]ethyl dihydrogen phosphate trihydrate	n/a	1/19/2010	Treatment of acute myeloid leukemia	AstraZeneca Pharmaceuticals LP
116	2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxyethyl]-quinoline succinic acid	n/a	6/2/2014	Treatment of Huntington's disease.	Pfizer Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
117	2-[4-[[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	3/18/2015	Treatment of homozygous familial hypercholesterolemia (HoFH)	CymaBay Therapeutics, Inc.
118	2-[4-[[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	4/15/2015	Treatment of patients with Frederickson Type I or V hyperlipoproteinemia	CymaBay Therapeutics, Inc.
119	2-[4-Methoxy-3-(2-m-tolylethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/2013	Treatment of patients with systemic sclerosis	Sanofi U. S., Inc.
120	2-[[[(1r,4r)-4-[[[4-chlorophenyl](phenyl)carbamoyloxy)methyl]cyclohexyl]methoxy] acetic acid	n/a	8/28/2014	Treatment of pulmonary arterial hypertension	Arena Pharmaceuticals, Inc.
121	2-{3-[(3R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl]{2,2-diphenylethyl)amino}butoxy]phenyl}acetic acid	n/a	6/16/2015	Treatment of glioblastoma multiforme.	Rgenix, Inc.
122	2-{3-[(3R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl]{2,2-diphenylethyl)amino}butoxy]phenyl}acetic acid	n/a	6/16/2015	Treatment of ovarian cancer.	Rgenix, Inc.
123	2-{3-[(3R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl]{2,2-diphenylethyl)amino}butoxy]phenyl}acetic acid	n/a	6/23/2015	Treatment of malignant melanoma stages IIB to IV.	Rgenix, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
124	2-0-Butyryl-1-0-octyl-myo- inositol 3,4,5,6- tetrakisphosphate	n/a	8/15/2003	Treatment of cystic fibrosis	Inologic, Inc.
125	2-0-desulfated heparin	Aeropin	9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
126	20-mer complementary to Akt mRNA	n/a	12/10/2004	Treatment of stomach cancer	Rexahn Corporation
127	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of pancreatic cancer	Rexahn Corporation
128	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of ovarian cancer	Rexahn Corporation
129	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of renal cell carcinoma	Rexahn Corporation
130	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of glioblastoma	Rexahn Corporation
131	225Ac-lintuzumab	n/a	11/25/2014	Treatment of acute myelogenous leukemia	Actinium Pharmaceuticals, Inc.
132	24,25 dihydroxycholecalciferol	n/a	2/27/1987	Treatment of uremic osteodystrophy.	Lemmon Company
133	2-amino-2-[2-[2-chloro-4-[[3- (phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3- propanediol hydrochloride	n/a	10/6/2015	Prevention of graft versus host disease.	Novartis Pharmaceuticals Corporation
134	2-chloroethyl-3-sarcosinamide- 1-nitrosourea	Sarmustine	11/15/2001	Treatment for malignant glioma	Pangene Corporation

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
135	2-chloroethyl-3-sarcosinamide-1-nitrosourea	n/a	8/3/2001	Treatment for malignant gliomas	Lawrence Panasci, MD
136	2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Can-Fite BioPharma Ltd.
137	2'-deoxycytidine	n/a	9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D.
138	2-Ethylbutyl (2S)-2-{{(S)-{{(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate	n/a	9/18/2015	Treatment of Ebola virus disease	Gilead Sciences, Inc.
139	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde	n/a	12/29/2015	Treatment of sickle cell disease (SCD).	Global Blood Therapeutics, Inc.
140	2-hydroxypropyl-B-cyclodextrin	Kleptose	2/18/2013	Treatment of Niemann Pick disease, type C.	Vtesse, Inc.
141	2-iminobiotin	n/a	2/24/2009	Treatment of perinatal asphyxia.	Neurophyxia B.V.
142	2-methoxyestradiol	Pulmolar	4/11/2005	Treatment of pulmonary arterial hypertension	PR Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
143	2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/2012	Treatment of amyotrophic lateral sclerosis	LifeSplice Pharma LLC
144	2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate	n/a	4/9/2015	Treatment of anal cancer	Eli Lilly and Company
145	2S,4R ketoconazole	n/a	3/9/2012	Treatment of endogenous Cushing's syndrome	Cortendo AB (HQ address)
146	3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	3/23/2000	Treatment of von Hippel-Lindau disease.	Sugen, Inc.
147	3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	9/11/1998	Treatment of Kaposi's sarcoma.	Sugen, Inc.
148	3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)	n/a	7/14/2015	Treatment of fibrodysplasia ossificans progressiva.	La Jolla Pharmaceutical Company, Inc.
149	3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)	n/a	7/14/2015	Treatment of fibrodysplasia ossificans progressiva.	La Jolla Pharmaceutical Company, Inc.
150	3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	n/a	3/2/2010	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
151	3,4 diaminopyridine and choline bitartrate	n/a	4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	MS Therapeutics Limited
152	3,4-diaminopyridine	n/a	12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company
153	3,5,3'-triiodothyroacetate	n/a	9/20/2000	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D.
154	3,5-diiodothyropropionic acid	n/a	5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Zarion Pharmaceuticals P/L
155	3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid	n/a	12/23/2014	Prevention of acute attacks of angioedema in individuals with hereditary angioedema	BioCryst Pharmaceuticals, Inc.
156	3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}pyridin-2-amine bis-mesylate	n/a	11/9/2015	Treatment of Proteus Syndrome.	ArQule, Inc.
157	3-bromopyruvate	n/a	3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
158	3-bromopyruvate	n/a	4/29/2014	Treatment of pancreatic cancer	PreScience Labs, LLC
159	3-Chloro-4-(6-hydroxy-2-quinolinyl)-benzoic acid	n/a	1/13/2016	Treatment of cystic fibrosis	Nivalis Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
160	3-chloro-4-fluorophenyl-[4-fluoro-4-[[[5-methylpyrimidin-2-ylmethyl)amino)methyl]piperidin-1yl]methanone	n/a	10/25/2013	Treatment of Rett syndrome	Neurolix, Inc.
161	3-fluoro-5-[5-(2-methylthiazol-4-ylethynyl)-pyridin-2-yl]-benzotrile dihydrochloride	n/a	7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Seaside Therapeutics
162	3-pentylbenzenacetic acid sodium salt	n/a	2/11/2015	Treatment of idiopathic pulmonary fibrosis.	ProMetic Life Sciences, Inc.
163	4-(2-fluorophenyl)-6-methyl-2-(1-piperziny)	n/a	10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Dynogen Pharmaceuticals, Inc.
164	4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/2005	Treatment of Huntington's disease.	Teva Branded Pharmaceutical Products R&D
165	4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	AbbVie

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
166	4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl)piperazin-1-yl)-N-({3-nitro-4-[tetrahydro-2H-pyran-4-ylmethyl]amino]phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	9/20/2012	Treatment of chronic lymphocytic leukemia	AbbVie, Inc
167	4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid	n/a	3/24/2015	Prevention of scarring post ab externo glaucoma surgery	Clanotech AB
168	4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride	n/a	4/15/2013	Treatment of fibrodysplasia ossificans progressiva	La Jolla Pharmaceutical Company, Inc.
169	4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one	n/a	5/4/2015	Treatment of congenital long QT syndrome	Gilead Sciences, Inc.
170	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of diffuse large B-cell lymphoma	Kiadis Pharma Canada, Inc.
171	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of follicular lymphoma	Kiadis Pharma Canada, Inc.
172	4,5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
173	4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Provectus Pharmaceuticals, Inc.
174	4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide	n/a	2/8/2016	Treatment of retinitis pigmentosa	Shire HGT, Inc.
175	4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate	n/a	11/18/2015	Treatment of patients with Duchenne Muscular Dystrophy.	ARMGO Pharma, Inc.
176	4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol	n/a	9/23/2011	Treatment of idiopathic pulmonary fibrosis	Celgene Corporation
177	4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide	n/a	7/30/2008	Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.	SuperGen, Inc.
178	4-[131I]iodo-L-phenylalanine	n/a	1/4/2011	Treatment of glioma.	Therapeia GmbH & Co KG
179	4-[2-(3-Propyl-[1,2,4]oxadiazol-5-yl)-vinyl]-benzene-1,2-diol	n/a	10/4/2011	Treatment of chronic myeloid leukemia	Piramal Enterprises Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
180	4-[4-[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt	n/a	9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Deciphera Pharmaceuticals, LLC
181	4-[[[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino]-3-methoxybenzoic acid	n/a	5/19/2014	Treatment of Acute Myeloid Leukemia	Roche Genentech
182	40K PEGylated recombinant factor IX	n/a	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease)	Novo Nordisk, Inc.
183	4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one	n/a	9/23/2014	Treatment of pancreatic cancer.	Rexahn Pharmaceuticals, Inc.
184	4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone	n/a	8/22/2007	Treatment of hepatocellular carcinoma.	Ligand Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
185	4-Aminopyridine	n/a	12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Acorda Therapeutics, Inc.
186	4-aminosalicylic acid	Pamisyl (P-D), Rezipas (Squibb)	12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D.
187	4-aminosalicylic acid	Paser Granules	4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Jacobus Pharmaceutical Co., Inc.
188	4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/2006	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev,
189	4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl	n/a	9/29/2015	Treatment of cerebral cavernous malformation.	REursion Pharmaceuticals, LLC
190	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/2010	Treatment of pancreatic cancer.	Apogee Biotechnology Corporation
191	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	n/a	4/18/2011	Treatment of progressive supranuclear palsy.	Mithridion, Inc.
192	5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide	n/a	1/15/2015	Treatment pulmonary arterial hypertension	Gilead Sciences, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
193	5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzop[d]oxazole	n/a	11/22/2011	Treatment of Duchenne Muscular Dystrophy	Summit Corporation plc
194	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/2007	Treatment of osteosarcoma (bone cancer)	Dr. Reddy's Laboratories, Inc.
195	5,5',5''-[Phosphinothiolydine-tris(imino-2,1-ethanediy)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	n/a	8/20/2003	Treatment of pancreatic cancer	Now Pharm AG
196	5,6-dihydro-5-azacytidine	n/a	5/11/1992	Treatment of malignant mesothelioma.	ILEX Oncology, Inc.
197	5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride	n/a	9/4/2014	Treatment of Huntington's disease	Prana Biotechnology Limited
198	5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one	n/a	6/18/2007	Prevention of acute radiation syndrome	Humanetics Corporation
199	5-[(E)-2-(4-hydroxyphenyl)ethenyl] benzene-1,3 diol	Resveratrol	3/13/2008	Treatment of MELAS syndrome	Sirtris Pharmaceuticals, Inc.
200	5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine	n/a	8/25/2009	Treatment of spinal muscular atrophy	Pfizer Incorporated
201	5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine	n/a	2/10/2015	Treatment of malignant mesothelioma	Verastem, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
202	5'-GAATATTAACAIACTGACAAGTC-3'	n/a	10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Sarepta Therapeutics, Inc.
203	5-aminolevulinic acid	Glolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV)	NX Development Corporation
204	5-aza-2'-deoxycytidine	n/a	8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.
205	5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+	n/a	3/31/2015	Treatment of diffuse large B-cell lymphoma.	Idera Pharmaceuticals, Inc.
206	5'-GCCATGGTTTTTCTCAGG-3'	n/a	10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Sarepta Therapeutics, Inc.
207	5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/2006	Treatment of sickle cell disease	Baxalta US, Inc.
208	5-imino-13-deoxydoxorubicin HCl	n/a	12/31/2015	Treatment of soft tissue sarcoma	Gem Pharmaceuticals, LLC
209	5-iodo-2'-deoxyribose	n/a	5/26/2006	Treatment of malignant glioma	Hana Biosciences, Inc.
210	6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-1-(tetrahydropyran-4-yl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one	n/a	9/4/2014	Treatment of sickle cell disease	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
211	6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate	n/a	4/14/2014	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
212	6,8-bis-benzylsulfanyl-octanoic acid	n/a	2/6/2006	Treatment of pancreatic cancer	Cornerstone Pharmaceuticals, Inc.
213	6,8-bis-benzylsulfanyl-octanoic acid	n/a	9/26/2013	Treatment of myelodysplastic syndrome	Cornerstone Pharmaceuticals, Inc.
214	6,8-bis-benzylsulfanyl-octanoic acid	n/a	8/22/2011	Treatment of acute myeloid leukemia.	Cornerstone Pharmaceuticals, Inc.
215	6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine	n/a	6/12/2014	Treatment of multiple myeloma	DARA BioSciences, Inc.
216	6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide	n/a	2/11/2016	Treatment of glioblastoma multiforme (GBM).	Upsher-Smith Laboratories, Inc.
217	68G-OPS202, small somatostatin analog labeled with 68Gallium	n/a	9/24/2014	Management of gastroenteropancreatic neuroendocrine tumors.	OctreoPharm Sciences GmbH
218	6-alpha-ethylchenodeoxycholic acid	n/a	4/9/2008	Treatment of primary sclerosing cholangitis	Intercept Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
219	6-amino-5-chloro-N-[1R]-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimidinecarboxamide	n/a	10/15/2013	Treatment of stage IIb-IV melanoma	Millennium Pharmaceuticals, Inc.
220	6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one	n/a	6/18/2015	Treatment of Netherton syndrome	Sixera Pharma AB
221	6-mercaptopurine oral liquid	n/a	12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Orbona Pharma Ltd
222	7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/2011	Treatment of gliomas.	Intsel Chimos SA
223	8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one	n/a	1/21/2015	Treatment of glioblastoma multiforme	RestorGenex Corporation
224	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride	n/a	9/3/2009	Treatment of ovarian cancer.	Merck Sharp & Dohme Corp.
225	8-methoxsalen	Uvadex	6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc.
226	90Y-DOTA-tyr3-Octreotide	n/a	1/20/2016	Treatment of neuroendocrine tumors	M. Sue O'Doriso, MD, PhD
227	90Y-hPAMA4	Pan-Cide	1/29/2004	Treatment of pancreatic cancer	Immunomedics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
228	9-nitro-20-(S)-camptothecin	n/a	9/16/1996	Treatment of pancreatic cancer.	SuperGen, Inc.
229	9-nitro-20-(S)-camptothecin	Camvirex	5/15/2001	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc.
230	a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy	n/a	4/29/2014	Treatment of Stage II to IV invasive cervical carcinoma	Advaxis, Inc.
231	A10 & AS2-1 Antineoplaston	n/a	9/3/2004	Treatment for patients with brain stem glioma	Burzynski Research Institute, Inc.
232	aaeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1	n/a	9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Sparks Therapeutics, Inc.
233	AAV-G6Pase vector	n/a	3/11/2013	Treatment of glycogen storage disease type Ia	GlyGenix Therapeutics, Inc.
234	abatcept	Orencia	5/30/2013	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Orban Biotech LLC
235	ABCA4 DNA nanoparticles	n/a	10/28/2015	Treatment of Stargardt Macular Degeneration	Copernicus Therapeutics, Inc.
236	abeotaxane inhibitor of microtubules	n/a	10/7/2011	Treatment of gliomas	Cortice Biosciences
237	abeotaxane inhibitor of microtubules	n/a	4/18/2011	Treatment of pediatric neuroblastoma.	Cortice Biosciences
238	Abetimus	n/a	7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
239	acadesine	n/a	3/3/2011	Treatment of chronic lymphocytic leukemia	Avanced In Vitro Cell Technologies, S.L.
240	acadesine	n/a	5/4/2011	Treatment of multiple myeloma	Advancell-Advanced In Vitro Cell Technologies S.A.
241	acamprosate	n/a	3/25/2013	Treatment of fragile X syndrome	Confluence Pharmaceuticals, LLC
242	Acetylcysteine	Mucomyst/Mucomyst 10 lv	8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company
243	acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals, Inc.
244	acetylcysteine effervescent tablets for oral solution	n/a	2/24/2015	Preventing hepatic injury from acetaminophin overdose	Arbor Pharmaceuticals, Inc.
245	acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminy-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginyлмаide disulfide	n/a	11/24/2015	Treatment of acute myeloid leukemia.	Genus Oncology, LLC
246	acetyl-l-carnitine	n/a	7/24/2012	Treatment of Fragile X syndrome	Sigma-Tau Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
247	acetyl-l-carnitine (ALC)	n/a	3/18/2011	Treatment of Rett syndrome	Sigma-Tau Pharmaceuticals, Inc.
248	Ac-Ile-Cys-Val-Trp(1-Me)-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys-Thr-AEEA-Lys-PEG 40KDa-Lys-AEEA-Thr-Cys-Arg-His-ALa-Gly-Trp-Asp-Gln-(1-Me)Trp-Val-Cys-Ile-Ac	n/a	4/20/2014	Treatment of paroxysmal nocturnal hemoglobinuria	Apellis Pharmaceuticals, Inc.
249	ActRIIB-IgG1)	n/a	8/16/2010	Treatment of Duchenne muscular dystrophy	Acceleron Pharma, Inc.
250	acyclovir	n/a	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	Fera Pharmaceuticals
251	Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus	n/a	3/17/2014	Treatment of ovarian cancer	Oncos Therapeutics
252	adalimumab	n/a	7/10/2014	Treatment of Behcet's disease	Mucora
253	adalimumab	Humira	5/13/2015	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	AbbVie, Inc.
254	adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	AbbVie, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
255	adalimumab	Humira	5/13/2014	Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis	AbbVie, Inc.
256	adalimumab	Humira	10/19/2006	Treatment of pediatric Crohn's disease.	AbbVie, Inc.
257	adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie Inc.
258	aden-associated virus vector serotype 9 expressing human alpha-L-iduronidase	n/a	9/29/2015	Treatment of mucopolysaccharidosis Type I (MSP I).	REGENXBIO, Inc.
259	adeno associated viral vector containing human ARSB gene	n/a	3/17/2011	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Fondazione Telethon
260	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Lysogene
261	adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	n/a	3/14/2014	Treatment of hemophilia B	Baxter Healthcare Corporation
262	Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/2007	Treatment of lipoprotein lipase deficiency	uniQure B.V.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
263	adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	n/a	11/18/2015	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	LYSOGENE
264	adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX	n/a	9/21/2015	Treatment of hemophilia B.	Spark Therapeutics, Inc.
265	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/2012	treatment of retinitis pigmentosa	Genable Technologies Limited
266	adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/2010	Treatment of Duchenne muscular dystrophy.	uniQure B.V.
267	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc.
268	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
269	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Gen Sight Biologics
270	Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/2007	Treatment of Pompe disease	Audentes Therapeutics, Inc.
271	adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/2007	Treatment of X-linked juvenile retinoschisis (XLRS).	Applied Genetic Technologies Corporation
272	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/2012	Treatment of homozygous familial hypercholesterolemia	ReGenX Biosciences LLC
273	adeno-associated viral vector expressing the human vascular endothelial growth factor gene	n/a	12/31/2015	Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated	Integene International Holding, LLC
274	adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene	n/a	11/5/2014	Treatment of choroideremia	NightstaRx Ltd.
275	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Laboratorios del Dr. Esteve, S.A.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
276	adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene	Calmarythm	10/2/2014	Treatment of catecholaminergic polymorphic ventricular tachycardia	Audentes Therapeutics, Inc.
277	adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene	n/a	3/18/2015	Treatment of Retinitis Pigmentosa due to autosomal recessive RPE65 gene mutations	Spark Therapeutics, Inc.
278	adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene	n/a	9/30/2014	Treatment of spinal muscular atrophy	AveXis, Inc.
279	adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene	n/a	7/16/2015	Treatment of mucopolysaccharidosis type II (Hunter syndrome).	Laboratorios del Dr. Esteve, S.A.
280	Adeno-associated virus serotype rh10 vector encoding the human factor IX gene	n/a	8/25/2015	Treatment of hemophilia B.	Dimension Therapeutics
281	adeno-associated virus transgene of follistatin	n/a	11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Milo Biotechnology
282	adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS)	n/a	11/16/2015	Treatment of X-linked retinoschisis	Paul A. Sievig, MD, PhD, National Eye Institute, NIH

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
283	Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter	n/a	9/4/2014	For the treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)	Columbia University Medical Center
284	adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII	n/a	2/29/2016	Treatment of Hemophilia A.	BioMarin Pharmaceutical, Inc.
285	adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Laboratorios del Dr. Esteve, S.A.
286	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/2011	Treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and myelofibrosis)	Eli Lilly and Company
287	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/2005	Treatment of malignant brain tumors	Advantagene, Inc.
288	adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	n/a	6/8/2015	Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)	PNP Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
289	Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex	n/a	7/23/2015	Treatment of malignant glioma.	Ziopharm Oncology, Inc.
290	adenovirus containing a human FAS-c gene	n/a	4/2/2012	Treatment of malignant glioma	Vascular Biogenics Ltd
291	adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma	n/a	10/1/2014	Treatment of glioma	DNAtrix, Inc.
292	Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)	n/a	9/4/2014	Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)	Etubics Corporation
293	adenovirus vaccine encoding reduced expression in immortalized cell protein	n/a	7/14/2015	Treatment of mesothelioma	MTG Biotherapeutics
294	Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadviii	12/15/1999	Treatment of hemophilia A.	GenStar Therapeutics Corporation
295	ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides	n/a	9/28/2012	Treatment of renal cell carcinoma in HLA-A*2 positive patients	Immatics Biotechnologies GmbH
296	A-dmDT390-bisFv(UCHT1)	Resimmune	10/9/2014	Treatment of cutaneous T-cell lymphoma	Angimmune, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
297	adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/2012	Treatment of MPS-1, including Hurler syndrome	Athersys, Inc.
298	adult hemogenic endothelial cells	n/a	5/27/2015	Treatment of aplastic anemia	HemoGenyx LLC
299	ADXS11-001	n/a	8/12/2013	Treatment of HPV-positive associated anal cancer	Advaxis, Inc.
300	aerosolized beractant	n/a	3/11/2013	Treatment of respiratory distress syndrome	Beena G. Sood, MD, MS
301	AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/2010	Treatment of ovarian cancer	Aeterna Zentaris
302	afamelanotide	n/a	12/11/2009	Treatment of solar urticaria	Clinuvel, Inc.
303	afamelanotide	n/a	2/4/2016	Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease)	Clinuvel Inc.
304	afamelanotide	n/a	7/17/2008	Treatment of erythropoietic porphyrias	Clinuvel Inc.
305	afamelanotide	n/a	5/14/2014	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Clinuvel, Inc.
306	afatinib	Gilotrif(R)	6/4/2014	Treatment of malignant brain and central nervous system tumors	Boehringer Ingelheim Pharmaceuticals, Inc.
307	afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Boehringer Ingelheim Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
308	afatinib	Gilotrif(R)	8/3/2015	Treatment of non-small cell lung cancer with squamous histology.	Boehringer Ingelheim Pharmaceuticals, INC.
309	a-Galactosidase A	Plant-Produced Human A-Glactosidase A	1/21/2003	Treatment of Fabry's disease	iBio, Inc.
310	Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Amedra Pharmaceuticals LLC
311	Albendazole	Albenza	1/18/1996	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	Amedra Pharmaceuticals LLC
312	Albuterol	n/a	3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc.
313	Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Chiron Corporation
314	Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Chiron Corporation
315	Aldesleukin	Proleukin	11/24/1998	For the treatment non-Hodgkin's lymphoma.	Prometheus Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
316	Aldesleukin	Proleukin	3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Prometheus Laboratories, Inc.
317	aldoxorubicin	n/a	9/24/2014	Treatment of ovarian cancer	CytRx Corporation
318	aldoxorubicin	n/a	9/24/2014	Treatment of small cell lung cancer	CytRx Corporation
319	aldoxorubicin	n/a	9/24/2014	Treatment of glioblastoma multiforme	CytRx Corporation
320	alectinib	n/a	1/27/2015	Treatment of ALK-positive non-small cell lung cancer	Genentech, Inc.
321	alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Genzyme Corporation
322	Alendronate disodium	Fosamax	2/13/2001	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D.
323	Alfentanil	n/a	7/8/2005	Management of postherpetic neuralgia	Cinergen, LLC
324	Alfentanil	n/a	8/9/2005	Treatment of painful HIV-associated neuropathy	Cinergen, LLC
325	alfimeprase	n/a	9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Niche Therapeutics, LLC
326	algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/2010	Treatment of pancreatic cancer.	NewLink Genetics Corporation
327	Alglucerase injection	Ceredase	7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
328	Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation
329	alicaforsen	n/a	6/24/2008	Treatment of pouchitis.	Atlantic Healthcare Limited
330	alisertib	n/a	7/12/2013	Treatment of small cell lung cancer	Millennium Pharmaceuticals, Inc.
331	alisertib	n/a	5/14/2012	Treatment of peripheral T-cell lymphoma	Millennium Pharmaceuticals, Inc.
332	Alitretinoin	Panretin	4/10/1992	Treatment of acute promyelocytic leukemia	Ligand Pharmaceuticals, Inc.
333	Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Eisai, Inc
334	allantoin	Alwextin	11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Scioderm, Inc.
335	all-cis-docosa-4,7,10,13,16,19-hexaenoic acid	Retriacyl	5/21/2014	Treatment of retinitis pigmentosa	Natac Pharma, S.L.
336	allogeneic cardiosphere-derived cells	n/a	4/21/2015	Treatment of Duchenne Muscular Dystrophy	Capricor, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
337	allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)	n/a	12/2/2010	Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neutropenia, thrombocytopenia, lymphopenia, and anemia).	Fate Therapeutics, Inc.
338	allogeneic Epstein-Barr virus cytotoxic T lymphocytes	n/a	2/4/2016	Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders.	ATARA Biotherapeutics, Inc.
339	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	12/29/2015	For the treatment of severe preeclampsia	Pluristem Therapeutics, Inc
340	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Pluristem Therapeutics, Inc.
341	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/2013	Treatment of Aplastic Anemia	Pluristem Therapeutics, Inc.
342	allogeneic hematopoietic stem cell	Atir	2/2/2010	Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
343	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Shire
344	Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Motorgraft (Tm)	1/17/2014	Treatment of Amyotrophic Lateral Sclerosis	California Stem Cell Inc.
345	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/1997	Treatment of pancreatic cancer	Applied Immunotherapeutics, LLC
346	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/2004	Treatment of retinitis pigmentosa	Neurotech USA, Inc.
347	Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro	n/a	1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	MolMed S.p.A.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
348	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Neurotech USA, Inc.
349	allopregnanolone	n/a	4/20/2014	Treatment of status epilepticus	Sage Therapeutics
350	allopregnanolone	n/a	7/12/2013	Treatment of Neimann-Pick disease, type C	La Jolla Pharmaceutical Company, Inc.
351	Allopurinol sodium	Aloprim For Injection	10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc
352	allosteric activator of the red blood cell-specific form of pyruvate kinase	n/a	3/24/2015	Treatment of pyruvate kinase deficiency	Agios Pharmaceuticals, Inc.
353	alpha melanotropin	n/a	9/2/2010	Treatment of chronic beryllium disease	mondoBIOTECH Laboratories AG
354	alpha1 proteinase inhibitor (human)	n/a	1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Grifols Therapeutics, Inc.
355	alpha-1 proteinase inhibitor (human)	Glassia	10/23/2014	Treatment of graft versus host disease	Kamada Ltd.
356	alpha-1 proteinase inhibitor (human)	Glassia	7/28/2011	Treatment of patients with recent onset (Kamada, Ltd.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
357	Alpha1-antitrypsin(human)	n/a	4/3/2008	Treatment of bronchiectasis	Kamada Ltd.
358	Alpha1-Proteinase Inhibitor (Human)	Arc-Api	9/1/2004	Treatment of cystic fibrosis	Kamada Ltd.
359	Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/2004	Inhalation therapy for the treatment of congenital deficiency of alpha1-proteinase inhibitor.	Kamada Ltd.
360	Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation
361	alpha1-proteinase inhibitor (human)	n/a	4/6/2012	Treatment of cystic fibrosis	Grifols Therapeutics, Inc.
362	alpha1-proteinase inhibitor (human)	Prolastin(R)-C	3/3/2015	Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.	Grifols Therapeutics, Inc.
363	alpha1-proteinase inhibitor (human)	n/a	2/20/2009	Treatment of cystic fibrosis	CSL Behring LLC
364	Alpha-galactosidase A	Cc-Galactosidase	6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	David Calhoun, Ph.D.
365	Alpha-galactosidase A	Fabrase	7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J. M.D.
366	Alpha-galactosidase A	Replagal	6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Shire Human Genetic Therapies, Inc.
367	Alpha-melanocyte stimulating hormone	n/a	8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
368	Alpha-tocopherol quinone	n/a	3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Penwest Pharmaceuticals Company
369	alpha-tocotrienol quinone	n/a	10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases.	Edison pharmaceuticals, Inc.
370	alteplase	Activase	1/27/2003	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Daniel F. Hanley, MD
371	altiratinib	n/a	8/19/2014	Treatment of glioblastoma multiforme.	Deciphera Pharmaceuticals, LLC
372	Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.
373	Alvocidib	n/a	4/13/2007	Treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Tolero Pharmaceuticals, Inc.
374	alvocidib	n/a	4/21/2014	Treatment of acute myeloid leukemia	Tolero Pharmaceuticals, Inc.
375	ALX-0081 nanobody, directed towards the human A1 domain of von Willebrand factor	n/a	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Ablynx NV
376	Amantadine HCl	n/a	7/20/2015	Treatment of levodopa-induced dyskinesia	Osmotica Pharmaceutical Corporation
377	Amantadine hydrochloride	Nurelin	4/9/2015	Treatment of levodopa-induced dyskinesia	Adamas Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
378	amatuximab	n/a	9/28/2012	Treatment of mesothelioma	Morphotek, Inc.
379	ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Gilead Colorado
380	ambroxol	n/a	6/29/2011	Treatment of Gaucher disease	Belrose Pharma, Inc.
381	amifampridine phosphate	n/a	3/3/2015	Treatment of congenital myasthenic syndromes	Catalyst Pharmaceuticals
382	amifampridine phosphate	n/a	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Catalyst Pharmaceuticals, Inc.
383	Amifostine	Ethyol	10/4/1999	Treatment of myelodysplastic syndromes.	Clinigen Group plc
384	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Clinigen Group plc
385	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Clinigen Group plc
386	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc.
387	Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
388	Amifostine	Ethyol	11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Clinigen Group plc
389	amikacin sulfate	n/a	1/5/2015	Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	PlumeStars s.r.l.
390	Aminocaproic acid	Caprogel	1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School
391	aminolevulinic acid hydrochloride	Levulan	3/20/2007	Treatment of esophageal dysplasia	DUSA Pharmaceuticals, Inc.
392	Aminosalicyclic acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Jacobus Pharmaceutical Company
393	Aminosidine	Gabbromicina	5/14/1993	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D.
394	Aminosidine	Gabbromicina	11/15/1993	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D.
395	Aminosidine	Paromomycin	9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D.
396	aminosidine	Paromomycin	3/29/2005	Treatment of visceral leishmaniasis	The Institute for One World Health
397	Amiodarone	Amio-Aqueous	8/17/1993	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
398	Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories
399	amitriptyline and ketamine	Amiket(Tm)	1/19/2010	Treatment of postherpetic neuralgia	Immune Pharmaceuticals, Inc.
400	Ammonium tetrathiomolybdate	Coprexia	1/31/1994	Treatment of Wilson's disease.	Pipex Pharmaceuticals, Inc.
401	ammonium tetrathiomolybdate	n/a	5/5/2008	Treatment of idiopathic pulmonary fibrosis	Pipex Pharmaceuticals, Inc.
402	amphotericin B	n/a	9/15/2010	Treatment of visceral leishmaniasis.	iCo Therapeutics Inc.
403	Amphotericin B inhalation powder	n/a	12/15/2005	Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies	Novartis Pharmaceuticals Corporation
404	Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Liposome Company, Inc.
405	Amyl nitrite, sodium nitrite, sodium thiosulfate	Cyanide Antidote Kit	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
406	amylopectin	n/a	3/24/2015	Treatment of glycogen storage disease types Ia and Ib	Michael K. Davis, MD, MBA
407	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/2011	Treatment of hemophilia B	uniQure, B.V.
408	ANA-conjugated dactinomycin nanoemulsion	n/a	7/7/2015	Treatment of Ewing sarcoma	NanoSmart Pharmaceuticals, Inc.
409	Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp.
410	Anagrelide	Agrylin	7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp.
411	Anagrelide	Agrylin	6/11/1985	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp.
412	anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Swedish Orphan Biovitrum AB (publ)
413	Ananain, comosain	Vianain	1/21/1992	For the enzymatic debridement of severe burns.	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
414	Anatibant	n/a	4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Xytis, Inc.
415	Ancrod	Viprinex	10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company
416	andexanet alfa	n/a	2/23/2015	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	Portola Pharmaceuticals
417	Angiotensin (1-7)	n/a	11/26/2013	Treatment of limb-girdle muscular dystrophy	US Biotest, Inc.
418	Angiotensin (1-7)	n/a	2/8/2016	Treatment of LAMA2-related muscular dystrophy	Tarix Orphan, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
419	angiotensin (1-7)	n/a	8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	US Biotest, Inc.
420	angiotensin (1-7)[A(1-7)]	n/a	7/25/2013	Treatment of Duchenne muscular dystrophy	US Biotest, Inc.
421	Angiotensin 1-7	Marstem	8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation
422	Angiotensin 1-7	n/a	2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals
423	angiotensin 1-7	n/a	6/17/2010	To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and anemia)in hematopoietic stem cell transplants.	US Biotest, Inc.
424	angiotensin 1-7	n/a	1/29/2010	Treatment of sarcoma.	W. Jeffrey Petty, MD
425	Angiotensin-(1-7)	n/a	9/13/2011	Treatment of pulmonary arterial hypertension.	US Biotest, Inc.
426	anisina	n/a	7/14/2015	Treatment of neuroblastoma.	Novogen Ltd

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
427	anlotinib hydrochloride	n/a	12/31/2015	Treatment of ovarian cancer	Advenchen Laboratories, LLC
428	antagonist of the complement 5a receptor	n/a	11/17/2014	Treatment of atypical hemolytic uremic syndrome	ChemoCentryx, Inc.
429	antagonist of the complement 5a receptor	n/a	6/2/2014	Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome.	ChemoCentryx, Inc.
430	antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9	n/a	12/23/2014	Treatment of Waldenstrom's macroglobulinemia	Idera Pharmaceuticals, Inc.
431	anthrax immune globulin	n/a	9/3/2009	Treatment of inhalation anthrax disease	Emergent Biosolutions, Inc.
432	anthrax immune globulin (human)	n/a	7/29/2008	Treatment of inhalational anthrax	Cangene Corp. - Emergent Biosolutions
433	anti human Nogo-A human monoclonal antibody	n/a	10/20/2008	Treatment of acute spinal cord injury	Novartis Pharmaceuticals Corporation
434	antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/2002	Treatment of renal cell carcinoma	AEterna Zentaris, Inc.
435	Anti-Beta1 integrin monoclonal antibody	n/a	8/7/2014	Treatment of glioblastoma	OncoSynergy, Inc.
436	anti-Beta1 integrin monoclonal antibody	n/a	1/13/2015	Treatment of ovarian cancer	OncoSynergy, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
437	Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E	n/a	7/29/2014	Treatment of ovarian cancer	Genentech, Inc.
438	antibody drug conjugate consisting of fully human anti-guanlyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E	n/a	7/21/2014	Treatment of gastric cancer	Millennium Pharmaceuticals, Inc.
439	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/2013	Treatment of graft versus host disease	Xenikos BV
440	anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/2008	Treatment of Hodgkin lymphoma	Xencor, Inc.
441	Antiepilepsirine	n/a	3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital
442	Anti-eTau Humanized IgG4 Monoclonal Antibody	n/a	5/13/2015	Treatment of Progressive Supranuclear Palsy	Britol-Myers Squibb Company
443	Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Grifols Biologicals Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
444	Antihemophilic factor (recombinant)	Refacto, Xyntha	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Wyeth Pharmaceuticals, Inc.
445	Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation
446	antihemophilic factor (recombinant), Fc fusion protein	Eloctate	11/23/2010	Treatment of hemophilia A	Biogen Idec Inc.
447	antihemophilic factor (recombinant), porcine sequence	Obizur	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Baxalta US, Inc.
448	Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	CSL Behring
449	anti-inhibitor coagulant complex	Feiba	4/12/2013	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Baxalta US, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
450	anti-interferon-gamma Fab from goats	n/a	11/18/2003	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, Inc.
451	anti-Lewis Y humanized monoclonal antibody	n/a	3/9/2012	Treatment of ovarian cancer	Recepta Biopharma S.A.
452	antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/2012	Treatment of mesothelioma	Bayer HealthCare Pharmaceuticals, Inc.
453	antineoplaston A10, antineoplaston AS2-1	n/a	11/21/2008	Treatment of gliomas	Burzynski Research Institute, Inc.
454	antinuclear antibody conjugated liposomal doxorubicin	n/a	2/3/2015	Treatment of Ewing's sarcoma.	NanoSmart Pharmaceuticals, Inc.
455	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/2005	Treatment of acute myeloid leukemia	Lorus Therapeutics, Inc.
456	antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
464	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/2005	Treatment of primary malignant brain tumors	Bradmer Pharmaceuticals, Inc.
465	Antithrombin III (human)	Atnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB
466	Antithrombin III (human)	Thrombate lii	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation
467	Antithrombin III human	Antithrombin lii Human	1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross
468	anti-thymocyte globulin [rabbit]	Thymoglobulin	5/25/2010	Prophylaxis of acute organ rejection in patients receiving renal transplants	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
469	Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/1993	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research
470	anti-T-lymphocyte immune globulin, rabbit	Atg-Fresenius(R)	3/26/2010	Prevention of graft versus host disease (GVHD)	Neovii Biotech NA, Inc.
471	anti-T-lymphocyte immune globulin, rabbit	n/a	9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Neovii Biotech NA, Inc.
472	anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)	n/a	11/17/2014	Treatment of pediatric ulcerative colitis (0 through 16 years of age)	Avaxia Biologics, Incorporated
473	Antivenin crotaline (pit-viper) equine immune F(ab)2)	Anavip	1/29/2004	Treatment of envenomation by Crotaline snakes	Rare Disease Therapeutics, Inc.
474	Antivenin, crotalidae polyvalent immune Fab (ovine)	Crofab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc.
475	Antivenom (crotalidae) purified (avian)	n/a	2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc.
476	antroquinonol	n/a	7/23/2015	Treatment of hepatocellular carcinoma	Golden Biotechnology Corporation
477	antroquinonol	Hocena(R)	4/30/2015	Treatment of acute myeloid leukemia	Golden Biotechnology Corporation
478	antroquinonol	n/a	1/21/2015	Treatment of pancreatic cancer	Golden Biotechnology Corp.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
479	apolipoprotein E mimetic peptide	n/a	12/3/2012	Treatment of homozygous familial hypercholesterolemia	LipimetiX Development, LLC
480	Apomorphine	n/a	7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc.
481	Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	US WorldMeds, LLC
482	Apomorphine hydrochloride	n/a	5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	NeuroHealing Pharmaceuticals, Inc.
483	apremilast	n/a	1/17/2013	Treatment of Behcet's disease	Celgene Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
484	Aprotinin	Trasylol	11/17/1993	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	Bayer Corporation
485	AQ-13 (4-aminoquinoline analog)	n/a	9/12/2008	Treatment of malaria	Immtech Pharmaceuticals, Inc.
486	Arenegyr	n/a	8/22/2008	Treatment of malignant pleural mesothelioma	MolMed S.p.A.
487	Arginine butyrate	n/a	4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D.
488	arimoclomol	n/a	3/29/2005	Treatment of amyotrophic lateral sclerosis	CytRx Corporation
489	arimoclomol citrate	n/a	1/13/2015	Treatment of Neimann-Pick disease, type C	Orphazyme ApS
490	aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Otsuka Pharmaceutical Development

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
491	arsenic	Trisenox	11/2/2001	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Teva Branded Pharmaceutical Products R&D, Inc.
492	Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Cephalon
493	Arsenic trioxide	Trisenox	4/28/2000	Treatment of multiple myeloma.	TEVA Branded Pharmaceutical Products R & D, Inc.
494	Arsenic trioxide	Trisenox	5/13/2003	Treatment of chronic lymphocytic leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
495	Arsenic trioxide	Trisenox	3/4/2005	Treatment of malignant glioma	Teva Branded Pharmaceutical Products R&D, Inc.
496	arsenic trioxide	Trisenox	10/18/2001	Treatment of chronic myeloid leukemia	Teva Branded Pharmaceutical Products R*D, Inc.
497	arsenic trioxide	Trisenox	6/13/2003	Treatment of liver cancer	Teva Branded Pharmaceutical Products R&D, Inc.
498	arsenic trioxide	Trisenox	7/17/2000	Treatment of myelodysplastic syndrome.	Teva Branded Pharmaceutical Products R&D, Inc.
499	arsenic trioxide capsule (oral)	n/a	11/2/2015	Treatment of acute promyelocytic leukemia.	Orsenix Holdings BV
500	artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Novartis Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
501	Artesunate	n/a	7/19/1999	Treatment of malaria.	World Health Organization
502	Artesunate	n/a	3/28/2006	Immediate treatment of malaria	US Army Medical Materiel Development Activity
503	arylsulfatase A (rhASA)	n/a	2/27/2008	Treatment of metachromatic leukodystrophy	Shire Human Genetic Therapies, Inc.
504	ascorbic acid	n/a	5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Murigenetics SAS
505	Ascorbic acid	Ascor L 500	8/31/2007	Treatment of scurvy	McGuff Pharmaceuticals Inc.
506	Asfotase alfa	n/a	9/12/2008	Treatment of hypophosphatasia	Alexion Pharmaceuticals, Inc.
507	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	GlaxoSmithKline Biologicals, S.A.
508	ataluren	n/a	9/1/2004	For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene	PTC Therapeutics, Inc.
509	ataluren	Translarna	12/10/2014	Treatment of mucopolysaccharidosis type I	PTC Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
510	ataluren	n/a	1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene	PTC Therapeutics, Inc.
511	ataluren	n/a	9/1/2015	Treatment of aniridia	PTC Therapeutics, Inc.
512	ataluren	n/a	3/10/2008	Treatment of spinal muscular atrophy	PTC Therapeutics, Inc.
513	Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc.
514	Atovaquone	Mepron	8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development
515	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/2007	Treatment of primary central nervous system malignancies	TVAX Biomedical, LLC
516	auranofin	Ridaura	4/30/2010	Treatment of amebiasis	Ctr for Discovery & Innovation in Parasitic Diseas

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
517	autologous adipose derived mesenchymal stromal cells	n/a	10/22/2014	Treatment of amyotrophic lateral sclerosis	Mayo Clinic
518	autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 - based lentiviral vector, EFS-ADA	n/a	10/21/2014	Treatment of adenosine deaminase deficient severe combined immunodeficiency	Donald B. Kohn, MD - Professor, UC-UCLA
519	Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)	n/a	11/13/2014	Treatment of acute lymphoblastic leukemia (ALL)	Juno Therapeutics, Inc.
520	autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)	n/a	1/15/2015	Treatment of severe combined immune deficiency-X1	Boston Children's Hospital
521	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/2010	Treatment of Wiskott Aldrich syndrome	GlaxoSmithKline Intellectual Property Development

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
522	autologous CD34+ hematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/2012	Treatment of andrenoleukodystrophy	bluebird bio, Inc.
523	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	2/26/2014	For the treatment of Sickle Cell Disease	bluebird bio Inc.
524	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/2013	Treatment of B-thalassemia major and intermedia	bluebird bio, Inc.
525	autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	11/6/2014	Treatment of acute lymphoblastic leukemia (inclusive of B-cell acute lymphoblastic leukemia)	Juno Therapeutics, Inc.
526	autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/2013	Prevention of graft rejection following solid organ transplantation	iREG Medical AB
527	Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/2007	Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy	Cellular Bioengineering, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
528	autologous dendritic cells pulsed with allogeneic tumor cell lysate	n/a	5/6/2014	Treatment of malignant mesothelioma	Amphera BV
529	Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	Dcvax-Brain	11/29/2002	Treatment of primary brain malignant cancer	Northwest Biotherapeutics, Inc.
530	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1-glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/2010	Treatment of ovarian cancer.	Prima Biomed Ltd.
531	Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc.
532	Autologous Engineered Skin Substitute	Permaderm	6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Amarantus BioScience Holdings, Inc.
533	autologous Epstein-Barr virus specific T-cells	n/a	3/9/2015	Treatment of Epstein-Barr virus positive non-Hodgkin lymphomas.	Cell Medica, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
534	autologous ex vivo expanded CD4+-enriched leukocytes treated with the demethylating agent 5-aza-2-â-deoxycytidine	Alecsat	9/13/2013	Treatment of glioblastoma multiforme	CytoVac A/S
535	autologous genetically modified human dermal fibroblasts	n/a	6/10/2014	Treatment of dystrophic epidermolysis bullosa.	Fibrocell Technologies, Inc.
536	Autologous incubated macrophage	n/a	9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Proneuron Biotechnologies, Inc.
537	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Theralux Photodynamic Therapy	4/3/2008	Treatment of chronic graft versus host disease	Kiadis Pharma Canada, Inc.
538	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Biovest International, Inc.
539	autologous neo-uninary conduit	n/a	6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Tengion, Inc.
540	Autologous olfactory neural progenitors	Rhinocytes	2/1/2008	Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C	RhinoCyte, Inc.
541	autologous olfactory neural progenitors	Rhinocytes	12/31/2008	Treatment of amyotrophic lateral sclerosis	RhinoCyte, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
542	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	TissueTech, Inc.
543	autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	Kite Pharma, Inc.
544	Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	1/31/2014	For the treatment of Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals Corporation
545	autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	3/14/2014	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
546	autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line	n/a	5/6/2015	Treatment of glioblastoma	Sebastiano Gattoni-Celli, MD
547	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/2002	Treatment of metastatic melanoma	Agenus, Inc.
548	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/2002	Treatment of renal cell carcinoma	Agenus, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
549	autologous umbilical cord blood	n/a	7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Duke University
550	autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Glaxo Group Limited
551	Autolymphocyte therapy	n/a	7/12/1994	Treatment of renal cell carcinoma.	Cytogen Corporation
552	avicin d	n/a	3/24/2015	Treatment of multiple myeloma	Avicin Therapeutics Ltd.
553	aviptadil	n/a	2/22/2005	Treatment of pulmonary arterial hypertension	Mondobiotech Laboratories AG
554	Azacitidine	Vidaza	6/18/2008	Treatment of acute myeloid leukemia	Celgene Corporation
555	azacitidine	Vidaza	12/3/2001	Treatment of myelodysplastic syndromes	Celgene Corporation
556	Azathioprine	Imuran	9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc.
557	aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Gilead Sciences (formerly Corus Pharma)
558	Azurin-p28	n/a	12/2/2015	Treatment of glioma.	CDG Therapeutics, Inc.
559	Bacillus Calmette-Guerin vaccine	n/a	8/9/2006	Treatment of stage IIb through IV metastatic melanoma	OncoVac Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
560	Bacillus subtilis oxalate decarboxylase	n/a	2/29/2016	Treatment of pediatric hyperoxaluria	Allena Pharmaceuticals
561	Bacitracin	Altracin	3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc.
562	Baclofen	Lioresal Intrathecal	9/26/1994	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc.
563	baclofen	Gablofen	10/28/2015	Treatment of complex regional pain syndrome.	Mallinckrodt, Inc.
564	baclofen	Lioresal Intrathecal	11/10/1987	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc.
565	baclofen	n/a	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Metacel Pharmaceuticals, LLC
566	baclofen	n/a	12/2/2003	Treatment of dystonia	Medtronic Neurological
567	bacterium Bacteroides thetaiotaomicron	n/a	9/26/2013	Treatment of active Crohn's disease in the pediatric population	4D Pharma Research Ltd

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
568	Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Salix Pharmaceuticals, Inc.
569	Bardoxolone	n/a	8/6/2008	Treatment of pancreatic cancer	Reata Pharmaceuticals, Inc.
570	bardoxolone	n/a	3/30/2015	Treatment of pulmonary arterial hypertension	Reata Pharmaceuticals, Inc.
571	Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation
572	basimglurant	n/a	3/9/2012	Treatment of Fragile X Syndrome	Hoffmann-La Roche, Inc.
573	beclomethasone	n/a	3/4/2009	Treatment of pediatric patients with ulcerative colitis	Aptalis Pharma US, Inc.
574	beclomethasone 17,21-dipropionate	n/a	11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Soligenix, Inc
575	beclomethasone 17,21-dipropionate	Orbec(R)	7/24/2009	Treatment of gastrointestinal symptoms with chronic graft versus host disease in patients undergoing allogeneic hematopoietic cell transplantation	Soligenix, Inc.
576	beclomethasone 17,21-dipropionate	Bec	8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Soligenix, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
577	beclomethasone 17,21-dipropionate	n/a	12/18/2007	Treatment of pediatric patients with Crohn disease.	Soligenix, Inc.
578	Beclomethasone dipropionate	n/a	3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Soligenix, Inc.
579	bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol	Sirturo	1/10/2005	Treatment of active tuberculosis	Janssen Research & Development, LLC
580	belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Bristol-Myers Squibb Company
581	Belinostat	Beleodaq	9/3/2009	Treatment of peripheral T-cell lymphoma (PTCL).	Spectrum Pharmaceuticals, Inc.
582	beloranib	n/a	1/15/2013	Treatment of Prader-Willi syndrome	Zafgen, Inc.
583	bendamustine for 50 ml admixture	n/a	7/2/2014	Treatment of chronic lymphocytic leukemia	Eagle Pharmaceuticals, INC.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
584	bendamustine for 50ml admixture	n/a	7/2/2014	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Eagle Pharmaceuticals, Inc.
585	Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Cephalon, Inc.
586	bendamustine hydrochloride	Treanda	11/26/2013	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Cephalon, Inc.
587	bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/2013	Treatment of chronic lymphocytic leukemia	Supratek Pharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
588	Bendamustine oral dosage formulation	n/a	11/5/2015	Treatment of chronic lymphocytic leukemia	Exinda Theapeutics LLC
589	benznidazole	n/a	4/14/2014	Treatment of Chagas disease	Chemo Research, S.L.
590	benzoate	Naben	7/6/2012	Treatment of pediatric schizophrenia	SyneuRx International (Taiwan) Corp.
591	Benzoate and phenylacetate	Ucephan	1/21/1986	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	Immunex/Immunex
592	benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp.
593	Benzophenone-3, octylmethoxycinnamate, avobenzene, titanium dioxide, zinc oxide	Total Block VI Spf 75	8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd.
594	Benzydamine hydrochloride	Tantum	5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
595	Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid	Pre-Pen/Mdm	9/28/1987	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	AllerQuest LLC
596	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome	Ross Laboratories
597	Beractant	Survanta Intratracheal Suspension	12/20/1993	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories
598	Beraprost	n/a	4/29/1999	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	LungRx, Inc.
599	beraprost sodium 314d	n/a	12/22/2011	Treatment of pulmonary arterial hypertension	Lung Rx, Inc.
600	Beta alethine	Betathine	3/24/1997	Treatment of metastatic melanoma.	Dovetail Technologies, Inc.
601	Beta alethine	Betathine	3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
602	Betahistine dihydrochloride	n/a	11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Floyd R. Sallee, M.D., Ph.D.
603	Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Jazz Pharmaceuticals
604	betamethasone	n/a	10/7/2015	Treatment of Ataxia Telangiectasia.	Grace Therapeutics, LLC
605	Betulinic acid	n/a	8/9/2007	Topical treatment of metastatic melanoma	Advanced Life Sciences, Inc. (ALS)
606	bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma	Genentech, Inc.
607	bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Genentech, Inc.
608	bevacizumab	Avastin	10/20/2004	Treatment of pancreatic cancer	Genentech, Inc.
609	bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Genentech, Inc.
610	bevacizumab	Avastin	11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Genentech, Inc.
611	bevacizumab	Avastin	10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Genentech, Inc.
612	bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Genentech, Inc.
613	bevacizumab	n/a	10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Terence M. Davidson, MD
614	bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Genentech, Inc.
615	bevacizumab	Avastin	1/27/2016	Treatment of mesothelioma	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
616	Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Eisai, Inc.
617	bezafibrate	Bezalip	7/24/2013	For therapeutic treatment of Barth syndrome	Barth Syndrome Foundation, Inc.
618	BF2.649 (Pitolisant)	n/a	5/17/2010	Treatment of narcolepsy	Bioprojet Pharma
619	bifidobacterium infantis 35624	n/a	3/24/2008	Treatment of pediatric ulcerative colitis	Alimentary Health Limited
620	bifidobacterium longum infantis 35624	n/a	1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health Limited
621	Bindarit	n/a	2/3/1998	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc.
622	binimetinib	n/a	11/19/2013	Treatment Stage IIB-IV melanoma.	Array BioPharma, Inc.
623	binimetinib	n/a	7/31/2014	Treatment of ovarian cancer	Array Biopharma, Inc.
624	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc.
625	biocarbonate infusate	Normocarb Hf	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Dialysis Solutions, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
626	Bio-engineered oral mucosal tissue	n/a	4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	TissueTech, Inc.
627	Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/2000	Treatment of sickle cell disease.	ICAgen Inc.
628	bisantrene HCl	n/a	2/14/2014	Treatment of acute myeloid leukemia	Update Pharma, Inc.
629	bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine	Fang	10/22/2014	Treatment of Ewing's sarcoma	Gradalis, Inc.
630	bi-shRNA furin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	2/17/2012	Treatment of stage IIB to IV melanoma	Gradalis, Inc.
631	bi-shRNA furin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	4/18/2011	Treatment of ovarian cancer	Gradalis, Inc.
632	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Merrimack Pharmaceuticals, inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
633	bispecific antibody (monoclonmal antibody)	n/a	8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Merrimack Pharmaceuticals, Inc.
634	bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Sanofi-Aventis US, Inc.
635	bivalent anti-human myostatin adnectin-IgG1	n/a	2/10/2015	Treatment of duchenne muscular dystrophy	Bristol-Myers Squibb Co.
636	bivalirudin	Angiomax	11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	The Medicines Company
637	Bleomycin	Blenoxane	2/9/1999	Treatment of pancreatic cancer.	Genetronics, Inc.
638	Bleomycin	n/a	12/20/2010	Treatment of pancreatic cancer.	CIRJ Company Ltd.
639	Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute
640	Blinatumomab	n/a	5/16/2008	Treatment of chronic lymphocytic leukemia	Amgen, Inc.
641	blinatumomab	n/a	5/16/2008	Treatment of acute lymphocytic leukemia	Amgen, Inc.
642	blinatumomab	n/a	5/16/2008	Treatment for hairy cell leukemia.	Amgen, Inc.
643	blinatumomab	n/a	5/16/2008	Treatment of prolymphocytic leukemia	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
644	blinatumomab	n/a	2/6/2006	Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement	Amgen, Inc.
645	Bone marrow-derived mononuclear cells	n/a	5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	t2cure GmbH
646	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.
647	bortezomib	Velcade	5/30/2012	Treatment of mantle cell lymphoma.	Millennium Pharmaceuticals, Inc.
648	bortezomib	Velcade	1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.
649	bortezomib	Velcade	2/3/2015	Treatment of acute lymphoblastic leukemia	Millennium Pharmaceuticals, Inc.
650	Bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd.
651	bosutinib	Bosulf	2/24/2009	Treatment of chronic myelogenous leukemia	Wyeth Pharmaceuticals, Inc.
652	Botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc.
653	Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Allergan, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
654	Botulinum toxin type A	n/a	9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc.
655	Botulinum toxin type A	Dysport	8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Biopharm Limited
656	Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited
657	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
658	Botulinum toxin type A	Dysport	3/23/1989	Treatment of essential blepharospasm.	Porton International, Inc.
659	Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Soltice Neurosciences, LLC
660	Botulinum toxin type F	n/a	10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited
661	botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)	n/a	6/29/2011	Treatment of botulism.	Cangene Corporation
662	Botulism immune globulin	Babybig	1/31/1989	Treatment of infant botulism.	California Department of Health Services
663	Bovine colostrum	n/a	11/19/1990	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM
664	Bovine immunoglobulin concentrate, Cryptosporidium parvum	Sporidin-G	3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
665	bovine lactoferrin	n/a	2/23/2015	Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams)	Metrodora Therapeutics, LLC
666	bovine lactoferrin	n/a	2/19/2015	Prevention of late-onset sepsis in very low birth weight infants	Metrodora Therapeutics, LLC
667	Bovine whey protein concentrate	Immuno-C	9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc.
668	Branched chain amino acids	n/a	12/23/1988	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center
669	brentuximab vedotin	Adcetris	10/23/2008	Treatment of anaplastic large cell lymphoma	Seattle Genetics, Inc.
670	brentuximab vedotin	Adcetris	4/15/2013	Treatment of patients with peripheral T-cell lymphoma, not otherwise specified	Seattle Genetics, Inc.
671	brentuximab vedotin	Adcetris	9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	Seattle Genetics, Inc.
672	brentuximab vedotin	Adcetris(R)	1/31/2014	Treatment of patients with diffuse large B-cell lymphoma.	Seattle Genetics, Inc.
673	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
674	brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Seattle Genetics, Inc.
675	Brilliant Blue G	Dorc Ilm-Blue	7/31/2012	To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders	Dutch Ophthalmic Research Center
676	brilliant blue G	Brilliant Peel	12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Fluron GmbH - Subsidiary of Geuder AG
677	Brimonidine	Alphagan	2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc.
678	Brivaracetam	n/a	10/5/2005	Treatment of symptomatic myoclonus	UCB Pharma, Inc.
679	Broxuridine	Broxine/Neomark	9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc.
680	Bruton's Tyrosine Kinase (Btk) Inhibitor	n/a	5/13/2015	Treatment of chronic lymphocytic leukemia (CLL).	Acerta Pharma BV
681	bryostatin 1	n/a	3/31/2015	Treatment of Fragile X Syndrome.	Neurotrope BioScience, Inc.
682	bryostatin-1	n/a	12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc.
683	Bucillamine	n/a	10/22/2015	Treatment of cystinuria	Revive Therapeutics, Ltd.
684	budesonide	n/a	12/20/2006	Treatment of patients with eosinophilic esophagitis	Shire ViroPharma Incorporated

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
685	budesonide	Nefecon	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Pharmalink AB
686	budesonide	Uceris	5/6/2013	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Santarus, Inc.
687	Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma	Lukare Medical, LLC
688	Buffered Ursodeoxycholic Acid	Ursocarb	9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Digestive Care, Inc.
689	bupivacaine	Transdur	6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	Impax Laboratories, Inc.
690	Buprenorphine hydrochloride	Subutex	6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc.
691	buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Reckitt Benckiser Pharmaceuticals, Inc.
692	Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Otsuka Pharmaceutical Company

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
693	Busulfan	Spartaject	4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc.
694	Busulfan	Spartaject	7/7/1997	Treatment of primary brain malignancies.	SuperGen, Inc.
695	busulfan	Partaject	11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc.
696	Buthionine sulfoxamine	n/a	10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	USC-CHLA Institute for Pediatric Clinical Research
697	Buthionine sulfoxamine	n/a	10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
698	butylidenephthalide	n/a	8/5/2015	Treatment of Malignant Glioma	Everfront Biotech, Inc.
699	Butyrylcholinesterase	n/a	3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc.
700	Butyrylcholinesterase	n/a	9/30/1992	Treatment of post-surgical apnea.	Shire Laboratories Inc.
701	C1 esterase inhibitor (human)	n/a	8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
702	C1 esterase inhibitor (human)	Cinryze(R)	7/16/2004	Treatment of angioedema	Shire
703	C1-esterase inhibitor (recombinant)	Ruconest	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Santarus, Inc.
704	C1-esterase-inhibitor, human, pasteurized	Berinert	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	CSL Behring LLC
705	C20-D3-retinyl acetate	n/a	9/16/2010	Treatment of Stargardt's disease	Alkeus pharmaceuticals, Inc.
706	C21H27O10P	Minnelide	3/30/2015	Treatment of gastric cancer.	Minneamrita Therapeutics, LLC
707	C24H28N8O7S2	n/a	4/2/2015	Treatment of diffuse large B-cell lymphoma (DLBCL).	Curis, Inc.
708	C66H100N6O27	n/a	3/11/2013	Treatment of of hepatocellular carcinoma	GenSpera, Inc.
709	cabozantinib	Cometriq	11/29/2010	Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.	Exelixis, Inc.
710	Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	O.P.R. Development, L.P.
711	caffeine and sodium benzoate	n/a	8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Luitpold Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
712	Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation
713	Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Fresenius Medical Care North America
714	Calcium acetate	n/a	6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company
715	calcium benzoate and risperidone	n/a	12/20/2010	Treatment of pediatric patients with schizophrenia	University of California, Los Angeles
716	Calcium carbonate	R & D Calcium Carbonate/600	6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc.
717	Calcium gluconate	Calgonate	11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp.
718	Calcium gluconate gel	H-F Gel	5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calgonate Corporation
719	Calcium gluconate gel 2.5%	n/a	9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc.
720	calfactant	Infasurf	9/5/2000	Treatment of acute respiratory distress syndrome (ARDS)	ONY, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
721	calfactant	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc.
722	camostat	n/a	5/18/2011	Treatment of chronic pancreatitis	NIXS Corporation
723	canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Novartis Pharmaceuticals Corporation
724	canakinumab	n/a	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Novartis Pharmaceuticals Corporation
725	canakinumab	Ilaris	12/5/2013	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Novartis Pharmaceuticals Corporation
726	canakinumab	Ilaris	12/5/2013	Treatment of familial mediterranean fever	Novartis Pharmaceuticals Corporation
727	canakinumab	Ilaris	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Novartis Pharmaceuticals Corporation
728	cannabidiol	n/a	7/23/2015	Treatment of infantile spasms	Insys Therapeutics, Inc.
729	cannabidiol	n/a	11/17/2014	Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)	Insys Therapeutics, Inc.
730	cannabidiol	n/a	4/22/2015	Treatment of neonatal hypoxic ischemic encephalopathy	GW Pharma Ltd.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
731	cannabidiol	n/a	11/14/2013	Treatment of Dravet syndrome.	GW Pharma Ltd.
732	cannabidiol	n/a	9/24/2014	Treatment of glioma	Insys Therapeutics, Inc.
733	cannabidiol	n/a	8/20/2014	Treatment of glioblastoma multiforme	Insys Therapeutics, Inc.
734	cannabidiol	n/a	7/1/2014	Treatment of Dravet syndrome	Insys Therapeutics, Inc.
735	cannabidiol	n/a	6/23/2014	Treatment of Lennox-Gastaut syndrome	Insys Therapeutics, Inc.
736	cannabidiol	n/a	2/23/2016	Treatment of Fragile X syndrome	Zynerba Pharmaceuticals, Inc.
737	cannabidiol	n/a	7/14/2015	Prevention of Graft versus Host Disease (GVHD).	Talent biotechs Ltd.
738	cannabidiol;	n/a	2/27/2014	Treatment of Lennox-Gastaut syndrome	GW Pharma Ltd.
739	cantharidin	n/a	7/24/2012	Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa	Orenova Group, LLC
740	cantrixil	n/a	4/20/2015	Treatment of ovarian cancer	CanTx, Inc.
741	caprine hyperimmune serum against HIV lysate	n/a	10/28/2009	Treatment of amyotrophic lateral sclerosis	Daval International Limited
742	caprine hyperimmune serum against HIV lysate	n/a	2/14/2014	Treatment of systemic sclerosis	Daval International Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
743	Capsaicin	n/a	9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Centrexion Corporation
744	Capsaicin	n/a	8/3/2005	Treatment of postherpetic neuralgia.	TheraQuest Biosciences, LLC
745	capsaicin	n/a	10/23/2002	Treatment of erythromelalgia	Acorda Therapeutics, Inc.
746	capsaicin	Qutenza	5/2/2003	Treatment of painful HIV-associated neuropathy	Acorda Therapeutics, Inc.
747	capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Acorda Therapeutics, Inc.
748	carbenoxolone	n/a	7/2/2014	Treatment of Huntington's Disease	Oxalys Pharmaceuticals, Inc.
749	carbetocin	n/a	4/11/2014	Treatment of Prader Willi syndrome	Ferring Pharmaceuticals, Inc.
750	carbon dioxide	n/a	12/17/2015	Treatment of trigeminal neuralgia	Capnia, Inc.
751	carbon monoxide	n/a	9/28/2012	Treatment of sickle cell disease	Hillhurst Biopharmaceuticals, Inc.
752	carboxy pyrrolidine hexanoyl pyrrolidine carboxylate	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
753	cardiotrophin-1	n/a	6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Digna Biotech, S.L.
754	cardiotrophin-1	n/a	10/16/2014	Prevention of ischemia-reperfusion injury in kidney transplant recipients	Digna Biotech, S.L.
755	cardiotrophin-1	n/a	9/13/2011	Treatment of acute liver failure	Digna Biotech S.L.
756	carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
757	carglumic acid	Carbaglu	6/17/2014	Treatment of organic acidemias	Orphan Europe SARL
758	carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe SARL
759	carisbamate	n/a	3/16/2012	Management of patients with infantile spasms	SK Life Science, Inc.
760	carlumab	n/a	10/24/2006	Treatment of pancreatic cancer	Centocor, Inc.
761	Carmustine	n/a	7/3/2000	Treatment of intracranial malignancies.	Direct Therapeutics, Inc.
762	Cascara sagrada fluid extract	n/a	3/21/1989	Treatment of oral drug overdose to speed lower bowel evacuation.	Intramed Corporation
763	CaspaCIDE System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid	n/a	2/18/2016	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	Bellicum Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
764	Catumaxomab	Removab	6/9/2006	Treatment of ovarian cancer	Neoviibiotech North America, Inc.
765	catumaxomab	n/a	7/1/2009	Treatment of gastric cancer	Neoviibiotech North America, Inc.
766	CD40/CD80/CD86 modified autologous dendritic cell therapy	n/a	12/20/2013	Treatment Type 1 diabetes mellitus patients with residual beta cell function	DiaVacs, Inc.
767	cediranib	n/a	12/13/2010	Treatment of glioblastoma	National Institutes of Health
768	Ceftriaxone sodium	Rocephin	3/28/2006	Treatment of amyotrophic lateral sclerosis	Mass General Hospital
769	celiprolol	n/a	1/5/2015	Treatment of Ehlers-Danlos syndrome	Acer Therapeutics, Inc.
770	cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/2013	Prevention of graft versus host disease	Enlivex Therapeutics Ltd.
771	Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated
772	cenersen	Aezea	6/18/2008	Treatment of stage IIB through IV melanoma	Eleos, Inc.
773	cenersen	Aezea	2/27/2008	Treatment of chronic lymphocytic leukemia	Eleos, Inc.
774	cenersen	n/a	5/8/2006	Treatment of acute myeloid leukemia	Eleos, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
775	Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Rare Disease Therapeutics, Inc.
776	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Genzyme Corporation
777	ceritinib	Zykadia	9/27/2013	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Novartis Pharmaceuticals Corp.
778	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Advanced Life Sciences, Inc.
779	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Advanced Life Sciences, Inc.
780	cethromycin	n/a	2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Advanced Life Sciences, Inc.
781	cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	ImClone Systems Incorporated
782	Chelating agent delivering Holmium-166	n/a	2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation
783	chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/1990	Treatment of ovarian cancer.	Cytogen Corporation
784	Chenodeoxycholic acid	Chenofalk	1/29/2004	Treatment of cerebrotendinous xanthomatosis	Dr. Falk Pharma GmbH

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
785	chenodeoxycholic acid	n/a	2/12/2007	Treatment of cerebrotendinous xanthomatosis	Baxalta US, Inc.
786	chenodiol	Chenadal	3/22/2010	Treatment of cerebrotendinous xanthomatosis	Retrophin, Inc.
787	chenodiol	Chenix	9/21/1984	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age	Solvay
788	chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2	n/a	11/25/2014	Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)	BioMarin Pharmaceutical, Inc.
789	Chimeric monoclonal antibodies, c-alphaStx2	n/a	10/4/2005	For treatment of shiga-toxin producing bacterial infection	Thallion Pharmaceuticals, Inc.
790	chimeric monoclonal antibody against Claudin 6	n/a	3/18/2013	Treatment of ovarian cancer	Ganymed Pharmaceuticals AG
791	chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/2013	Treatment of pancreatic cancer	Ganymed Pharmaceuticals AG
792	chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/2012	Treatment of gastric cancer	GANYMED Pharmaceuticals AG

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
793	Chimeric monoclonal antibody to mesothelin	n/a	10/31/2006	Treatment of pancreatic cancer	Morphotek, Inc.
794	Chimeric, humanized monoclonal antibody to staphylococcus	n/a	8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc.
795	Chlorhexidine gluconate mouthrinse	Peridex	8/18/1986	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company
796	chlorobutanol/propylene glycol/hydrochloric acid	Patul-End	2/18/1997	Treatment of patulous eustachian tube	Ear Foundation
797	chloropyramine	n/a	10/22/2010	Treatment of pancreatic cancer	CurFAKtor Pharmaceuticals, LLC
798	chloroquine	n/a	5/20/2015	Treatment of glioblastoma multiforme.	DualTpharma B.,V.
799	Chlorotoxin	n/a	12/18/2007	Treatment of malignant glioma	Morphotek, Inc.
800	chlorotoxin	n/a	12/2/2008	Treatment of stage IIb, IIc, III & IV melanoma	Morphotek, Inc.
801	chlorotoxin conjugated to indocyanine green dye	n/a	6/23/2015	Diagnostic for the management of malignant brain tumors	Blaze Bioscience, Inc.
802	cholest-4-en-3-one, oxime	n/a	2/17/2009	Treatment of spinal muscular atrophy.	Genentech, Inc.
803	cholic acid	Cholbam	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Retrophin, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
804	Choline chloride	Intrachol	7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	QOL Therapeutics EU Ltd
805	Choline chloride	Intrachol	2/10/1994	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	QOL Therapeutics EU Ltd
806	choline tetrathiomolybdate	n/a	8/25/2011	Treatment of Wilson's disease.	Wilson Therapeutics AB
807	Chondrocyte-alginate gel suspension	n/a	12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc.
808	chromium picolinate and chromium histidinate	n/a	12/22/2014	Treatment of pediatric polycystic ovary syndrome (0 through 16 years of age)	JDS Therapeutics, LLC
809	Ciliary neurotrophic factor	n/a	1/30/1992	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc
810	cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc.
811	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
812	Cintredekin Besudotox	n/a	4/30/2010	Treatment of idiopathic pulmonary fibrosis	Insys Therapeutics, Inc.
813	ciprofloxacin	n/a	6/1/2011	The management of bronchiectasis	Aradigm Corporation
814	ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Bayer HealthCare Pharmaceuticals, Inc.
815	ciprofloxacin dry powder inhaler	n/a	4/17/2014	Treatment of non-cystic fibrosis bronchiectasis	Bayer HealthCare Pharmaceuticals, Inc.
816	cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate	n/a	1/19/2010	Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae	Medicines for Malaria Venture (MMV)
817	Cisplatin ChemoThin Wafer	n/a	11/3/2015	Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)	Privo Technologies
818	Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/2007	Treatment of osteosarcoma	Eleison Pharmaceuticals LLC
819	Cisplatin/epinephrine	Intradose	4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc.
820	Cisplatin/epinephrine	Intradose	9/7/2000	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
821	Citric acid, glucono-delta-lactone and magnesium carbonate	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc.
822	civamide	n/a	2/17/2009	Treatment of postherpetic neuralgia.	Winston Laboratories, Inc.
823	civamide	Zucapsaicin	12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc.
824	Cladribine	Mylinax	4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Johnson & Johnson Pharmaceutical R & D, LLC
825	Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute
826	cladribine	n/a	3/19/2015	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chord Therapeutics S.a.r.l.
827	clarithromycin, rifabutin, clofazimine	n/a	4/26/2011	Treatment of pediatric Crohn's disease.	RedHill Biopharma Ltd.
828	Clazosentan	Erajel	2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Actelion Pharmaceuticals Ltd.
829	clenbuterol	Spiropent, Ventipulmin	10/27/2014	Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease	Duke University Medical Center
830	Clindamycin	Cleocin	10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn
831	Clindamycin	Cleocin	10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
832	Clindamycin hydrochloride	n/a	8/9/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
833	clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Lundbeck, Inc.
834	clofarabine	Clofarex	3/14/2002	Treatment of acute myelogenous leukemia	Genzyme Corp (Ilex Products, Inc.)
835	clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Genzyme Corporation
836	Clofazimine	Lamprene	6/11/1984	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation
837	clofazimine	Lamprene	6/25/2014	Treatment of active tuberculosis	Novartis Pharmaceuticals Corp.
838	Clonazepam	Klonopin	8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc.
839	Clonazepam Intranasal Spray	n/a	12/19/2007	Treatment of recurrent acute repetitive seizures	Jazz Pharmaceuticals, Inc.
840	Clonidine	Duraclon	1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
841	Clotrimazole	n/a	4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D.
842	Clotrimazole	n/a	6/14/2005	Topical treatment of children and adults with pouchitis	AesRx, LLC
843	Clotrimazole	n/a	3/13/2006	Treatment of Huntington's disease	EnVivo Pharmaceuticals, Inc.
844	CNDO-109-activated allogeneic natural killer cells	n/a	6/18/2012	Treatment of acute myeloid leukemia	Coronado Biosciences, Inc.
845	Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company
846	Coagulation Factor IX (human)	Alphanine	7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation
847	Coagulation Factor IX (recombinant)	Benefix	10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc.
848	coagulation factor IX (recombinant)	Rixubis	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Baxalta US, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
849	Coagulation factor IX (recombinant), Fc fusion protein	Alprolix	10/30/2008	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Biogen Idec Inc.
850	Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
851	Coagulation factor VIIa (recombinant)	Novoseven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
852	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Novo Nordisk, Inc.
853	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors	Novo Nordisk, Inc.
854	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Novo Nordisk, Inc.
855	Coagulation factor VIIa (recombinant)	Novoseven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
856	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
857	coagulation factor VIIa (recombinant)	Novoseven Rt	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk Inc.
858	coagulation factor XIII A-subunit (recombinant)	Tretten	11/6/2003	Prophylaxis of bleeding associated with congenital factor XIII deficiency	Novo Nordisk, Inc.
859	cobimetinib	n/a	1/31/2014	Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation	Genentech, Inc.
860	coccidioidin SD Skin Test Antigen	n/a	12/19/2007	For the diagnosis of Coccidioidomycosis	Allermed Laboratories, Inc.
861	Coenzyme Q10	n/a	3/5/2001	Treatment of Huntington's disease	Integrative Therapeutics, Inc.
862	coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/2011	Treatment of Friedreich's Ataxia.	NBI Pharmaceuticals, Inc.
863	Colchicine	n/a	9/25/2007	Treatment of Behcet's Syndrome	AR Scientific, Inc.
864	colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	AR Holding Company, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
865	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages.	Glaxo Wellcome Inc.
866	collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Auxilium Pharmaceuticals, Inc.
867	collagenase clostridium histolyticum	Xiaflex	3/12/1996	Treatment of Peyronie's disease.	Auxilium Pharmaceuticals, Inc.
868	Combination of nivolumab and ipilimumab	n/a	10/9/2014	Treatment of Stage IIb to Stage IV melanoma	Bristol-Myers Squibb Company
869	combretastatin A 1 diphosphate	n/a	11/19/2012	Treatment of acute myelogenous leukemia	OXIGENE, Inc.
870	Combretastatin A4 Phosphate	n/a	7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXIGENE, Inc
871	Combretastatin A4 phosphate	n/a	5/8/2006	Treatment of ovarian cancer	OXIGENE, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
872	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	NanoViricides Incorporated
873	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/2001	Treatment of malignant tumors of the central nervous system	Xenova Biomedix Limited
874	conjugated bile acids	Cobartin	7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc.
875	Contulakin-G	n/a	7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Cognetix, Inc.
876	copanlisib	n/a	2/5/2015	Treatment of follicular lymphoma	Bayer HealthCare Pharmaceuticals, Inc.
877	copper histidine	n/a	5/14/2012	Treatment of Menkes disease	Stephen G. Kaler, M.D.
878	Cordycepin	n/a	7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	OncoVista, Inc.
879	corifungin	n/a	7/6/2011	Treatment of visceral leishmaniasis	Sandler Center for Drug Discovery
880	corifungin	n/a	8/22/2011	Treatment of amebic meningoencephalitis.	Ctr for Discovery & Innovation in Parasitic Diseas
881	Corticoreslin ovine triflutate	Acthrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
882	Corticotropin-releasing factor, human	Xerecept	4/6/1998	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc.
883	Coumarin	Onkolox	12/22/1994	Treatment of renal cell carcinoma.	Drossapharm LTD
884	Coxsackievirus A21	Cavatak	12/15/2005	Treatment of stage II (T4), stage III, and stage IV melanoma	Viralytics Limited
885	Creatine	Creapure	10/11/2005	Treatment of Huntington's disease	Marathon Pharmaceuticals, LLC
886	creatine	Creapure	2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc.
887	crenolanib	n/a	10/31/2012	Treatment of acute myelogenous leukemia	AROG Pharmaceuticals, LLC
888	crenolanib	n/a	3/18/2011	Treatment of soft tissue sarcoma	AROG Pharmaceuticals, LLC
889	crenolanib besylate	n/a	12/20/2010	Treatment of malignant glioma	AROG Pharmaceuticals, LLC
890	cridanimod	n/a	1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Kevelt Ltd.
891	crizotinib	Xalkori	9/13/2010	Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer	Pfizer, Inc.
892	crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
893	crizotinib	Xalkori	10/31/2012	Treatment of neuroblastoma	Pfizer
894	Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Fisons Corporation
895	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Fisons Corporation
896	cromolyn sodium for inhalation	n/a	12/9/2015	Treatment of mastocytosis.	Patara Pharma, LLC
897	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation
898	cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	n/a	8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center
899	cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD)	Alexion Pharmaceuticals, Inc.
900	Cyclo {{{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}}	n/a	12/20/2006	Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis	Lux Biosciences, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
901	cyclo(-γ-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt	n/a	6/24/2013	Treatment of acromegaly	Aspireo Pharmaceuticals Limited
902	Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-}. Al(III)	n/a	12/29/2015	Treatment of invasive aspergillosis.	Vical Incorporated
903	cyclocreatine	n/a	6/18/2012	Treatment of creatine transporter deficiency	Lumos Pharma
904	cyclophosphamide	Cyrevia(Tm)	6/7/2011	Treatment of systemic sclerosis.	Accentia Biopharmaceuticals, Inc.
905	cyclophosphamide	Cyrevia(Tm)	6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Accentia Biopharmaceuticals, Inc.
906	Cyclosporin A	Mitogard	10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Maas Biolab,LLC
907	Cyclosporine	n/a	11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	APT Pharmaceuticals, Inc.
908	Cyclosporine	Pluminiq	11/25/2003	Treatment of acute rejection in patients requiring allogeneic lung transplants	APT Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
909	cyclosporine	n/a	2/17/2009	Treatment of graft-versus-host disease	Sigmoid Pharma Limited
910	cyclosporine	n/a	2/17/2009	Prophylaxis of graft-versus-host disease	Sigmoid Pharma Limited
911	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty	Allergan, Inc.
912	cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer	Allergan, Inc.
913	Cyclosporine A	n/a	5/4/2007	Treatment of vernal keratoconjunctivitis	Santen SAS
914	cyclosporine A	n/a	9/30/2008	Prevention of corneal graft rejection	Santen SAS
915	cyclosporine A	Nova22007	4/9/2008	Treatment of herpes simplex virus stromal keratitis	Santen SAS
916	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/2000	Prevention of solid organ graft rejection.	RTP Pharma Corporation
917	Cyclosporine ophthalmic	Optimmune	11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia
918	cyclosporine; ciclosporin	Neurostat(R)/Ciclomulsion (R)	11/23/2010	Treatment of moderate to severe traumatic brain injury.	NeuroVive Pharmaceutical AB

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
919	Cys-His-Ala-Val-Cys	n/a	2/14/2008	For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV	Adherex Technologies, Inc.
920	Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc.
921	Cysteamine	Lynovex	9/11/2014	Treatment of cystic fibrosis	NovaBiotics Ltd.
922	Cysteamine	n/a	5/1/1986	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D.
923	cysteamine	n/a	9/11/2013	Treatment of pancreatic cancer	Raptor Pharmaceuticals, Inc.
924	cysteamine	n/a	8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Raptor Pharmaceuticals, Inc.
925	cysteamine	n/a	5/9/2008	Treatment of Huntington's disease	Raptor Therapeutics
926	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics, Inc.
927	Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc.
928	Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcftr.10	3/9/1995	Treatment of cystic fibrosis.	GenVec, Inc.
929	Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/1993	Treatment of cystic fibrosis.	Genetic Therapy, Inc.
930	Cytarabine liposomal	Depocyt	6/2/1993	Treatment of neoplastic meningitis.	Pacira Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
931	cytarabine liposome	Depocyt	1/30/2007	Treatment of gliomas	Bruce Frankel, MD
932	Cytarabine:daunorubicin liposome injection	n/a	8/22/2008	Treatment of acute myeloid leukemia	Celator Pharmaceuticals, Inc.
933	cytochrome C, flavin mononucleotide and thiamin diphosphate	n/a	6/17/2011	Treatment of mitochondrial disorders	NBI Pharmaceuticals, Inc.
934	cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate	n/a	12/17/2014	Treatment of pancreatic cancer in combination with ifosfamide	Nuvilex, Inc.
935	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/2006	For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations	Vical Inc.
936	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/2005	Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations	Astellas Pharma Global Development, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
937	Cytomegalovirus immune globulin (human)	Cytogam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	CSL Behring LLC
938	Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation
939	d6-tetrabenazine, deutetrabenazine	n/a	11/5/2014	Treatment of Huntington's Disease	Teva Pharmaceuticals, Inc.
940	dabrafenib	Tafinlar	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	Novartis Pharmaceuticals Corp.
941	dabrafenib	Tafinlar	2/8/2016	Treatment of malignant glioma with BRAF V600 mutation	Novartis Pharmaceuticals Corporation
942	dabrafenib	Tafinlar	10/20/2014	Treatment of patients with BRAF mutation positive non-small cell lung cancer	Novartis Pharmaceuticals Corp.
943	dabrafenib and trametinib	n/a	10/29/2015	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	Novartis Pharmaceuticals Corp.
944	dacetuzumab	n/a	8/13/2004	Treatment of multiple myeloma.	Seattle Genetics, Inc.
945	dacetuzumab	n/a	10/6/2005	Treatment of chronic lymphocytic leukemia	Seattle Genetics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
946	Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc.
947	dacomitinib	n/a	3/3/2015	Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.	Pfizer, Inc.
948	dalbavancin	Dalvance	3/30/2015	Treatment of acute osteomyelitis in children (0 through 16 years of age)	Durata Therapeutics International B.V.
949	dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Acorda Therapeutics
950	dantrolene sodium	n/a	9/25/2012	Treatment of heat stroke	Eagle Pharmaceuticals, Inc.
951	dantrolene sodium	n/a	2/17/2016	Treatment of Wolfram Syndrome	Washington University in St. Louis
952	dantrolene sodium suspension for injection	Ryanodex	8/16/2013	Treatment of malignant hyperthermia syndrome	Eagle Pharmaceuticals, Inc.
953	Dapsone	n/a	11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc.
954	Dapsone USP	Dapsone	12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company
955	Dapsone USP	Dapsone	1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
956	daratumumab	Humax (R) - Cd38	11/9/2015	Treatment of diffuse large B-cell lymphoma.	Janssen Research and Development, LLC
957	daratumumab	Humax(R)-Cd38	5/6/2013	Treatment of multiple myeloma.	Janssen Research & Development, LLC
958	daratumumab	n/a	8/6/2015	Treatment of follicular lymphoma	Janssen Research & Development, LLC
959	daratumumab	n/a	8/20/2015	Treatment of mantle cell lymphoma.	Janssen Research & Development, LLC
960	Darinaparsin	n/a	9/13/2010	Treatment of peripheral T-cell lymphoma.	Solasia Pharma K.K.
961	Dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
962	Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Bristol-Myers Squibb Company
963	dasiprotimut-T	Biovax Id	6/17/2010	Treatment of mantle cell lymphoma	Biovest International, Inc.
964	dasiprotimut-T	Biovaxid	10/28/2009	Treatment of follicular lymphoma	Biovest International, Inc.
965	Daunorubicin citrate liposome injection	Daunoxome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc.
966	Daunorubicin liposomal	n/a	9/5/2008	Treatment of acute myeloid leukemia	Diatos USA, LLC
967	davunetide	n/a	12/7/2009	Treatment of progressive supranuclear palsy.	Allon Therapeutics, Inc.
968	DCVAC OvCa	n/a	5/14/2013	Treatment of ovarian cancer	SOTIOS a.s.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
969	DEAE-rebeccamycin	n/a	3/1/2004	Treatment of bile duct tumors	Helsinn Healthcare SA
970	debrase	Debridase	8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd.
971	decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Otsuka Pharmaceutical Development
972	defactinib	n/a	2/12/2015	Treatment of ovarian cancer	Verastem, Inc.
973	Deferasirox	Exjade	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation
974	deferasirox	Exjade	2/24/2015	Treatment of chronic iron overload in alpha-thalassemia	Novartis Pharmaceuticals Corporation
975	deferiprone	n/a	7/31/2008	Treatment of Friedreich's ataxia	ApoPharma, Inc.
976	deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	ApoPharma, Inc. A Division of
977	deferiprone	n/a	9/1/2011	Treatment of superficial siderosis	ApoPharma, Inc.
978	deferoxamine starch conjugate	n/a	1/28/2005	Treatment of acute iron poisoning	Biomedical Frontiers, Inc.
979	deferoxamine starch conjugate	n/a	12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
980	Defibrotide	n/a	7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Crinos International
981	defibrotide	n/a	1/8/2007	For the prevention of hepatic veno-occlusive disease.	Gentium SpA
982	defibrotide	n/a	5/21/2003	For the treatment of hepatic veno-occlusive disease	Gentium SpA
983	deflazacort	Calcort	9/16/2010	Treatment of Duchenne muscular dystrophy	University of Rochester Medical Center
984	deflazacort	n/a	10/22/2015	Treatment of pediatric (0 through 16 years of age) juvenile idiopathic arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.	Marathon Pharmaceuticals, LLC
985	deflazacort	n/a	8/16/2013	Treatment of Duchenne muscular dystrophy	Marathon Pharmaceuticals, LLC
986	dehydrated alcohol	n/a	3/16/2012	Treatment of trigeminal neuralgia	Luitpold Pharmaceuticals, Inc.
987	dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Belcher Pharmaceuticals, LLC
988	Dehydroepiandrosterone (DHEA)	Fidelin	8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc.
989	Dehydroepiandrosterone sulfate sodium	n/a	1/29/1997	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
990	Dehydroepiandrosterone sulfate sodium	n/a	1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc.
991	delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione	n/a	12/2/2011	Treatment of Duchenne muscular dystrophy	ReveraGen Biopharma
992	delta-9-tetrahydrocannabinol and cannabidiol	n/a	12/3/2015	Treatment of glioma.	GW Research Ltd.
993	demcizumab	n/a	4/30/2014	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
994	dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha	n/a	6/7/2010	Treatment of glioblastoma or brain stem glioma	ImmunoCellular Therapeutics Ltd.
995	dendritic hybrid cell vaccine	Neuroblaxin	9/23/2011	Treatment of neuroblastoma	Orbis Health Solutions, LLC
996	dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene	n/a	1/6/2016	Treatment of soft tissue sarcoma.	Immune Design Corp.
997	denileukin diftitox	Ontak	4/30/2010	Treatment of peripheral T-cell lymphoma	Eisai, Inc.
998	denileukin diftitox	n/a	7/12/2013	Treatment of cutaneous T-cell lymphoma	Eisai Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
999	denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Eisai, Inc.
1000	denileukin diftitox	n/a	6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Eisai, Inc.
1001	denosumab	Xgeva	9/11/2013	Treatment of hypercalcemia in malignancy	Amgen, Inc.
1002	denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Amgen, Inc.
1003	Dermagraft	n/a	12/13/2010	Treatment of epidermolysis bullosa	Shire Regenerative Medicine, Inc.
1004	Deslorelin	Somagard	11/5/1987		Roberts Pharmaceutical Corp.
1005	Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/2004	Treatment of pemphigus vulgaris	Peptimmune, Inc.
1006	Desmopressin acetate	n/a	1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C.
1007	deutetrabenazine	n/a	1/13/2015	Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)	TEVA Pharmaceuticals
1008	dexamethasone intravitreal implant	Ozurdex	9/11/1998	Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis	Allergan
1009	dexamethasone phosphate	n/a	12/2/2008	Treatment of corneal graft rejection.	EyeGate Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1010	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/2012	Treatment of ataxia-telangiectasia	EryDel S.p.A.
1011	dexanabinol	n/a	8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Pharmos Corporation
1012	dexpramipexole	n/a	10/11/2007	Treatment of amyotrophic lateral sclerosis	Knopp Biosciences LLC
1013	Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn
1014	dexrazoxane	Totect(R)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Biocodex
1015	dexrazoxane hydrochloride	n/a	8/19/2014	Prevention of cardiomyopathy for children and adolescents 0 through 16 years of age treated with anthracyclines	Satiscor, LLC
1016	dextran 1	n/a	3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc.
1017	Dextran 70	Dehydrex	3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc.
1018	Dextran and deferoxamine	Bio-Rescue	3/8/1991	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1019	Dextran sulfate (inhaled, aerosolized)	Uendex	10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
1020	Dextran sulfate sodium	n/a	11/19/1987	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd.
1021	diacerein	n/a	10/15/2014	Treatment of epidermolysis bullosa	TWI Biotechnology, Inc.
1022	Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation
1023	diannexin	n/a	10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Astellas Pharma Global Development, Inc.
1024	diazepam (intranasal)	n/a	7/31/2012	Management of patients with acute repetitive seizures	Acorda Therapeutics, Inc.
1025	diazepam (intranasal)	n/a	11/16/2015	Management of acute repetitive seizures.	Neurelis Pharmaceuticals, Inc.
1026	diazepam auto-injector	n/a	5/30/2013	Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity	Meridian Medical Technologies-a Pfizer subsidiary

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1027	Diazepam viscous solution for rectal administration	n/a	2/25/1992	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Valeant Pharmaceuticals
1028	diazoxide	n/a	12/3/2012	Treatment of Prader Willi Syndrome	Sedogen, LLC
1029	diazoxide choline	n/a	5/13/2014	Treatment of Prader-Willi Syndrome	Essentialis, Inc.
1030	dichlorphenamide	n/a	9/2/2010	Treatment of primary periodic paralyses	Taro Pharmaceuticals
1031	Diethyldithiocarbamate	Imuthiol	4/3/1986	Treatment of AIDS.	Connaught Laboratories
1032	diethylenetriaminepentaacetate (DPTA)	n/a	4/14/2004	For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.	CIS-US
1033	Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.	Hameln Pharmaceuticals gmbh
1034	diferuloylmethane	n/a	6/13/2003	Treatment of cystic fibrosis	Allertein Therapeutics, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1035	difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Alcon Pharmaceuticals. Ltd.
1036	digitoxin	n/a	10/18/2001	Treatment of soft tissue sarcomas	SimRx Advisors LLC
1037	digitoxin	n/a	11/2/2001	Treatment of ovarian cancer	SimRx Advisors LLC
1038	digitoxin	n/a	5/27/2005	Treatment of cystic fibrosis	Silver Pharmaceuticals
1039	Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc.
1040	digoxin immune fab (ovine)	n/a	2/3/2012	Treatment of severe preeclampsia and eclampsia	Velo Bio, LLC
1041	Digoxin immune fab(ovine)	Digidote	3/11/1985	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp.
1042	dihydroartemisinin and piperazine	Eurartesim	1/8/2007	Treatment of uncomplicated malaria caused by "Plasmodium falciparum," Plasmodium vivax," Plasmodium malariae," or "Plasmodium ovale."	Sigma-Tau Pharmaceuticals, Inc.
1043	Dihydrotestosterone	Androgel -Dht	2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Besins Internaitonal, US Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1044	dimebon	n/a	5/12/2009	Treatment of Huntington's Disease.	Medivation, Inc.
1045	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Bellicum Pharmaceuticals, Inc.
1046	dimethyl fumarate	n/a	9/11/2013	Treatment of Friedreich's Ataxia	Gino Cortopassi
1047	Dimethyl sulfoxide	n/a	11/22/1994	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Abela Pharmaceuticals, Inc.
1048	dimethyl sulfoxide	n/a	5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Abela Pharmaceuticals, Inc.
1049	Dimethylsulfoxide	n/a	4/15/1997	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc.
1050	Dimethylsulfoxide	n/a	4/6/1998	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc.
1051	dinaciclib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Merck Sharp & Dohme Ltd.
1052	dinutuximab	n/a	12/20/2010	Treatment of neuroblastoma	United Therapeutics Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1053	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc.
1054	diphenylcyclophenone	n/a	6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr.
1055	Diphenylcyclopropenone gel	Samcyprone (Tm)	4/15/2015	Treatment of malignant melanoma stage IIB to IV	RXi Pharmaceuticals Corp.
1056	dipraglurant	n/a	12/29/2015	Treatment of levodopa-induced dyskinesias	Addex Pharma SA
1057	Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc.
1058	Disodium clodronate	n/a	6/16/1993	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc.
1059	Disodium clodronate tetrahydrate	Bonefos	3/5/1990	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc.
1060	D-mannitol and L-proline	Prodarsan	4/20/2009	Treatment of Cockayne syndrome	DNage B.V.
1061	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/2009	Treatment of ovarian cancer	BioCancell Therapeutics Ltd.
1062	DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	n/a	2/6/2014	Treatment of amyotrophic lateral sclerosis	ViroMed Co., Ltd.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1063	DNA plasmid vector expressing eIF5Ak50	n/a	12/13/2010	Treatment of multiple myeloma.	Senesco Technologies, Inc.
1064	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of diffuse large B cell lymphoma	Senesco Technologies, Inc.
1065	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of mantle cell lymphoma	Senesco Technologies, Inc.
1066	DNA plasmid vector expressing human IL-12 gene	n/a	4/4/2005	Treatment of ovarian cancer.	Celsion Corporation
1067	DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Leuvectin	4/28/2000	Treatment of renal cell carcinoma.	Vical Incorporated
1068	DNP-Modified autologous tumor vaccine	O-Vax	9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc.
1069	docosahexaenoic acid	n/a	4/27/2015	Treatment of sickle cell disease	Sancilio & Company, Inc.
1070	docosahexaenoic acid	n/a	6/1/2015	Treatment of short bowel syndrome	Sancilio and Company, Inc.
1071	docosahexaenoic acid, DHA	n/a	12/17/2014	Treatment of primary sclerosing cholangitis	Sancilio and Company, Inc.
1072	dodecafluoropentane emulsion	n/a	2/11/2016	Treatment of sickle cell disease	NuvOx Pharma

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1073	dodecafluoropentane emulsion (DDFPe)	n/a	12/2/2015	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme (GBM).	NuvOx Pharma
1074	domperidone	n/a	9/2/2011	Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding	Thomas W. Hale, RPh, PhD
1075	Doripenem	n/a	7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Shionogi, Inc.
1076	Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc.
1077	double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic	n/a	6/9/2015	Treatment of Alpha-1 Antitrypsin deficiency	Arrowhead Research Corporation
1078	double stranded RNA which targets the mutated KRAS oncogene	n/a	1/26/2015	Treatment of pancreatic cancer	Silenseed Ltd

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1079	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/2010	Treatment of pancreatic cancer	BioCancell Therapeutics Israel Ltd.
1080	dovitinib	n/a	9/26/2013	Treatment of adenoid cystic carcinoma	Novartis Pharmaceuticals Corporation
1081	DOXO-EMCH	n/a	4/18/2011	Treatment of adenocarcinoma of the pancreas.	CytRx Corporation
1082	doxofylline	n/a	2/14/2014	Treatment of bronchiectasis	Alitair Pharmaceuticals, Inc.
1083	doxorubicin	n/a	4/6/2015	Treatment of cutaneous T-cell lymphoma	Louis D. Faló, Jr.
1084	doxorubicin	n/a	8/25/2009	Treatment of hepatocellular carcinoma.	Delcath Systems, Inc.
1085	doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Johnson & Johnson Pharmaceutical Research & Dev.
1086	Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/2005	Treatment of esophageal carcinoma	Supratek Pharma Inc.
1087	Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Alza Corporation
1088	doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/2005	Treatment of hepatocellular carcinoma	BioAlliance Pharma
1089	doxorubicin with pluronics F-127 and L-61	n/a	2/20/2008	Treatment of gastric cancer	Supratek Pharma, Inc.
1090	D-peptide	Nerofe	2/4/2011	Treatment of acute myelogenous leukemia	Immune System Key, Ltd
1091	D-peptide of the sequence AKRHHGYKRKFH - NH2	Pulmadex	10/23/2002	Treatment of cystic fibrosis	Demegen, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1092	DPX-Survivac	n/a	7/14/2015	Treatment of ovarian cancer.	Immunovaccine Technologies, Inc.
1093	Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc.
1094	droxidopa	Northera	1/17/2007	Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.	Lundbeck LLC
1095	dry extract from Betulae Cortex (birch bark)	n/a	8/7/2014	Treatment of epidermolysis bullosa	Birken AG
1096	Duramycin	n/a	12/11/1997	Treatment of cystic fibrosis.	Lantibio, Inc.
1097	duvelisib	n/a	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Infinity Pharmaceuticals
1098	duvoglustat hydrochloride	n/a	6/18/2007	Treatment of Pompe disease	Amicus Therapeutics, Inc
1099	Dynamine	n/a	10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation
1100	Dynamine	n/a	2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation
1101	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1102	Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]	n/a	2/8/2016	Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.	Cidara Therapeutics, Inc.
1103	echinomycin	n/a	5/21/2015	Treatment of acute myeloid leukemia.	OncoImmune, Inc.
1104	echothiophate iodide	n/a	6/2/2014	Treatment of Stargardt's disease	Makindus, Inc.
1105	ecopipam hydrochloride	n/a	9/29/2010	Treatment of Tourette's syndrome in children 0-16 years old.	Psyadon Pharmaceuticals, Inc.
1106	ecopipam hydrochloride	n/a	7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Psyadon Pharmaceuticals, Inc.
1107	Eculizumab	n/a	9/21/2000	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc.
1108	eculizumab	n/a	6/12/2014	Treatment of Myasthenia Gravis.	Alexion Pharmaceuticals, Inc.
1109	eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Alexion Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1110	eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1111	eculizumab	Soliris	1/10/2014	Prevention of delayed graft function after renal transplantation	Alexion Pharmaceuticals, Inc.
1112	eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.
1113	eculizumab	n/a	3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc.
1114	eculizumab	Soliris	10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1115	Edaravone	n/a	5/12/2015	Treatment of amyotrophic lateral sclerosis	Mitsubishi Tanabe Pharma Corporation
1116	edaravone	n/a	3/12/2015	Treatment of amyotrophic lateral sclerosis	Treeway B.V.
1117	Edotreotide	Onalta(TM)	7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)
1118	efaproxiral	n/a	7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Allos Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1119	Efdispo (tm)	Efdispo (Tm)	1/15/2013	Treatment of Ewings Sarcoma.	TDP Biotherapeutics, Inc.
1120	Eflornithine	n/a	9/29/2006	Treatment of anaplastic glioma	Orbus Therapeutics, Inc.
1121	eflornithine	n/a	2/4/2011	Treatment of Familial Adenomatous Polyposis	Cancer Prevention Pharmaceuticals
1122	eflornithine	n/a	11/23/2010	Treatment of neuroblastoma	Cancer Prevention Pharmaceutical, Inc.
1123	Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel
1124	eflornithine HCL	n/a	4/7/2015	Treatment of gastric cancer	Cancer Prevention Pharmaceuticals, Inc.
1125	eflornithine plus sulindac	n/a	1/22/2013	Treatment of familial adenomatous polyposis	Cancer Prevention Pharmaceuticals, Inc.
1126	eicosapentaenoic acid	n/a	3/8/2011	Treatment of familial adenomatous polyposis	S.L.A. Pharma Ltd. (UK)
1127	elacytarabine	n/a	6/18/2008	Treatment of acute myeloid leukemia (AML)	Clavis Pharma ASA
1128	Elcatonin	n/a	9/25/1995	Intrathecal treatment of intractable pain.	Innapharma, Inc.
1129	Elesclomol	n/a	12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Synta Pharmaceuticals Corporation
1130	eliglustat	Cerdelga	9/17/2008	Treatment of Type I Gaucher disease	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1131	elosulfase alfa	Vimizim	5/15/2009	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	BioMarin Pharmaceutical Inc.
1132	elotuzumab	n/a	9/1/2011	Treatment of multiple myeloma	Bristol-Myers Squibb Company
1133	eltoprazine HCl	n/a	2/8/2016	Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.	Amarantus BioScience Holdings, Inc.
1134	eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	Novartis Pharmaceuticals Corp.
1135	eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	Novartis Pharmaceuticals Corp.
1136	emricasan	n/a	11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Conatus Pharmaceuticals Inc.
1137	Enadoline hydrochloride	n/a	1/28/1997	Treatment of severe head injury.	Warner-Lambert Company
1138	enalapril maleate (powder for oral solution)	Epaned	1/30/2013	Treatment of hypertension in pediatric patients	Silvergate Pharmaceuticals, Inc.
1139	Encapsulated porcine islet preparation	Betarx	7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx
1140	encapsulated spores from fecal microbiota	n/a	8/19/2015	Treatment of recurrent Clostridium difficile infection (CDI)	Seres Health, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1141	enchochleate amphotericin B	n/a	1/10/2014	Treatment of visceral leishmaniasis	Aquarius Biotechnologies, Inc.
1142	encorafenib	n/a	11/19/2013	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Array BioPharmas, Inc.
1143	encorafenib + binimetinib	n/a	11/19/2013	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Array BioPharma, Inc.
1144	Endothelin receptor B antagonist	n/a	1/21/2016	Treatment of malignant melanoma Stages IIB to IV.	ENB Therapeutics, LLC
1145	Engineered variant of recombinant human fibroblast growth factor 19	n/a	2/6/2014	Treatment of primary biliary cirrhosis	NGM Biopharmaceuticals, Inc.
1146	eniluracil	n/a	12/15/2005	Treatment of hepatocellular carcinoma.	Adherex Technologies, Inc.
1147	ensituximab	n/a	10/21/2010	Treatment of pancreatic cancer.	Neogenix Oncology, Inc.
1148	entrectinib;N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	12/22/2014	Treatment of neuroblastoma	Ignyta, Inc.
1149	Enzastaurin	n/a	9/19/2005	Treatment of glioblastoma multiforme	Denovo Biopharma LLC
1150	enzastaurin	n/a	3/4/2009	Treatment of diffuse large B-cell lymphoma	Denovo Biopharma LLC
1151	epacadostat	n/a	2/11/2016	Treatment of stage IIB-IV melanoma.	Incyte Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1152	Epidermal growth factor (human)	n/a	10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision
1153	Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company
1154	Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc.
1155	Epoetin alfa	n/a	12/20/1993	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev.,
1156	Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Amgen, Inc.
1157	Epoetin alpha	Procrit	8/27/1987	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute
1158	Epoetin alpha	Procrit	3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute
1159	Epoetin beta	Marogen	10/22/1987	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc.
1160	Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc.
1161	epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1162	epratuzumab	Lymphocide	7/13/1998	Treatment of non-Hodgkin's lymphoma	Immunomedics, Inc.
1163	epratuzumab	n/a	9/30/2008	Treatment of acute lymphoblastic leukemia	Immunomedics, Inc.
1164	Eprodinate	Kiacta(Tm)	4/6/1999	Treatment of secondary amyloidosis	C. T. Development America, Inc.
1165	Epstein-Barr virus-specific autologous cytotoxic T lymphocytes	n/a	6/12/2014	Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma)	FFCanVac Pte Ltd
1166	eptifibatide and iloprost	n/a	4/20/2012	Treatment of purpura fulminans	Thrombologic
1167	erdosteine	n/a	12/20/2013	Treatment of bronchiectasis.	Alitair Pharmaceuticals, Inc.
1168	eribulin mesylate	Halaven	5/14/2012	Treatment of soft tissue sarcoma	Eisai Inc.
1169	Erlotinib Hydrochloride	Tarceva	7/18/2003	Treatment of malignant gliomas	Genentech, Inc
1170	Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Jazz Pharmaceuticals, Inc.
1171	Erythropoietin (recombinant human)	n/a	8/19/1987	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp
1172	E-selectin antagonist	n/a	5/13/2015	Treatment of acute myeloid leukemia (AML)	GlycoMimetics, Inc.
1173	estradiol Gel	n/a	10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Ascend Therapeutics US, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1174	etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation
1175	etarfolatide	n/a	2/16/2000	For the identification of ovarian carcinomas	Endocyte, Inc.
1176	eteplirsen	n/a	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Sarepta Therapeutics, Inc.
1177	ethanolamine	Ethamolin	1/17/2014	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	QOL Medical, LLC
1178	Ethanolamine oleate	Ethamolin	3/22/1984	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	QOL Medical
1179	ethiodized oil injection	Lipiodol	9/26/2013	Management of patients with known hepatocellular carcinoma (HCC)	Guerbet LLC
1180	Ethyl eicosapentaenoate	n/a	4/6/2000	Treatment of Huntington's disease.	Laxdale Ltd.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1181	Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc.
1182	Etiocholanedione	n/a	11/3/1995	Treatment of aplastic anemia.	SuperGen, Inc.
1183	Etiocholanedione	n/a	5/7/1996	Treatment of Prader-Willi syndrome.	SuperGen, Inc.
1184	etirinotecan pegol	n/a	4/18/2011	Treatment of ovarian cancer.	Nektar Therapeutics
1185	everolimus	Afinitor	7/23/2012	Treatment of hepatocellular carcinoma	Novartis Pharmaceuticals Corporation
1186	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangiioleiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
1187	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
1188	everolimus	n/a	6/2/2014	Treatment of diffuse large B-cell lymphoma	Novartis Pharmaceuticals Corp.
1189	everolimus ointment	n/a	9/10/2015	Topical treatment of Tuberous Sclerosis Complex-related skin lesions	Aucta Pharmaceuticals, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1190	evinacumab	n/a	2/8/2016	Treat of homozygous familial hypercholesterolemia.	Regeneron Pharmaceuticals, Inc.
1191	evolocumab	Repatha	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Amgen Inc.
1192	Ex vivo cultured adult human mesenchymal stem cells	Prochymal(R)	12/14/2005	Treatment of acute graft versus host disease	Mesoblast, Inc.
1193	ex vivo cultured human mesenchymal stromal cells	n/a	5/8/2014	Prevention of graft rejection following solid organ transplantation	iCell Science AB
1194	Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn
1195	exendin-(9-39)	n/a	6/1/2011	Treatment of congenital hyperinsulinemic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children	The Children's Hospital of Philadelphia
1196	Exisulind	n/a	2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	OSI Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1197	Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	BioMarin Pharmaceutical, Inc.
1198	Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	BioMarin Pharmaceutical, Inc.
1199	Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/2009	Treatment of Duchenne Muscular Dystrophy.	BioMarin Pharmaceutical, Inc.
1200	Exon 52 specific phosphorothiate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	BioMarin Pharmaceutical, Inc.
1201	exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	BioMarin Pharmaceutical, Inc.
1202	Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	BioMarin Pharmaceutical, Inc.
1203	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Intercytex Ltd.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1204	expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/2013	Treatment of retinitis pigmentosa	ReNeuron Ltd
1205	Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass	n/a	5/14/2012	Treatment of multiple myeloma	Unicorn Pacific Corporation
1206	extract of sorghum bicolor extract	n/a	11/19/2012	Treatment of sickle cell disease	Invenux, LLC
1207	ex-vivo cultered adult human mesenchymal stem cells	Prochymal(R)	4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Mesoblast, Inc.
1208	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	TCA Cellular Therapy, LLC
1209	ezatiostat hydrochloride	Telintra	1/9/2013	Treatment of myelodysplastic syndrome	Telik, Inc.
1210	Facilitated DNA Plasmid Vaccine	n/a	3/8/1995	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics
1211	factor VIII mimetic bispecific antibody	n/a	1/10/2014	Treatment of hemophilia A	Genentech
1212	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	5/21/2003	Treatment of congenital FXIII deficiency	Novo Nordisk Pharmaceuticals, INC.
1213	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
1214	Fampridine	Neurelan	6/2/1997	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1215	farletuzumab	n/a	6/16/2006	Treatment of ovarian cancer	Morphotek, Inc.
1216	fecal microbiota	n/a	3/10/2014	Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease)	Rebiotx, Inc.
1217	Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories
1218	fenfluramine HCl	Brabafen	12/20/2013	For the Treatment of Dravet Syndrome	Zogenix, Inc.
1219	Fenobam hydrochloride	n/a	11/20/2006	Treatment of fragile X syndrome	Neuropharm, Ltd.
1220	Fenretinide	n/a	4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	McGill University
1221	Fenretinide	n/a	10/5/2005	Treatment of neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
1222	fenretinide	n/a	9/4/2013	Treatment of peripheral T-cell lymphoma	CerRx, Inc.
1223	fenretinide	n/a	9/4/2013	Treatment of cutaneous T-cell lymphoma	CerRx, Inc.
1224	fenretinide	n/a	2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Cancer Research UK
1225	ferric hexacyanoferrate (II) "Prussian Blue"	n/a	6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1226	ferumoxytol	n/a	4/6/2012	For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)	ArsNova Partners, LLC
1227	ferumoxytol	Feraheme	4/29/2011	For use in MR imaging for the mangement of brain tumors	Edward A. Neuwelt, MD
1228	ferumoxytol	n/a	10/7/2011	For use in magnetic resonance imaging in brain metastases	Oregon Health & Science University
1229	fialuridine	n/a	7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc.
1230	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34	n/a	2/1/2007	Treatment of solitary (unicameral) bone cysts	Kuros Biosurgery AG
1231	Fibrinogen (human)	n/a	8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation
1232	Fibronectin (human plasma derived)	n/a	9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1233	Fibronectin Peptide	n/a	6/29/2011	Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.	NeoMatrix Formulations, Inc.
1234	fidaxomicin	Dificid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Optimer Pharmaceuticals, Inc.
1235	filanesib	n/a	5/6/2014	Treatment of multiple myeloma.	Array BioPharma, Inc.
1236	Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm ³).	Amgen, Inc.
1237	Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc.
1238	Filgrastim	Neupogen	11/7/1996	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc.
1239	Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc.
1240	filgrastim	n/a	1/27/2015	Treatment of amyotrophic lateral sclerosis (ALS)	Neurovision Pharma GmbH

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1241	filgrastim	Neupogen	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
1242	filociclovir	n/a	11/29/2010	Treatment of active cytomegalovirus infections	Microbiotix, Inc.
1243	fingolimod	n/a	4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Novartis Pharmaceutical Corporation
1244	firtecan pegol	n/a	4/18/2011	Treatment of neuroblastoma.	Enzon Pharmaceuticals, Inc.
1245	FliC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Cleveland BioLabs, Inc.
1246	Floxuridine, FUDR	n/a	12/22/2004	Intraperitoneal treatment of gastric cancer.	Franco Muggia, M.D.
1247	flubendazole	n/a	1/23/2014	Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.	Janssen Research and Development, LLC
1248	flubendazole	n/a	10/25/2013	Treatment of onchocerciasis caused by Onchocerca volvulus	Janssen Research & Development, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1249	fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)	n/a	4/7/2015	For the diagnosis of glioma	Blue Earth Diagnostics Ltd.
1250	Fludarabine phosphate	Fludara	4/18/1989	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc.
1251	Fludarabine phosphate	Fludara	4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc.
1252	Fludarabine phosphate oral tablets	n/a	12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Sanofi-Aventis U.S., Inc.
1253	Flunarizine	Sibelium	1/6/1986	Treatment of alternating hemiplegia.	Janssen Research Foundation
1254	flunarizine hydrochloride	n/a	6/24/2013	Treatment of alternating hemiplegia	Marathon Pharmaceuticals, LLC
1255	Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, Inc.
1256	Fluorouracil	n/a	4/18/1990	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc.
1257	Fluorouracil	n/a	6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1258	Fluorouracil	n/a	10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
1259	Fluoxetine	Prozac	4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Hollander, Eric MD
1260	Fluoxetine	Prozac	4/30/1999	Treatment of autism.	Neuropharm, Ltd.
1261	fluticasone propionate	n/a	1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Forest Laboratories, Inc.
1262	fluticasone propionate	n/a	12/29/2015	Treatment of eosinophilic esophagitis	Banner Life Sciences, LLC
1263	Follitropin alfa, recombinant	Gonal-F	12/21/1998	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	EMD Serono, Inc.
1264	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1265	fosbretabulin tromethamine	n/a	12/29/2015	Treatment of neuroendocrine tumors	OXiGENE, Inc.
1266	fosfomycin/tobramycin	n/a	11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	CURx Pharmaceuticals, Inc.
1267	Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company
1268	fostamatinib disodium	n/a	8/25/2015	Treatment of immune thrombocytopenic purpura	Rigel Pharmaceuticals, INC.
1269	FTV1+GDP-fucose	n/a	3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	America Stem Cell, Inc.
1270	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
1271	Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	NovImmune S.A.
1272	fully human IgG2 monoclonal antibody that binds insulin receptors	n/a	10/25/2013	Treatment of congenital hyperinsulinism	BIOBLAST PHARMA LTD.
1273	fully human IgG2 monoclonal antibody that binds insulin receptors	n/a	6/9/2015	Treatment of congenital hyperinsulinism	XOMA (US) LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1274	fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/2013	Treatment of growth hormone deficiency	Versartis, Inc.
1275	Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Edimer Pharmaceuticals, Inc.
1276	G17DT Immunogen	Gastrimmune(Tm)	7/10/2002	Treatment of adenocarcinoma of the pancreas	Cancer Advances, Inc.
1277	G17DT Immunogen	Gastrimmune(Tm)	7/18/2002	Treatment of gastric cancer	Cancer Advances, Inc.
1278	gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Depomed, Inc.
1279	gabapentin	Neurontin	7/5/1995	Treatment of amyotrophic lateral sclerosis	Warner-Lambert Company
1280	gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	XenoPort, Inc.
1281	Gallium (68Ga) edotreotide	n/a	7/1/2015	Diagnostic for the clinical management of neuroendocrine tumors.	Advanced Accelerator Applications, USA

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1282	Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide	n/a	12/31/2013	Diagnostic for the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumors	Advanced Accelerator Applications
1283	Gallium-68 (DOTA0-Phe1-Tyr3)octreotide	n/a	10/25/2013	The management of neuroendocrine tumors	University of Iowa Hospital & Clinics
1284	Gamma hydroxybutyrate	n/a	12/3/1987	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc.
1285	Gammalinolenic acid	n/a	7/27/1994	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D.
1286	Ganaxolone	n/a	5/25/1994	Treatment of infantile spasms.	Marinus Pharmaceuticals, Inc.
1287	ganaxolone	n/a	3/24/2015	Treatment of Protocadherin 19 (PCDH19) female epilepsy.	Marinus Pharmaceuticals, Inc.
1288	ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Sirion Therapeutics, Inc.
1289	Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products
1290	ganitumab	n/a	11/23/2010	Treatment of pancreatic cancer.	Amgen

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1291	Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/2009	Treatment of pancreatic cancer	Astrimmune Ltd.
1292	gefitinib	Iressa	8/26/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	AstraZeneca Pharmaceuticals LP
1293	gemcabene	n/a	2/6/2014	Treatment of homozygous familial hypercholesterolemia	Gemphire Therapeutics, Inc.
1294	gemcitabine	n/a	12/30/2015	Treatment of upper tract urothelial carcinoma	TARIS Biomedical LLC
1295	gemcitabine	n/a	1/11/2016	Treatment of cholangiocarcinoma.	InnoPharmax, Inc.
1296	gemcitabine ready-to-use	n/a	6/24/2015	Treatment of ovarian cancer	Sun Pharmaceutical Industries Ltd.
1297	gemcitabine ready-to-use	n/a	6/24/2015	Treatment of pancreatic cancer	Sun Pharmaceutical Industries Ltd.
1298	Gemtuzumab zogamicin	Mylotarg	11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories
1299	gene encoding chimeric CD40 ligand	n/a	2/4/2009	Treatment of chronic lymphocytic leukemia	Memgen, LLC
1300	genetically engineered herpes simplex virus (G207)	n/a	4/29/2002	Treatment of malignant glioma	Aettis, Inc.
1301	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/1997	Treatment of Crohn's disease.	Celltech Chiroscience Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1302	Geneticin	n/a	6/6/2005	Treatment of amoebiasis.	ProcesScience, Inc (PSI)
1303	Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc.
1304	Gentamicin liposome injection	Maitec	7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc.
1305	gevokizumab	n/a	2/21/2014	Treatment of pyoderma gangrenosum	XOMA (US) LLC
1306	gevokizumab	n/a	7/27/2010	Treatment of Behcet's disease	XOMA (US) LLC
1307	gevokizumab	n/a	8/20/2012	Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis	XOMA (US) LLC
1308	givinostat	n/a	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Italfarmaco SpA
1309	Glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA
1310	glatiramer acetate	Copaxone	11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Teva Neurosciences, Inc.
1311	Glatiramer acetate for injection	Copaxone	6/5/2001	Treatment of primary-progressive multiple sclerosis	Teva Pharmaceuticals USA
1312	glioma derived cell lysates and irradiated cells	n/a	1/12/2011	Treatment of glioma.	Epitopoietic Research Corp.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1313	glucagon	n/a	12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Biodel, Inc.
1314	glucagon infusion	G-Pump (Tm)	9/25/2014	Prevention of chronic, severe hypoglycemia related to congenital hyperinsulinism	Xeris Pharmaceuticals, Inc.
1315	glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	BTG International Inc.
1316	glufosfamide	n/a	9/18/2006	For treatment of pancreatic cancer.	Eleison Pharmaceuticals LLC
1317	Glutamine	Nutrestore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Emmaus Medical, Inc.
1318	Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/2010	Treatment of glioma	to-BBB technologies BV
1319	glyburide	n/a	2/8/2016	Treatment of acute subarachnoid hemorrhage	Remedy Pharmaceuticals, Inc.
1320	glyburide	n/a	9/29/2015	Treatment of acute spinal cord injury	Remedy Pharmaceuticals, Inc.
1321	glycylafilin	n/a	8/22/2008	Prevention of delayed graft function after solid organ transplantation	ProtAffin Biotechnologie AG

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1322	glycerol phenylbutyrate	Ravicti	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Horizon Pharma, Inc.
1323	Glyceryl tri (4-phenylbutyrate)	n/a	5/24/2005	Treatment of spinal muscular atrophy	Ucyclyd Pharma, Inc
1324	Glyceryl trioleate and glyceryl trierucate	n/a	2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D.
1325	glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Shionogi, Inc.
1326	glycopyrrolate 2%	n/a	6/17/2010	Treatment of Frey's syndrome	Wellesley Therapeutics, Inc.
1327	glycosylated recombinant human interleukin-7	n/a	9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Cytheris, Inc.
1328	glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/2013	Treatment of Fragile X Syndrome	Neuren Pharmaceuticals, Ltd.
1329	glycyl-L-2-methylpropyl-L-glutamic acid	n/a	2/11/2015	Treatment of Rett syndrome	Neuren Pharmaceuticals, Ltd.
1330	Glyeraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/2010	Treatment of pediatric multiple sclerosis	BPT Pharmaceuticals, Inc.
1331	GNE Lipoplex	n/a	11/13/2008	Treatment of hereditary inclusion body myopathy-2	Gradalis, Inc.
1332	GNE plasmid(H001)	n/a	3/26/2010	Treatment of hereditary inclusion body myopathy type 2	HIBM Research Group
1333	golimumab	Simponi	3/16/2012	Treatment of pediatric ulcerative colitis	Janssen Biotech, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1334	golimumab	Simponi Aria	4/2/2015	Treatment of polyarticular juvenile idiopathic arthritis in pediatric patients (0 through 16 years of age)	Janssen Research & Development, LLC
1335	golnerminogene pradenovec	Tnferade(Tm) Biologic	10/28/2009	Treatment of pancreatic cancer.	GenVec, Inc.
1336	Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc.
1337	Gossypol	n/a	10/22/1990	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D.
1338	Gp100 adenoviral gene therapy	n/a	3/25/1997	Treatment of metastatic melanoma.	Genzyme Corporation
1339	granulocyte macrophage colony stimulating factor	n/a	8/27/2008	Treatment of cystic fibrosis	DrugRecure Aps
1340	granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF	n/a	7/24/2013	Treatment of soft tissue sarcoma	Oncos Therapeutics
1341	Growth hormone releasing factor	n/a	8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Valeant Pharmaceuticals North America
1342	growth hormone releasing hormone, 1-44 human amide	n/a	2/23/2016	Treatment of growth hormone deficiency	Hollenbeck Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1343	guadecitabine	n/a	9/29/2015	Treatment of acute myeloid leukemia.	Astex Pharmaceuticals, Inc.
1344	guanfacine	Tenex	8/5/1999	Treatment of fragile X syndrome.	Watson Laboratories, Inc.
1345	gusperimus trihydrochloride	n/a	6/29/2011	Treatment of Wegener's granulomatosis	Nordic Group B.V.
1346	GVAX melanoma	n/a	12/23/2010	Treatment of stage IIb to IV melanoma	Aduro BioTech, Inc.
1347	glyceryl tri (4-pheynlybutyrate)	n/a	9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Hyperion Therapeutics, Inc.
1348	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminy-(D)arginyl-(D)arginine acetate salt	n/a	12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	CanBas Company, Ltd.
1349	Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals
1350	Halofuginone	Stenorol	2/7/2000	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd.
1351	halofuginone hydrobromide	n/a	10/13/2011	Treatment of Duchenne Muscular Dystrophy	Halo Theraeputics, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1352	Hanferon	Hanferon	3/9/2012	Treatment of Behcet's disease	HanAll BioPharma Co., Ltd.
1353	Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Surgeon General of the U. S. Army
1354	heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/2004	Active tuberculosis	Cadila Pharmaceuticals Limited, Inc.
1355	heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc.
1356	heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Cadila Pharmaceuticals Limited
1357	heat killed whole cell mycobacterium obuense	n/a	9/23/2014	Treatment of pancreatic cancer	Immodulon Therapeutics Limited
1358	Heat Shock Protein (hsp60) antigen	Diapep277	5/21/2012	For use in type 1 diabetic mellitus patients with residual beta-cell function	Andromeda Biotech, LTD
1359	Heat Shock Protein 70	n/a	3/18/2011	Treatment of amyotrophic lateral sclerosis	ALS Biopharma, LLC
1360	hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist	n/a	8/27/2014	Hematopoietic support in patients with acute lymphoblastic leukemia (ALL)	Novartis Pharmaceuticals Corporation
1361	Heme arginate	Normosang	3/10/1988	Treatment of symptomatic stage of acute porphyria.	Orphan Europe SARL

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1362	Heme arginate	Normosang	3/1/1994	Treatment of myelodysplastic syndromes.	Orphan Europe
1363	Hemin	Panhematin	3/16/1984	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyrin.	Abbott Laboratories
1364	Hemin and zinc mesoporphyrin	Hemex	12/20/1993	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D.
1365	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/2007	Treatment of cardiogenic shock	Apex Bioscience, Inc.
1366	heparan sulfate mimetic	n/a	5/29/2014	Treatment of pancreatic cancer	Momenta Pharmaceuticals, Inc.
1367	heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	n/a	10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	BioArctic Neuroscience AB
1368	Heparin sodium	n/a	6/29/2006	Treatment of cystic fibrosis	Ockham Biotech Limited
1369	Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/2006	Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams	Trillium Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1370	hepatitis B immune globulin (human)	Hepagam	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Cangene Corporation
1371	Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Biotest Pharmaceuticals Corporation
1372	hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Green Cross Corp.
1373	Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Biotest Pharmaceuticals Corporation
1374	hepcortespernolisimut-L	n/a	12/17/2014	Treatment of hepatocellular carcinoma	Immunitor, Inc.
1375	Heptadecasodium salt of an 18-base residue phosphorothioate oligonucleotide	n/a	4/18/2011	Treatment of spinal muscular atrophy	Isis Pharmaceuticals, Inc.
1376	herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter	n/a	12/23/2014	Treatment of pancreatic cancer	Karcinolys S.A.S.
1377	Herpes simplex virus gene	n/a	10/16/1992	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc.
1378	heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/2012	Treatment of urea cycle disorders	Promethera Biosciences
1379	heterologous human liver derived progenitor cells	n/a	3/9/2012	Treatment of Crigler-Najjar syndrome	Promethera Biosciences
1380	hexasodium phytate	n/a	12/2/2012	Treatment of calciophylaxis	Laboratoris Sanifit, S.L.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1381	HIRMAb-IDS	n/a	5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	ArmaGen Technologies, Inc.
1382	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2	n/a	1/13/2016	Treatment of retinal detachment	ONL Therapeutics, Inc
1383	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/2013	Treatment of retinal detachment	ONL Therapeutics, Inc
1384	Histamine	Ceplene	12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	EpiCept Corporation
1385	Histamine	Maxamine	2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	EpiCept Corporation
1386	Histrelin	n/a	5/3/1991	Treatment of acute intermittent porphyria, hereditary coproporphyrinuria, and variegated porphyria.	Anderson, Karl E., M.D.
1387	Histrelin	Supprelin La	11/18/2005	Treatment of central precocious puberty	Endo Pharmaceuticals Solutions, Inc.
1388	Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
1389	HLA-A2-selective gp100-specific T cell redirector	n/a	1/21/2016	Treatment of uveal melanoma.	Immunocore Ltd
1390	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/1999	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated
1391	H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/2012	Treatment of Kaposi sarcoma	Immuno Tech, Inc.
1392	homoharringtonine	n/a	2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1393	HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Gliknik, Inc.
1394	HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	ISA Therapeutics BV
1395	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alya-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/2013	Treatment of subarachnoid hemorrhage	NoNO, Inc.
1396	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH	n/a	4/11/2014	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	NoNO, Inc.
1397	Hu1D10, humanized monoclonal antibody	Remitogen	11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	PDL BioPharma, Inc.
1398	human allogeneic bone marrow derived osteoblastic cells	Allob	1/10/2014	Treatment of osteonecrosis	Bone Therapeutics SA
1399	human allogeneic bone marrow derived osteoblastic cells	n/a	11/9/2015	Treatment of osteogenesis imperfecta.	Bone Therapeutics SA
1400	Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells	n/a	9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Mesoblast, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1401	Human alpha 2,6 sialyltransferase adenoviral gene therapy	n/a	4/4/2005	Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.	Falk Center for Molecular Therapeutics
1402	Human anti-CD30 monoclonal antibody	n/a	9/27/2004	Treatment of Hodgkin's disease	Bristol-Myers Squibb, Inc.
1403	human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/2004	Treatment of mycosis fungoides	Emergent Product Development Seattle, LLC
1404	human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/2008	Treatment of multiple myeloma	BioInvent International AB
1405	Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/2008	Treatment of osteonecrosis	Bone Therapeutics S.A.
1406	human coagulation factor VIII	Octanate	12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	OCTAPHARMA USA, Inc.
1407	human coagulation factor XI	Hemoleven	11/8/2007	Treatment of severe congenital Factor XI deficiency.	Laboratoire francais du Fractionnement et des Biot
1408	human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI)	n/a	11/3/2015	Treatment of patients with cystic fibrosis.	Shire

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1409	Human cytomegalovirus immunoglobulin	n/a	12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Biotest Pharmaceuticals Corporation
1410	Human factor X	Coagadex	11/8/2007	Treatment of hereditary factor X deficiency	Bio Products Laboratory
1411	human fibrinogen concentrate, pasteurized	Riastap	3/13/2008	Treatment of fibrinogen deficient patients.	CSL Behring, LLC
1412	human fully IgG1 antibody specific for CD33	n/a	6/19/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
1413	human gammaglobulin	Oralgam	11/14/2003	Treatment of idiopathic inflammatory myopathies	Latona Life Sciences, Inc.
1414	human gammaglobulin	Oralgam	5/25/2001	Treatment for juvenile rheumatoid arthritis	Latona Life Sciences, Inc.
1415	human gammaglobulin	Oralgam	9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Latona Life Sciences, Inc.
1416	human glial restricted progenitor cells and their progeny	Q-Cells	9/11/2013	Treatment of amyotrophic lateral sclerosis	Q Therapeutics, Inc.
1417	human haptoglobin	n/a	11/19/2013	Treatment of sickle cell disease	BioProducts Laboratory Limited
1418	Human Hemin	n/a	8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Borders Technology Management Ltd

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1419	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/2011	Treatment of acute liver failure	Alfact Innovation SAS
1420	human heterologous liver cells	n/a	2/14/2011	Treatment of urea cycle disorders	Cytonet GmbH & Co. KG
1421	human IgG1k monoclonal antibody	n/a	10/16/2013	Treatment of systemic sclerosis	MedImmune
1422	Human immune globulin	Flebogamma(R) 5% Dif	3/29/2006	Treatment of post-polio syndrome	Instituto Grifols, S.A.
1423	Human immunoglobulin anti-CD30 monoclonal antibody	n/a	1/10/2006	Treatment of CD30+ T-cell lymphoma	Bristol-Myers Squibb
1424	human insulin (rDNA)	n/a	4/6/2015	Treatment of short bowel syndrome (SBS).	Nutrinia, Ltd.
1425	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Orban Biotech, LLC
1426	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Stemline Therapeutics, Inc.
1427	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/2011	Treatment of acute myeloid leukemia.	Stemline Therapeutics, Inc.
1428	human laminin-111	n/a	9/23/2011	Treatment of merosin (laminin-alpha2) deficient congenital muscular dystrophy type 1A.	Prothelia, Inc.
1429	human leukocyte antigen-A2 restricted peptides	n/a	1/26/2015	Treatment of glioma.	Stemline Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1430	human leukocyte-derived cytokine mixture	n/a	7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	IRX Therapeutics, Inc.
1431	human MHC non-restricted cytotoxic T-cell line	n/a	7/6/2012	Treatment of ovarian cancer	Galileo Research srl
1432	Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F	n/a	5/29/2014	Treatment of glioblastoma multiforme	AbbVie, Inc.
1433	Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CuraGen Corporation
1434	human monoclonal antibody against human interleukin 13 (IL-13)	n/a	10/15/2013	Treatment of eosinophilic esophagitis	Novartis Pharmaceuticals Corporaton
1435	human monoclonal antibody directed against active plasma kallikrein	n/a	11/26/2013	Treatment of hereditary angioedema (HAE)	Dyax Corporation
1436	Human monoclonal antibody directed against serotype O11 Pseudomonas aeruginosa	Aerumab 11	9/18/2006	Treatment of hospital acquired pneumonia caused by serotype O11 positive Pseudomonas aeruginosa	Kenta Biotech Limited
1437	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Kenta Biotech Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1438	Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	n/a	12/16/2013	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Omeros Corporation
1439	Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/2010	Treatment of ovarian cancer	Ortho Biotech
1440	human monoclonal antibody targeting human sclerostin	n/a	2/29/2016	Treatment of osteogenesis imperfecta.	Mereo Biopharma 3 Limited
1441	human monoclonal anti-PA antibody	n/a	10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Emergent Product Development Gaithersburg, Inc.
1442	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Octapharma USA, Inc.
1443	Human plasma derived conagulation protein-Factor XI	n/a	4/30/2014	For the treatment of congenital Factor XI deficiency	Cambryn Biologics
1444	human plasminogen	n/a	6/7/2010	Treatment of ligneous conjunctivitis	Kedrion, S.p.A.
1445	human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Prophylix Pharma AS

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1446	Human prothrombin complex concentrate	Octaplex	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Octapharma USA, Inc.
1447	human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor	n/a	7/6/2012	Treatment of idiopathic pulmonary fibrosis	FibroGen, Inc.
1448	Human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interleukin-17A	n/a	2/4/2016	Treatment of pediatric (0 through 16 years of age) juvenile idiopathic arthritis (JIA) categories excluding systemic JIA	AbbVie, Inc.
1449	human recombinant mesencephalic, astrocyte derived neurotrophic factor	n/a	12/22/2014	Treatment of retinitis pigmentosa	Amarantus BioScience Holdings, Inc.
1450	human retinal progenitor cells	n/a	7/23/2012	Treatment of retinitis pigmentosa	jCyte, Inc.
1451	human soluble receptor-Fc fusion protein that targets human activin A	n/a	10/14/2015	Treatment of ovarian cancer.	Atara Biotherapeutics
1452	human spinal cord derived neural stem cells	n/a	2/4/2011	Treatment of amyotrophic lateral sclerosis	Neuralstem, Inc.
1453	Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/2006	Treatment of pancreatic cancer	GemVax A/S

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1454	Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/1989	Treatment of AIDS.	MicroGeneSys, Inc.
1455	human trivalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3)	n/a	10/22/2014	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
1456	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/2009	Treatment of liver cancer	Molecular Medicine S.p.A. (Molmed)
1457	human umbilical cord blood-derived mesenchymal stem cells	Pneumostem	11/26/2013	Prevention of bronchopulmonary dysplasia	MEDIPOST America, Inc.
1458	Human Wilms tumor protein 1 peptides	n/a	12/23/2015	Treatment of acute myeloid leukemia	SELLAS Life Sciences Group
1459	Human wilms tumor protein 1 peptides	n/a	2/23/2016	treatment of mesothelioma.	SELLAS Life Sciences Group
1460	Human/Murine Chimeric Monoclonal antibody to Endoglin	n/a	1/20/2016	Treatment of soft tissue sarcoma.	Tracon Pharmaceuticals, Inc.
1461	Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/2013	Treatment of neuroblastoma	Memorial Sloan-Kettering Cancer Center

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1462	humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19	n/a	2/10/2016	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	MedImmune, LLC
1463	Humanized anti-CD3 monoclonal antibody	n/a	9/29/2006	Treatment of recent-onset Type I diabetes	MacroGenics, Inc.
1464	humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	n/a	6/30/2014	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chugai Pharma USA, LLC
1465	Humanized anti-tac	Zenapax	3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc.
1466	humanized Fc engineered monoclonal antibody against CD19	n/a	4/29/2014	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	MorphoSys AG
1467	humanized Fc engineered monoclonal antibody against CD19	n/a	12/1/2014	Treatment of diffuse large B-cell lymphoma.	MorphoSys AG
1468	humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Prothena Therapeutics Limited
1469	humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/2011	Treatment of follicular lymphoma	MENTRIK Biotech, LLC
1470	humanized IgG2 antibody	n/a	7/22/2008	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Selexys Pharmaceuticals Corp.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1471	humanized IgG4 monoclonal antibody	n/a	12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ transplantation	Opsona Therapeutics
1472	humanized immunoglobulin monoclonal antibody against CD38	n/a	5/22/2014	Treatment of multiple myeloma.	Sanofi U.S. Services, Inc.
1473	humanized monoclonal antibodies hu1B7 and hu11E6	n/a	9/11/2014	Treatment of Bordetella pertussis	Synthetic Biologics, Inc.
1474	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/2010	Treatment of idiopathic pulmonary fibrosis	Biogen Idec, Inc.
1475	humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47	n/a	8/20/2015	Treatment of acute myeloid (myelogenous) leukemia.	Stanford University
1476	humanized monoclonal antibody that targets the alpha-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473)	n/a	5/5/2015	Treatment of acute myeloid leukemia	Janssen Research & Development, LLC
1477	humanized monoclonal antibody to tissue factor	n/a	4/26/2011	Treatment of pancreatic cancer.	Morphotek, Inc.
1478	Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/2011	Treatment of soft tissue sarcoma	Morphotek

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1479	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Stromedix, Inc.
1480	humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/2011	Treatment of chronic lymphocytic leukemia	Emergent Product Development Seattle, LLC
1481	humanized, afucosylated IgG1 kappa monoclonal antibody	n/a	12/3/2009	Treatment of scleroderma	MedImmune
1482	hyaluronic acid	n/a	3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	CoTherix
1483	Hydralazine	n/a	4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Bioniche Pharma USA LLC
1484	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of myelodysplastic syndrome	Neolpharma S.A.DE C.V.
1485	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of cutaneous T-cell lymphoma.	Neolpharma S.A.DE C.V.
1486	hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO)	n/a	3/9/2015	Treatment of amyotrophic lateral sclerosis.	Alsonex Pty Ltd
1487	hydrocortisone modified release capsules	Chronocort	3/18/2015	Treatment of congenital adrenal hyperpasia	Diurnal Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1488	hydrocortisone modified release capsules	Chronocort(R)	9/3/2015	Treatment of adrenal insufficiency.	Diurnal Ltd.
1489	hydrocortisone modified release tabs	Duocort	6/18/2008	Treatment of adrenal insufficiency	Shire ViroPharma, Inc.
1490	hydrocortisone oral granules	Infacort(R)	5/13/2015	Treatment of pediatric adrenal insufficiency (0 through 16 years of age).	Diurnal Limited
1491	Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	SERB, S.A.
1492	Hydroxocobalamin	n/a	9/22/2000	Treatment of acute cyanide poisoning	Jazz Pharmaceuticals
1493	hydroxycarbamide (hydroxyurea)	Siklos	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	addmedica Laboratories
1494	hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	KV Pharmaceutical Company
1495	Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/2010	Treatment of Niemann Pick Disease, Type C	Sphingo Biotech, LLC
1496	Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute
1497	hydroxyurea	Pedroxia	3/16/2015	Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.	Ebelle D'Ebelle Pharmaceuticals LLC
1498	hydroxyurea	n/a	4/15/2005	Treatment of pediatric patients with sickle cell anemia.	UPM Pharmaceuticals, Inc.
1499	Hypericin	n/a	8/3/2000	Treatment of glioblastoma multiforme.	HyBiopharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1500	Hypericin	n/a	2/7/2000	Treatment of cutaneous T-cell lymphoma.	Soligenix, Inc.
1501	Hypothiocyanite and lactoferrin	Meveol	11/5/2009	Treatment of cystic fibrosis	Alaxia Biotechnologies Sante
1502	I(131)-TM-601 (chlorotoxin)	n/a	2/14/2002	Treatment of malignant glioma	Morphotek, Inc.
1503	ibalizumab	n/a	10/20/2014	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	TaiMed Biologics, Inc.
1504	ibrutumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Spectrum Pharmaceuticals, Inc.
1505	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, Inc.
1506	ibrutinib	Imbruvica	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Pharmacyclics, Inc.
1507	ibrutinib	n/a	5/30/2013	Treatment of small lymphocytic lymphoma	Pharmacyclics, Inc.
1508	ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma	Pharmacyclics, Inc.
1509	ibrutinib	n/a	10/23/2013	Treatment of diffuse large B-cell lymphoma	Pharmacyclics, Inc.
1510	ibrutinib	n/a	5/16/2013	Treatment of multiple myeloma	Pharmacyclics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1511	ibrutinib	Imbruvica	2/2/2016	Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)	Pharmacyclics, Inc.
1512	ibrutinib	n/a	9/8/2014	Treatment of follicular lymphoma	Pharmacyclics, Inc.
1513	ibrutinib	Imbruvica	2/5/2015	Treatment of nodal marginal zone lymphoma	Pharmacyclics, Inc.
1514	ibrutinib	Imbruvica	2/5/2015	Treatment of splenic marginal zone lymphoma	Pharmacyclics, Inc.
1515	ibudilast	n/a	6/1/2015	Treatment of Krabbe disease.	MediciNova, Inc.
1516	Ibuprofen i.v. solution	Salprofen	10/29/1996	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC
1517	Ibuprofen lysine	Neoprofen	10/29/1996	Treatment of patent ductus arteriosus	Lundbeck, Inc.
1518	icatibant	Firazyr	11/25/2003	Treatment of angioedema	Shire Orphan Therapies
1519	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation
1520	Idarubicin HCl for injection	Idamycin	7/25/1988	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1521	idarucizumab	n/a	5/28/2015	To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure	Boehringer Ingelheim Pharmaceuticals, Inc.
1522	idebenone	n/a	5/22/2009	Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)	Santhera Pharmaceuticals Limited
1523	idebenone	n/a	10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Santhera Pharmaceuticals Limited
1524	idebenone	n/a	3/25/2004	Treatment of Friedreich's ataxia	Santhera Pharmaceuticals LLC
1525	idebenone	n/a	2/16/2007	Treatment of Duchenne muscular dystrophy	Santhera Pharmaceuticals Limited
1526	idelalisib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
1527	idelalisib	Zydelig	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Gilead Sciences, Inc.
1528	idelalisib	Zydelig	9/26/2013	Treatment of follicular lymphoma	Gilead Sciences, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1529	idelalisib	n/a	9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia	Gilead Sciences, Inc.
1530	idelalisib	n/a	10/15/2013	Treatment of extranodal marginal zone lymphoma	Gilead Sciences, Inc.
1531	idelalisib	n/a	10/15/2013	Treatment of nodal marginal zone lymphoma.	Gilead Sciences, Inc.
1532	idelalisib	n/a	10/15/2013	Treatment of splenic marginal zone lymphoma	Gilead Sciences, Inc.
1533	Idoxuridine	n/a	4/8/1996	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc.
1534	IDUA-HIRMAb fusion protein	Agt-181	1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	ArmaGen Technologies, Inc.
1535	idursulfase	Elaprased	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Shire Human Genetic Therapies, Inc.
1536	idursulfase beta	n/a	2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Green Cross Corp.
1537	idursulfase IT	n/a	9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Shire Human Genetic Therapies
1538	iduvec	n/a	1/21/2011	Treatment of Mucopolysaccharidosis Type I	Zebraic Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1539	iferanserin (S-MPEC)	n/a	12/13/2010	For use in pulmonary arterial hypertension.	Sam Amer & Company, Inc.
1540	Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute
1541	ifosfamide	n/a	8/7/1985	Treatment of soft tissue and bone sarcomas	Bristol-Myers Squibb Company
1542	IgG1 chimeric monoclonal antibody	n/a	6/22/2011	Treatment of multiple myeloma.	Immune System Therapeutics Ltd
1543	IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/2013	Treatment of malignant glioma	Activartis Biotech GmbH
1544	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/2000	Treatment of astrocytic glioma.	Medicenna Therapeutics, Inc.
1545	iloprost	n/a	4/6/2012	Treatment of pulmonary arterial hypertension	Algorithm Sciences, LLC
1546	Iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	CoTherix, Inc.
1547	Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals Corporation
1548	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
1549	Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Novartis Pharmaceuticals Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1550	Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Novartis Pharmaceuticals Corporation
1551	Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Novartis Pharmaceuticals Corporation
1552	imatinib mesylate	n/a	5/6/2014	Treatment of progressive multifocal leukencephalopathy	Inhibikase Therapeutics, Inc.
1553	imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Novartis Pharmaceuticals Corporation
1554	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
1555	Imciromab pentetate	Myoscint	1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
1556	imetelstat	n/a	12/23/2015	Treatment of myelodysplastic syndrome	Janssen Research & Development, LLC
1557	imetelstat	n/a	6/11/2015	Treatment of myelofibrosis	Janssen Research & Development, LLC
1558	Imexon	n/a	11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation
1559	imexon	Amplimexon	8/12/2005	Treatment of ovarian cancer.	AmpliMed Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1560	Imiglucerase	Cerezyme	11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation
1561	Imiquimod	n/a	12/3/2014	Treatment of carcinoma in situ (CIS) of the urinary bladder	Telormedix SA
1562	Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Vital Therapies, Inc.
1563	Immune Globulin (Human)	Gamunex(R)-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Grifols Therapeutics, Inc.
1564	immune globulin (human)	n/a	3/2/2010	Treatment of Guillain-Barre syndrome	Octapharma USA, Inc.
1565	Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/2004	Treatment of the West Nile virus infection	OMRIX Biopharmaceuticals, Ltd.
1566	immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Baxalta US, Inc.
1567	Immune Globulin Intravenous (human)	Carimune Nf	5/4/2004	Treatment for Guillain Barre Syndrome	ZLB Bioplasma AG
1568	Immune globulin intravenous, human	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation
1569	immune globulin intraveous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Bio Products Laboratory

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1570	Immune Globulin Subcutaneous (Human), 20% Liquid	Hizentra	8/18/2014	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	CSL Behring
1571	immunoglobulin G degrading enzyme of Streptococcus pyogenes	n/a	9/10/2015	Prevention of antibody mediated organ rejection in solid organ transplant patients.	Hansa Medical AB
1572	immunologically active synthetic peptides	n/a	6/1/2015	Treatment of Hemophilia A	Apitope International NV
1573	Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation
1574	Imported fire ant venom, allergenic extract	n/a	5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.
1575	Inalimarev and falimarev	n/a	1/10/2006	Treatment of adenocarcinoma of the pancreas	Therion Biologics Corporation
1576	inBreath airway transplant system	n/a	9/4/2014	To restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection	Harvard Apparatus Regenerative Technology, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1577	Indium-111 pentetreotide	Neuroendomedix	6/16/2006	Treatment of neuroendocrine tumors	Radiolotope Therapy of America (RITA) Foundation
1578	Inecalcitol	n/a	5/14/2014	Treatment of chronic lymphocytic leukemia	Hybrigenics, S.A.
1579	inecalcitol	n/a	8/3/2015	Treatment of acute myeloid leukemia.	Hybrigenics, S.A.
1580	Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc.
1581	Infliximab	Remicade	5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc.
1582	infliximab	Remicade	10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
1583	infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Centocor, Inc.
1584	infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Janssen Biotech Inc.
1585	inhibitor of microRNA-451	n/a	2/4/2011	Treatment of polycythemia vera	miRagen Therapeutics, Inc.
1586	Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST	n/a	10/2/2014	Treatment of gastrointestinal stromal tumors (GIST)	Deciphera Pharmaceuticals, LLC
1587	Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/2010	Treatment of hemophilia A and hemophilia B.	Baxter Healthcare Corporation, Baxter BioScience
1588	inolimomab	Leukotac	10/23/2002	Treatment of graft versus host disease	Jazz Pharmaceuticals
1589	Inosine pranobex	Isoprinosine	9/20/1988	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1590	inotuzumab ozogamicin	n/a	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Pfizer, Inc.
1591	insecticidal toxin derived from Bacillus thuringiensis	n/a	9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	University of California, San Diego
1592	Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc.
1593	Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc.
1594	Interferon alfa-2a (recombinant)	Roferon-A	10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
1595	Interferon alfa-2a (recombinant)	Roferon-A	5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc.
1596	Interferon alfa-2a (recombinant)	Roferon-A	5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1597	Interferon alfa-2a (recombinant)	Roferon-A	4/18/1988	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc.
1598	Interferon alfa-2a (recombinant)	Roferon-A	5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc.
1599	Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1600	Interferon beta-1a	Rebif	3/11/1996	Treatment of patients with secondary progressive multiple sclerosis.	EMD Serono, Inc.
1601	Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Biogen, Inc.
1602	Interferon beta-1a (recombinant human)	n/a	7/24/1992	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc.
1603	Interferon beta-1a (recombinant)	Rebif	12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
1604	Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories
1605	Interferon gamma	n/a	10/11/2007	Treatment of idiopathic pulmonary fibrosis	mondoBIOTECH Laboratories AG
1606	interferon gamma	n/a	11/4/2011	Treatment of Friedreich's ataxia	Roberto Testi, MD
1607	Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Horizon Pharma Ireland Limited
1608	Interferon gamma-1b	Actimmune	12/4/1995	Treatment of renal cell carcinoma.	Horizon Pharma Ireland Limited
1609	Interferon gamma-1b	Actimmune	9/30/1996	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	Horizon Pharma Ireland Limited
1610	interferon gamma-1b	Actimmune	10/1/2014	Treatment of Friedreich's Ataxia	Horizon Pharma Ireland Limited
1611	Interferon-alfa-1b	n/a	4/17/2001	Treatment of multiple myeloma	Ernest C.Borden

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1612	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/2012	Treatment of chronic hepatitis D	Medgenics, Inc.
1613	interleukin-1 receptor antagonist anakinra	Kineret	9/15/2015	Treatment of Still's disease including systemic juvenile idiopathic arthritis and adult-onset Still's disease.	Swedish Orphan Biovitrum AB
1614	Interleukin-1 receptor antagonist, human recombinant	Antril	9/23/1991	Treatment of juvenile rheumatoid arthritis.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1615	Interleukin-1 receptor antagonist, human recombinant	Antril	10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1616	Interleukin-1 Trap	n/a	4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Regeneron Pharmaceuticals, Inc.
1617	Interleukin-2	Teceleukin	5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1618	Interleukin-2	Teleleukin	2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
1619	Interleukin-2	Teceleukin	2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1620	Interleukin-2	Teceleukin	5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1621	Intraoral fluoride releasing system	lfrs	7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc.
1622	intravenous carbamazepine	n/a	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Lundbeck LLC
1623	Intravenous immune globulin	Vitigam	7/26/2007	Treatment of Stage IIB to IV malignant melanoma	GammaCan Ltd.
1624	Intravenous immune globulin (human) 10%	Octagam(R)	7/31/2008	Treatment of stiff-person syndrome	Octapharma USA, Inc.
1625	intraventricular nimodipine	n/a	5/28/2015	Treatment of subarachnoid hemorrhage	Edge Therapeutics, Inc.
1626	iobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	GE Healthcare, Inc.
1627	iobenguane I 123	Adreview	12/1/2006	For the diagnosis of pheochromocytomas	GE Healthcare, Inc.
1628	iobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Molecular Insight Pharmaceuticals
1629	iobenguane I 131	n/a	7/5/2007	Treatment of neuroendocrine tumors	Jubilant DraxImage, Inc.
1630	iobenguane Sulfate I-123	Omaclear	10/17/2005	For scintigraphic detection, localization and staging of neuroblastoma.	Brogan Pharmaceuticals, LLC
1631	iobenguane sulfate I-123	Omaclear	10/21/2005	For the detection, localization, and staging of pheochromocytomas.	Brogan Pharmaceuticals, Inc.
1632	Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/1984	For use in adrenal cortical imaging.	David E. Kuhl, M.D.
1633	Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1634	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab') ₂ bispecific monoclonal antibody	Pentacea	2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C.
1635	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	131ichtnt-1	2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc.
1636	Ipatasertib	n/a	4/30/2014	For the treatment of gastric cancer including cancer of the gastro-esophageal junction.	Genentech, Inc.
1637	ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Pharmaceutical Research Insti
1638	iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeitische Fabrik GMBH & Co, KG
1639	isavuconazonium sulfate	Cresemba	5/6/2013	Treatment of invasive aspergillosis	Astellas Pharma Global Development Inc.
1640	isavuconazonium sulfate	n/a	10/20/2014	Treatment of invasive candidiasis/candidemia	Astellas Pharma Global Development, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1641	isavuconazonium sulfate	Cresemba	10/25/2013	Treatment of zygomycosis	Astellas Pharma Global Development Inc.
1642	Isobutyramide	Isobutyramide Oral Solution	12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D.
1643	Isobutyramide	n/a	5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation
1644	isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor	n/a	6/9/2015	Treatment of acute myeloid leukemia (AML)	Agios Pharmaceuticals, Inc.
1645	isocitrate dehydrogenase 2-mutant inhibitor	n/a	6/12/2014	Treatment of acute myelogenous leukemia	Celgene Corporation
1646	isofagomine tartrate	n/a	1/10/2006	Treatment of Gaucher disease	Amicus Therapeutics, Inc.
1647	isotretinoin	n/a	4/10/2014	Treatment of congenital ichthyosis	Patagonia Pharmaceuticals, LLC
1648	Itraconazole suspension	n/a	10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Fairfield Clinical Trials, LLC
1649	ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Vertex Pharmaceuticals, Inc.
1650	ixazomib citrate	n/a	2/18/2011	Treatment of multiple myeloma	Millennium Pharmaceuticals
1651	Japanese encephalitis vaccine (live, attenuated)	n/a	5/19/1999	Prevention of Japanese encephalitis.	Glovax Co., Ltd.
1652	Japanese encephalitis vaccine, inactivated, adsorbed	Ixiaro	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Intercell AG

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1653	ketotifen	n/a	2/25/2015	Treatment of mastocytosis	Melbourne Laboratories LLC
1654	Kre-Celazine	n/a	4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	All American Pharmaceutical & Natural Foods Corpor
1655	L. reuteri	n/a	8/1/2013	Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams	Infant Bacterial Therapeutics
1656	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/1994	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc.
1657	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/1996	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc.
1658	L-5 Hydroxytryptophan	n/a	11/1/1984	Treatment of postanoxic intention myoclonus.	Watson Laboratories, Inc.
1659	L-5-hydroxytryptophan	n/a	1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc.
1660	Lactic acid	Aphthaid	6/29/1999	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc.
1661	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)	n/a	1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1662	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	n/a	1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc.
1663	Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis	n/a	3/24/2015	Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams	Sigma-Tau Pharmaceuticals, Inc.
1664	lactobacillus brevis CD2	n/a	10/4/2011	Treatment Behcet's disease	VSL Pharmaceuticals, Inc.
1665	laminin-111 (human)	n/a	7/21/2011	Treatment of Duchenne Muscular Dystrophy	Prothelia, Inc.
1666	L-amino acids, vitamins and minerals combined with omega-3 fatty acids	n/a	1/12/2011	Treatment of patients with pediatric Crohn's disease	Immunopath Profile, Inc.
1667	L-aminocarnityl-succinyl-leucyl- argininal-diethylacetal	n/a	1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	CepTor Corporation
1668	Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development
1669	Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	IPSEN, Inc.
1670	lanreotide acetate	Somatuline Depot	8/25/2011	Treatment of neuroendocrine tumors	Ipsen Biopharmaceuticals, Inc.
1671	lanreotide acetate	n/a	9/8/2011	Treatment of symptoms associated with carcinoid syndrome	Ipsen Biopharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1672	lapatinib	Tykerb	5/29/2009	Treatment of ErbB2 positive gastric cancer	Novartis Pharmaceuticals Corp.
1673	lapatinib ditosylate hydrochloride	Tykerb	5/29/2009	Treatment of ErbB2 positive esophageal cancer	Novartis Pharmaceuticals Corp.
1674	L-arginyl-L-isooleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/2013	Treatment of acute radiation syndrome	Soligenix, Inc.
1675	Laromustine	Cloretazine	3/27/2014	Treatment of acute myelogenous leukemia	Nanotherapeutics, Inc.
1676	laromustine	Onrigin	10/21/2004	Treatment of acute myelogenous leukemia	Vion Pharmaceuticals, Inc.
1677	laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
1678	L-asparaginase	n/a	3/27/2014	Treatment of acute myeloid leukemia	ERYTECH Pharma S.A.
1679	L-asparaginase encapsulated in red blood cells	Graspa	7/6/2012	Treatment of pancreatic cancer.	ERYTECH Pharma
1680	L-asparaginase encapsulated in red blood cells	Graspa	1/6/2010	Treatment of acute lymphoblastic leukemia	Erytech Pharma
1681	late stage human motor neuron progenitors	Motorgraft(Tm)	11/25/2009	Treatment of spinal muscular atrophy	California Stem Cell, Inc.
1682	Latrodectus immune F(ab)2	Analatro	6/18/2001	Treatment of black widow spider envenomations	Instituto Bioclon, S.A. de C.V.
1683	L-baclofen	Neuralgon	1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Osmotica Pharmaceutical Corp.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1684	L-baclofen	n/a	12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Osmotica Pharmaceutical Corp.
1685	L-baclofen	n/a	7/13/1990	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D.
1686	L-baclofen	n/a	1/6/1998	Treatment of trigeminal neuralgia	Osmotica Pharmaceutical Corp.
1687	L-cycloserine	n/a	8/1/1989	Treatment of Gaucher's disease.	Lev, Meir M.D.
1688	L-cysteine	n/a	5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Brigham and Women's Hospital
1689	lebrikizumab	n/a	3/9/2015	Treatment of idiopathic pulmonary fibrosis	Genentech, Inc.
1690	Leflunomide	n/a	10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W.
1691	lenalidomide	Revlimid	3/28/2011	Treatment of diffuse large B-cell lymphoma	Celgene Corporation
1692	lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Celgene Corporation
1693	lenalidomide	Revlimid	4/29/2015	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Celgene Corporation
1694	lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Celgene Corporation
1695	lenalidomide	Revlimid	9/20/2001	Treatment of multiple myeloma	Celgene Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1696	lenalidomide	Revlimid	1/17/2007	Treatment of chronic lymphocytic leukemia	Celgene Corporation
1697	lenalidomide	Revlimid	9/17/2013	Treatment of follicular lymphoma	Celgene Corporation
1698	Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/2010	Treatment of Stargardt disease	Sanofi US Services, Inc.
1699	Lentiviral vector containing the human MY07A gene	Ushstat(Tm)	5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Sanofi US Services, Inc.
1700	Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Memorial Sloan-Kettering Cancer Center
1701	lenvatinib	n/a	3/26/2014	Treatment of stage IIB to Stage IV melanoma	Eisai, Inc.
1702	lenvatinib	n/a	3/27/2014	Treatment of hepatocellular carcinoma	Eisai, Inc.
1703	lenvatinib	Lenvima	12/27/2012	Treatment of follicular, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer	Eisai, Inc.
1704	Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel
1705	Lestaurtinib	n/a	3/24/2006	Treatment of acute myeloid leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
1706	lestaurtinib	n/a	9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Teva Branded Pharmaceutical Products R&D, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1707	letermovir	n/a	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Merck Sharpe & Dhome Corporation
1708	Leucovorin	Leucovorin Calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation
1709	Leucovorin	Leucovorin Calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation
1710	leukocyte interleukin	Multikine	5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	CEL-SCI Corporation
1711	leukotriene A4 hydrolase inhibitor	n/a	1/26/2015	Treatment of cystic fibrosis	Celtaxsys, Inc.
1712	Leupeptin	n/a	9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc.
1713	Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Tap Pharmaceuticals, Inc.
1714	levetiracetam	Keppra	4/30/2010	Treatment of neonatal seizures	University of California
1715	Levocarnitine	Carnitor	4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc.
1716	Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1717	Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc.
1718	Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc.
1719	Levocarnitine	Carnitor	11/22/1993	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc.
1720	levocarnitine	Carnitor	11/15/1989	1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity	Sigma-Tau Pharmaceuticals, Inc.
1721	Levodopa and carbidopa	Duodopa	1/18/2000	Treatment of late stage Parkinson's disease	AbbVie, Inc.
1722	Levofloxacin	n/a	2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Forest Research Institute, Inc.
1723	Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Spectrum Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1724	levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Spectrum Pharmaceuticals, Inc.
1725	levomefolate calcium	n/a	2/10/2015	Treatment of megaloblastic anemia caused by folate deficiency	Cox Biosciences LLC
1726	Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation
1727	levothyroxine sodium	n/a	4/26/2011	The preservation of organ function in brain-dead organ donors.	Fera Pharmaceuticals, LLC
1728	L-glutamine	n/a	8/1/2001	Treatment of sickle cell disease	Emmaus Medical, Inc.
1729	L-glutamyl-L-tryptophan	n/a	10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Implicit Bioscience Pty Ltd
1730	Lidocaine patch 5%	Lidoderm Patch	10/24/1995	For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.	Teikoku Pharma USA, Inc.
1731	Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals
1732	liposomal α -galactosylceramide	Lip. Alpha Galactosylceramide	9/28/2012	Prevention of graft-versus-host disease	REGiMMUNE Corporation

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1733	liposomal amikacin	Arikace	3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Insmed, Inc.
1734	liposomal amikacin	Arikace	8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Insmed, Inc.
1735	liposomal amikacin	Arikace	3/25/2013	Treatment infections caused by non-tuberculous mycobacteria	Insmed, Inc.
1736	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc.
1737	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of histoplasmosis.	Fujisawa USA, Inc.
1738	Liposomal amphotericin B	Ambisome	12/6/1996	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc.
1739	Liposomal annamycin	n/a	6/17/2005	Treatment of acute myeloid leukemia	Callisto Pharmaceuticals, Inc.
1740	Liposomal annamycin	n/a	6/17/2005	Treatment of acute lymphoblastic leukemia	Callisto Pharmaceuticals, Inc.
1741	liposomal busulfan	Busulipo	6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation	Pharmalink AB
1742	Liposomal ciprofloxacin for inhalation	n/a	12/27/2006	Management of bronchiectasis	Aradigm Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1743	Liposomal ciprofloxacin for inhalation	n/a	4/19/2006	Management of cystic fibrosis	Aradigm Corporation
1744	liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/2012	For the management of cystic fibrosis	Aradigm Corporation
1745	Liposomal cisplatin	Lipova-Pt	5/23/2006	Treatment of ovarian cancer	Eleison Pharmaceuticals LLC
1746	Liposomal cyclosporin A	Cyclospire	4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D.
1747	liposomal cyclosporine	n/a	5/11/2009	Treatment of bronchiolitis obliterans	PARI Pharma GmbH
1748	liposomal cyclosporine for inhalation	n/a	6/24/2008	Prevention of bronchiolitis obliterans.	PARI Pharma GmbH
1749	Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/2006	Treatment of soft tissue sarcomas	GP-Pharm SA
1750	liposomal encapsulated paclitaxel	n/a	1/21/2015	Treatment of ovarian cancer	Insys Therapeutics, Inc.
1751	liposomal gadodiamide	n/a	11/12/2008	Treatment of glioma.	MedGenesis Therapeutix, Inc.
1752	Liposomal Glutathione	n/a	4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Your Energy Systems, LLC
1753	liposomal irinotecan	n/a	7/21/2011	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1754	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolidpalmitoyl	Immther	6/10/1998	Treatment of Ewing's sarcoma.	Endorex Corp.
1755	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolidpalmitoyl	Immther	6/10/1998	Treatment of osteosarcoma.	Endorex Corp.
1756	Liposomal nystatin	Nyotran	6/13/2000	Treatment of invasive fungal infections.	The University of Texas
1757	liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide	n/a	4/27/2015	Treatment of acute myeloid leukemia	Bio-Path Holdings, Inc.
1758	liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/2003	Treatment of chronic myelogenous leukemia	Bio-Path, Inc.
1759	liposomal topotecan hydrochloride	n/a	10/30/2008	Treatment of gliomas	MedGenesis Therapeutix, Inc.
1760	liposome encapsulated paclitaxel	n/a	12/3/2014	Treatment of gastric cancer	Insys Therapeutics, Inc.
1761	Liposome encapsulated recombinant interleukin-2	n/a	6/20/1994	Treatment of cancers of the kidney and renal pelvis	Oncothyreon Canada, Inc.
1762	Liposome encapsulated recombinant interleukin-2	n/a	11/25/1991	Treatment of brain and CNS tumors.	Oncothyreon Canada, Inc.
1763	lisinopril oral solution	n/a	10/14/2015	Treatment of hypertension in pediatric patients 0 through 16 years of age.	Silergate Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1764	lisinopril oral solution	n/a	1/27/2015	Treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age)	BioRamo, LLC
1765	Lisofylline	n/a	6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc.
1766	listeria monocytogenes	n/a	9/5/2013	Treatment of pancreatic cancer	Aduro BioTech, Inc.
1767	lisuride	n/a	1/17/2013	Treatment of pulmonary arterial hypertension	Sinoxa Pharma GmbH
1768	lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/2010	Treatment of Huntington's disease.	Medesis Pharma
1769	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	5/21/2014	Treatment of osteosarcoma.	Advaxis, Inc.
1770	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Advaxis, Inc.
1771	live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/2010	Treatment of Familial Adenomatous Polyposis	Marina Biotech

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1772	Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38	Not Determined	3/24/2015	Treatment of mesothelioma.	Aduro BioTech, Inc.
1773	LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL	n/a	5/4/2015	Treatment of pancreatic cancer	Lokon Pharma AB
1774	Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc.
1775	lomitapide	n/a	3/3/2011	Treatment of Familial Chylomicronemia	Aegerion Pharmaceuticals, Inc.
1776	lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Aegerion Pharmaceuticals, Inc.
1777	Lonafarnib	n/a	11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Eiger Biopharmaceuticals, Inc.
1778	lonafarnib	n/a	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome	The Progeria Research Foundation, Inc.
1779	long acting recombinantFactor VIIa-CTP3	n/a	2/27/2014	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	PROLOR Biotech, Ltd

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1780	L-ornithine phenylacetate	n/a	4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disease	Ocera Therapeutics, Inc.
1781	losartan	n/a	12/12/2011	Treatment of Marfan Syndrome	National Marfan Foundation
1782	low molecular weight dextran sulfate	lbsolvmir(R)	7/6/2011	Treatment to mobilize progenitor cells prior to stem cell transplantation	TikoMed AB
1783	low molecular weight dextran sulfate	lbsolvmir	10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	TikoMed AB
1784	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Araim Pharmaceuticals, Inc.
1785	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/2009	Prevention of delayed graft function following renal transplant	Araim Pharmaceuticals, Inc.
1786	L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Nyxis Neurotherapies, Inc.
1787	L-tyrosine-L-serine-L-leucine	Cms-024	9/10/2004	Treatment of hepatocellular carcinoma.	CMS Peptides Patent Holding Company Limited
1788	lucerastat	n/a	10/29/2015	Treatment of Fabry Disease.	Actelion Pharmaceuticals Ltd
1789	Lucinactant	Surfaxin(R), Aerosurf(R)	10/21/2010	Treatment of cystic fibrosis.	Discovery Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1790	Lucinactant	Surfaxin	7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc.
1791	Lucinactant	Surfaxin	10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Discovery Laboratories, Inc.
1792	Lucinactant	Surfaxin	5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Discovery Laboratories, Inc
1793	Lucinactant	Surfaxin	10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc.
1794	lumacaftor/ivacaftor	Orkambi	6/30/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
1795	lurbinectedin	n/a	8/20/2012	Treatment of ovarian cancer	PharmaMar USA, Inc.
1796	lutetium (177Lu)-edotreotide	n/a	5/21/2015	Treatment of gastro-entero-pancreatic neuroendocrine tumors	ITG Isotope Technologies Garching GmbH
1797	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Vivendy Therapeutics LTD
1798	lyso-thermosensitive liposomal doxorubicin	Thermodox (R)	3/17/2009	Treatment of hepatocellular carcinoma	Celsion Corporation
1799	MA09-hRPE cells	n/a	2/2/2010	Treatment of Stargardt's macular dystrophy.	Advanced Cell Technology, Inc.
1800	macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Actelion Pharmaceuticals Ltd

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1801	Mafenide acetate solution	Sulfamylon Solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc.
1802	Mafosfamide	n/a	1/21/2003	Treatment of neoplastic meningitis	Baxter Healthcare Corporation
1803	MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Gliknik, Inc.
1804	magnesium lysinate bis eicosapentaenoate	n/a	12/23/2015	Treatment of familial adenomatous polyposis.	Thetis Pharmaceuticals
1805	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be administered	CMC Contrast AB
1806	Manganese superoxide dismutase mimetic	n/a	2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Galera Therapeutics, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1807	Mannitol	Bronchitol	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Pharmaxis Ltd.
1808	mannopentaose phosphate sulfate	n/a	4/27/2004	Treatment of high-risk Stage II, Stage III, and Stage IV melanoma	Medigen Biotechnology Corp.
1809	maribavir	n/a	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	Shire ViroPharma, Inc.
1810	maribavir	n/a	2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	Shire ViroPharma, Inc.
1811	Marijuana	n/a	5/25/1999	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc.
1812	Marizomib	n/a	12/13/2013	Treatment of multiple myeloma	Triphase Research and Development I Corp.
1813	marizomib	n/a	9/21/2015	Treatment of malignant glioma.	Triphase Research & Development I Corp.
1814	masitinib	n/a	9/14/2005	Treatment of mastocytosis	AB Science
1815	masitinib	n/a	4/20/2005	Treatment of malignant gastrointestinal stromal tumors	AB Science
1816	masitinib	n/a	7/21/2009	Treatment of patients with pancreatic cancer	AB Science

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1817	masitinib mesylate	n/a	3/18/2015	Treatment of amyotrophic lateral sclerosis.	AB Science
1818	masitinib mesylate	n/a	9/14/2015	Treatment of gastric cancer including cancer of the gastroesophageal junction	AB Science
1819	Matrix metalloproteinase inhibitor	Galardin	12/5/1991	Treatment of corneal ulcers.	Glycomed, Inc
1820	MaxAdFVIII	n/a	3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics Corporation
1821	maytansinoid conjugated humanized monoclonal antibody against FOLR1	n/a	7/14/2014	Treatment of ovarian cancer	ImmunoGen, Inc.
1822	Mazindol	Sanorex	12/8/1986	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D.
1823	mebendazole	Vermox 500 Mg Chewable Tablets	9/3/2014	Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).	Janssen Pharmaceutical Research & Development, LLC
1824	Mecamylamine	Inversine	10/14/1998	Treatment of Tourette's syndrome.	Targacept, Inc.
1825	Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Ipsen Biopharmaceuticals, Inc.
1826	mecasermin	Iplex	12/3/2007	Treatment of myotonic dystrophy	Insmed, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1827	mecasermin rinfabate	n/a	9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Premacure AB
1828	mecasermin rinfabate	Iplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Insmmed, Inc.
1829	mecasermin rinfabate	Iplex	7/23/2012	Treatment of amyotrophic lateral sclerosis	PCUT BioPartners, Inc.
1830	mecasermin, recombinant human insulin-like growth factor-1	Increlex	9/21/2015	Treatment of Rett Syndrome.	Keck Graduate Institute of Applied Life Sciences
1831	meclorethamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Actelion Pharmaceuticals Ltd.
1832	Medroxyprogesterone acetate	Hematrol	2/22/2001	Treatment of immune thrombocytopenic purpura.	ZaBeCor Pharmaceutical Company, LLC
1833	Mefloquine HCl	Mephaquin	7/22/1987	Treatment and prevention of chloroquine-resistant Falciparummalaria	Mepha AG
1834	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1835	Megestrol acetate	Megace	4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (= \geq 10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute
1836	Melanoma autologous dendritic cell vaccine	n/a	9/6/2006	Treatment of stage IIIb through IV metastatic melanoma	Caladrius Biosciences
1837	Melanoma cell vaccine	Canvaxin	10/13/1994	Treatment of invasive melanoma.	CancerVax Corporation
1838	Melanoma peptide vaccine	n/a	3/29/2005	Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma	Bristol-Myers Squibb Research Inst
1839	Melanoma vaccine	Melacine	12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc.
1840	melarsoprol-hydroxypropylbetadex	n/a	9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,
1841	Melatonin	Circadin	7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Neurim Pharmaceuticals, Ltd.
1842	Melatonin	n/a	11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D.
1843	melatonin	n/a	4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Scharper S.p.A.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1844	meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc.
1845	Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc.
1846	melphalan	n/a	11/19/2012	Treatment of retinoblastoma	Icon Bioscience, Inc.
1847	melphalan	n/a	7/14/2015	Treatment of cholangiocarcinoma.	Delcath Systems, Inc.
1848	melphalan	n/a	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Spectrum Pharmaceuticals, INC.
1849	melphalan	n/a	11/19/2012	Treatment of Stage IIB through IV melanoma	OncoTx, LLC
1850	melphalan flufenamide hydrochloride	n/a	3/16/2015	Treatment of plasma cell myeloma, also referred to as multiple myeloma	Oncopeptides AB
1851	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with cutaneous melanoma.	Delcath Systems, Inc.
1852	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Delcath Systems, Inc.
1853	melphalan hydrochloride	n/a	9/26/2013	Treatment of patients with hepatocellular carcinoma	Delcath Systems, Inc.
1854	melphalan hydrochloride	n/a	5/22/2009	Treatment of neuroendocrine tumors	Delcath Systems, Inc.
1855	Menadione Sodium Bisulfite	n/a	5/14/2014	For the treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1856	menadione sodium bisulfite	n/a	5/14/2014	Treatment of autosomal dominant polycystic liver disease	IC-MedTech Corporation
1857	menaquinone	Menaquinonegold	9/4/2012	Treatment of calciphylaxis	Nu Science Trading, LLC
1858	menatetrenone	Mk4(R)	11/2/2010	Treatment of acute promyelocytic leukemia.	NBI Pharmaceuticals, Inc.
1859	menatetrenone	Mk4	3/17/2011	Treatment of acute myeloid leukemia	NBI Pharmaceuticals, Inc.
1860	menatetrenone	Mk4(R)	11/2/2010	Treatment of hepatocellular carcinoma (HCC).	NBI Pharmaceuticals, Inc.
1861	menatetrenone	Mk4(R)	2/4/2011	Treatment of myelodysplastic syndrome.	NBI Pharmaceuticals, Inc.
1862	menatetrenone and Vitamin D3	n/a	8/22/2011	Treatment of myelodysplastic syndrome	NBI Pharmaceuticals, Inc.
1863	mepivacaine	n/a	1/8/2007	Treatment of postherpetic neuralgia	Relmada Therapeutics, Inc.
1864	mepivacaine	n/a	10/18/2006	Treatment of painful HIV-associated neuropathy	Relmada Therapeutics, Inc.
1865	mepolizumab	n/a	7/14/2011	Treatment of Churg-Strauss Syndrome.	GlaxoSmithKline LLC
1866	mepolizumab	n/a	5/28/2004	For first-line treatment in patients with hypereosinophilic syndrome	GlaxoSmithKline LLC
1867	mercaptopurine oral solution	Purixan	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Nova Laboratories Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1868	mesalamine	Canasa	1/19/2010	Treatment of pediatric ulcerative colitis	Aptalis Pharma US, Inc.
1869	mesalamine and N-acetylcysteine	n/a	9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Altheus Therapeutics, Inc.
1870	mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Shire
1871	mesencephalic, astrocyte-derived neurotrophic factor	n/a	9/10/2015	Treatment of retinal artery occlusion.	Amarantus BioScience Holdings, Inc.
1872	mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	BrainStorm Cell Therapeutics Ltd.
1873	Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation
1874	metadoxine	n/a	12/16/2013	Treatment of Fragile X Syndrome	Alcobra, Inc.
1875	met-enkephalin; Met-N	n/a	2/18/2011	Treatment of pancreatic cancer.	NBI Pharmaceuticals, Inc.
1876	metformin	n/a	5/29/2014	Treatment of pediatric polycystic ovary syndrome	EffRx Pharmaceuticals SA
1877	Methionine/L-methionine	n/a	8/21/1996	Treatment of AIDS myelopathy.	Genopia USA, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1878	Methotrexate	Amethopterin	8/28/2014	Treatment of Myasthenia Gravis	The Universtiy of Kanasa Medical Center
1879	methotrexate	n/a	8/20/2009	Treatment of acute lymphoblastic leukemia	Orbona Pharma Ltd
1880	methotrexate oral liquid formulation	n/a	3/18/2015	Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.	Chesapeake Therapeutics
1881	methotrexate oral solution	n/a	5/28/2015	Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)	Silvergate Pharmaceuticals, Inc.
1882	methotrexate oral solution	n/a	8/27/2015	Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age	Silvergate Pharmaeuticals, Inc.
1883	Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Lederle Laboratories
1884	Methotrexate with laurocapram	Methotrexate/Azone	10/15/1990	Topical treatment of mycosis fungoides.	Echo Therapeutics, Ltd.
1885	Methoxsalen	Uvadex	10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1886	methoxsalen	Uvadex	5/12/1994	For the prevention of acute rejection of cardiac allografts	Therakos, Inc.
1887	Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-Asparaginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[n/a	4/18/2011	Prevention of ischemia reperfusion injury associated with solid organ transplantation	Endotis Pharma
1888	methylene blue	n/a	7/24/2012	Treatment of methemoglobinemia	Fera Pharmaceuticals, LLC
1889	methylene blue injection	n/a	8/11/2012	Treatment of congenital and acquired methemoglobinemia	Luitpold Pharmaceuticals, Inc.
1890	methylene blue0.5%	n/a	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Provepharm SAS
1891	methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/2013	Treatment of cutaneous T-cell lymphoma	TetraLogic Pharmaceuticals
1892	metreleptin	n/a	8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Aegerion Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1893	metreleptin	Myalept	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Aegerion Pharmaceuticals, Inc.
1894	Metronidazole	Metrogel	10/24/1991	Treatment of perioral dermatitis.	Galderma Laboratories, Inc.
1895	metronidazole	n/a	9/17/2008	Treatment of pouchitis	Avivia Project BV
1896	metronidazole	n/a	4/26/2011	Treatment of pouchitis.	S.L.A. Pharma Limited (UK)
1897	Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Galderma Laboratories, Inc.
1898	Metronidazole 10% ointment	n/a	11/8/2007	Topical treatment of active perianal Crohn's disease	SLA Pharma (UK) Ltd
1899	metyrapone	n/a	9/25/2012	Treatment of Cushing's syndrome	Laboratoire HRA Pharma
1900	metyrosine	Demser	7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Cerberus Princeton, LLC
1901	mexiletine	n/a	9/2/2010	Treatment of nondystrophic myotonia	University of Rochester Medical Center
1902	mibefradil	n/a	8/25/2009	Treatment of glioblastoma multiforme.	Cavion, LLC
1903	mibefradil	n/a	10/16/2008	Treatment of pancreatic cancer.	Cavion, LLC
1904	mibefradil	n/a	6/15/2007	Treatment of ovarian cancer	Cavion, LLC
1905	miconazole	n/a	5/22/2014	Treatment of fungal otitis externa (otomycosis)	Hill Dermaceuticals, Inc.
1906	Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1907	Microvesiculated modified glycosylated tissue factor	n/a	10/11/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.	Thrombotargets Corp.
1908	Microvesiculated modified glycosylated tissue factor	n/a	1/25/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients	Thrombotargets Corp.
1909	midazolam	n/a	7/24/2012	Treatment of nerve agent-induced seizures	Meridian Medical Technologies, Inc.
1910	midazolam	n/a	10/20/2009	Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)	Upsher-Smith Laboratories, Inc.
1911	midazolam	n/a	2/4/2016	Treatment of status epilepticus	Meridian Medical Technologies, Inc.
1912	midazolam	n/a	2/8/2016	Treatment of seizures induced by organophosphorous insecticide poisoning.	Meridian Medical Technologies, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1913	midazolam	n/a	5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	UCB, Inc
1914	midazolam	n/a	2/18/2016	Treatment of status epilepticus	Shire Development LLC
1915	Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Shire
1916	Midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Novartis Oncology
1917	Midostaurin	n/a	7/7/2009	Treatment of acute myeloid leukemia	Novartis Pharmaceuticals Corporation
1918	mifamuritide	Junovan	6/5/2001	Treatment of osteosarcoma	Millennium Pharmaceuticals, Inc.
1919	Mifepristone	n/a	2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	HRA Pharma
1920	mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrome	Corcept Therapeutics, Inc.
1921	mifepristone	Korlym	1/14/2016	Treatment of ovarian cancer.	Corcept Therapeutics, Inc.
1922	migalastat hydrochloride	n/a	2/25/2004	Treatment of Fabry Disease	Amicus Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1923	miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd
1924	miglustat	Zavesca (R)	11/12/2008	Treatment of the neurological manifestations of Niemann-Pick disease,type C.	Actelion Pharmaceuticals Ltd
1925	milatuzumab	n/a	3/10/2008	Treatment of multiple myeloma	Immunomedics, Inc.
1926	milatuzumab	n/a	6/24/2008	Treatment of chronic lymphocytic leukemia.	Immunomedics, Inc.
1927	milciclib maleate	n/a	9/20/2012	Treatment of thymic epithelial tumors.	Tiziana Life Sciences PLC
1928	miltefosine	Impavido	10/10/2006	Treatment of leishmaniasis.	Knight Therapeutics (USA)
1929	miltefosine	Miltex/Impavido	3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	ExperGen Drug Development GmbH
1930	Minnelide	Minnelide (Tm)	2/18/2013	Treatment of pancreatic cancer	Minneamrita Therapeutics, LLC
1931	Minocycline hydrochloride	n/a	3/28/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
1932	mipomersen	Kynamro	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Genzyme Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1933	misoprostol	Gymiso	1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Gynuity Health Projects, LLC
1934	Mitoguazone	Apep	3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc.
1935	Mitolactol	n/a	7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Targent, Inc.
1936	Mitolactol	n/a	1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Targent, Inc..
1937	mitomycin	n/a	6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Mobius Therapeutics, LLC
1938	mitomycin	n/a	1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Mobius Therapeutics, LLC
1939	mitomycin	Mitogel	9/8/2014	Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)	TheraCoat, Ltd.
1940	Mitomycin-C	n/a	8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1941	mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mobius Therapeutics, LLC
1942	Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Serono, Inc.
1943	Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Serono, Inc.
1944	Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Serono
1945	Mitoxantrone HCl	Novantrone	7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories
1946	Mixture of 2 anti-rabies humanized monoclonal immunoglobulin (Ig)G1k antibodies	n/a	10/7/2015	Post-exposure prophylaxis against rabies virus infection	Synermore Biologics Co., Ltd
1947	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of acute myelogenous leukemia.	Millennium Pharmaceuticals
1948	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of Myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.
1949	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/1998	Treatment of small cell lung cancer	Immunomedics, Inc.
1950	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc.
1951	Mocetinostat	n/a	6/12/2014	Treatment of myelodysplastic syndrome	Mirati Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1952	mocetinostat	n/a	8/7/2014	Treatment of diffuse large B-cell lymphoma	Mirati Therapeutics, Inc.
1953	MOD-423 hGH analogue	n/a	9/29/2010	Treatment of growth hormone deficiency	OPKO Biologics Ltd.
1954	Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc.
1955	modified a-cobratoxin	n/a	9/1/2015	Treatment of pediatric multiple sclerosis (0 through 16 years of age).	Nutra Pharma Corporation
1956	modified human papillomavirus capsid protein conjugated to a near infrared dye	n/a	4/8/2015	Treatment of uveal melanoma	Aura Biosciences, Inc.
1957	modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/2013	Treatment of achondroplasia	BioMarin Pharmaceutical, Inc.
1958	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Gencia Corporation
1959	mogamulizumab	n/a	11/2/2010	Treatment of peripheral T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.
1960	mogamulizumab	n/a	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.
1961	mogamulizumab	n/a	7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Kyowa Hakko Kirin Pharma, Inc.
1962	monarsen	n/a	11/14/2003	Treatment of myasthenia gravis	Bioline Rx, Ltd.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1963	mongersen	n/a	7/20/2015	Treatment of pediatric Crohn's disease	Celgene Corporation
1964	monoclonal antibody	n/a	1/21/2011	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women.	Theraclone Sciences
1965	monoclonal antibody 11-1F4	n/a	12/7/2009	For use as a radioimaging agent in amyloidosis	Alan Solomon, M.D.
1966	monoclonal antibody 11-1F4	n/a	12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Alan Solomon, M.D.
1967	monoclonal antibody 3F8	n/a	10/16/2008	Treatment of neuroblastoma	United Therapeutics Corporation
1968	monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus	n/a	8/25/2014	Treatment of Ebola virus infection	LeafBio, Inc.
1969	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	MassBiologics-University of MA Medical School
1970	Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/1993	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc.
1971	monoclonal antibody Hu3F8	n/a	1/10/2014	Treatment of osteosarcoma	Memorial Sloan-Kettering Cancer Center

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1972	monoclonal antibody targeting eotaxin-2	n/a	10/29/2015	Treatment of idiopathic pulmonary fibrosis.	ChemomAb, Ltd.
1973	monoclonal antibody targeting eotaxin-2	n/a	1/6/2015	Treatment of systemic sclerosis	ChemomAb, Ltd.
1974	Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/1996	Treatment of epithelial ovarian cancer.	Quest PharmaTech, Inc.
1975	Monolaurin	Glylorin	4/29/1993	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc.
1976	monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C	n/a	7/29/2014	Treatment of pancreatic cancer.	Millennium Pharmaceuticals, Inc.
1977	Mononuclear enriched fraction of human umbilical cord blood	U-Cord-Cell(R)	9/15/2015	Treatment of amyotrophic lateral sclerosis (ALS).	Saneron CCEL Therapeutics, Inc.
1978	Monoctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc.
1979	Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc.
1980	motexafin gadolinium	Xcytrin	1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1981	mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37	n/a	3/24/2015	Treatment of chronic lymphocytic leukemia (CLL).	Boehringer Ingelheim Pharmaceuticals, Inc.
1982	mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/2012	Treatment of neuroblastoma.	APEIRON Biologics AG
1983	moxetumomab pasudotox	n/a	6/28/2013	Treatment of acute lymphoblastic leukemia	MedImmune, LLC
1984	moxetumomab pasudotox	n/a	11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	MedImmune, LLC
1985	moxetumomab pasudotox	n/a	11/15/2007	Treatment of hairy cell leukemia	MedImmune, LLC
1986	moxidectin	n/a	9/29/2010	Treatment of onchocerciasis volvulus in children and adults.	Medicines Development Limited
1987	mPEG-r-crisantaspase	Asparec(Tm)	2/1/2010	Treatment of acute lymphoblastic leukemia.	Jazz Pharmaceuticals, Inc.
1988	MTC-DOX for Injection	n/a	1/3/2001	Treatment of hepatocellular carcinoma	FeRx Incorporated
1989	mTOR kinase inhibitor (CC-223)	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Celgene Corporation
1990	multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200)	n/a	12/7/2015	Treatment of ovarian cancer.	Tapimmune, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1991	Multi-ligand somatostatin analog	n/a	7/27/2004	Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.	Novartis Pharmaceuticals Corporation
1992	Multi-peptide cancer vaccine	n/a	6/23/2013	Treatment of multiple myeloma	OncoPep, Inc.
1993	Multistem(r)	n/a	9/15/2010	Prophylaxis of graft vs host disease	Athersys, Inc.
1994	Multi-vitamin infusion (neonatal formula)	n/a	12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P.
1995	multi-vitamin infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Mayne Pharma (USA) Inc.
1996	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc.
1997	Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	Theragyn	3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1998	murine monoclonal antibody against CD26	Beqedina	2/18/2011	Treatment of graft versus host disease	Adienne S.A.
1999	MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin	n/a	9/23/2014	Treatment of Neuroblastoma	MabVax Therapeutics, Inc.
2000	Mx-dnG1	Rexin-G	6/24/2008	Treatment of osteosarcoma.	Epeius Biotechnologies Corporation
2001	Mx-dnG1	Rexin-G(R)	6/24/2008	Treatment of soft tissue sarcoma	Epeius Biotechnologies Corporation
2002	Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies Corporation
2003	Mycobacterium avium sensitin RS-10	n/a	10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut
2004	mycobacterium vaccae	n/a	8/20/2010	Treatment of tuberculosis	Immodulon Therapeutics Ltd
2005	myo-inositol	n/a	4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Abbott Nutrition

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2006	N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide	n/a	11/17/2014	Treatment of Duchenne muscular dystrophy	Catabasis Pharmaceuticals, Inc.
2007	N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide mesylate salt	n/a	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	AstraZeneca Pharmaceuticals LP
2008	N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxopyrrolidin-1-yl)propyl]-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide	n/a	11/17/2014	Treatment of optic neuritis	Bionure Farma SL
2009	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/2007	Treatment of Hodgkin's lymphoma	Mirati Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2010	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/2008	Treatment of acute myeloid leukemia	Mirati Therapeutics, Inc.
2011	N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide	n/a	10/15/2014	Treatment of AL Amyloidosis	ProteoTech, Inc.
2012	N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	n/a	11/26/2013	Treatment of gliomas	Kinex Pharmaceuticals, Inc.
2013	N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl}oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate	n/a	10/21/2014	Treatment of ovarian cancer	Amgen, Inc.
2014	N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl)-L-cysteinyl-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteinyl-L-arginine amide, cyclic (4-13)-disulfide	n/a	7/6/2012	For use to mobilize hematopoietic stem cells (HSCs) from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	BioLineRx, Ltd.
2015	N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine	n/a	2/18/2016	Treatment of glioma.	Flag Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2016	N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride salt	n/a	3/18/2009	Treatment of acute myeloid leukemia	Ambit Biosciences Corporation
2017	N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine	n/a	10/29/2015	Treatment of malaria.	Donald J. Krogstad, MD
2018	N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl(phenyl)amino}pyrimidin-4-yl)benzamide	n/a	8/5/2010	Treatment of myelofibrosis	Gilead Sciences, Inc.
2019	N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	n/a	10/17/2005	Treatment of multiple myeloma.	AB Science
2020	N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)	n/a	4/6/2012	Treatment of mercury toxicity	CTI Science Limited
2021	N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride	n/a	1/29/2010	Treatment of pancreatic cancer	EMD Serono, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2022	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/12/2011	Treatment of acute myeloid leukemia (AML).	EMD Serono, Inc.
2023	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	1/7/2015	For the treatment of Cushing's Syndrome	Atterocor, Inc.
2024	N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-[[3-(dimethylamino)pyrrolidin-1-yl]methyl]-3-(trifluoromethyl)benzamide	n/a	12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	CytRx Corporation
2025	N-[4-(trifluoromethyl)phenyl]5-methylisoxazole-4-carboxamide	n/a	5/25/1995	Treatment of malignant glioma.	Sugen, Inc.
2026	N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/1996	Treatment of ovarian cancer.	Sugen, Inc.
2027	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/12/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer	Ignyta, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2028	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/3/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer	Ignyta, Inc.
2029	N-[[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide	n/a	2/4/2011	Treatment of tuberculosis.	Sequella, Inc.
2030	N1,N14,-diethyl-3,12,-dihydroxyhomospermine	n/a	8/7/2014	Treatment of pancreatic cancer	Sun BioPharma, Inc.
2031	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/2000	For pancreatic cancer	SmithKline Beecham Pharmaceuticals
2032	N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/2008	Treatment of multiple myeloma	Biotest Pharmaceuticals Corporation
2033	nabumetone	n/a	5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Cook Pharma
2034	N-acetyl cysteine amide	n/a	12/31/2013	Treatment of retinitis pigmentosa	Brighton Biotech, Inc.
2035	N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/2000	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc.
2036	N-acetylcysteine	n/a	9/9/2002	Treatment of acute liver failure	Cumberland Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2037	N-acetylcysteine	n/a	7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Edward A. Neuwelt, MD
2038	N-acetylcysteine and sodium thiosulfate	n/a	8/31/2015	Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).	Edward A. Neuwelt, MD
2039	N-acetylgalactosamine-4-sulfatase, recombinant human	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc.
2040	N-acetyl-glucosamine thiazoline	n/a	2/6/2006	Treatment of adult Tay-Sachs disease	ExSAR Corporation
2041	N-Acetylmannosamine (ManNAc)	n/a	4/5/2010	Treatment of hereditary inclusion body myopathy type 2	Altamira Bio, Inc. (ABIO)
2042	N-acetyl-procainamide	n/a	12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas
2043	N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/2007	Treatment of tuberculosis.	Sequella, Inc.
2044	Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Syntex (USA), Inc.
2045	naloxone	n/a	11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Elorac, Inc.
2046	naltrexone	n/a	2/23/2015	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2047	naltrexone	n/a	1/19/2010	Treatment of Crohn's disease in pediatric patients	TNI BioTech, Inc.
2048	naltrexone	n/a	1/13/2015	Treatment of autoimmune hepatitis	TaiwanJ Pharmaceuticals Co., Ltd.
2049	Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals
2050	naltrexone/clonidine combination	n/a	4/14/2014	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC
2051	nano-diamino-tetraiodothyroacetic acid	n/a	7/9/2015	Treatment of glioblastoma multiforme (GBM)	NanoPharmaceuticals, LLC
2052	nano-diamino-tetraiodothyroacetic acid	n/a	10/28/2015	Treatment of pancreatic cancer	NanoPharmaceuticals, LLC
2053	NanoDTPA(tm)	n/a	6/17/2011	Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium	Nanotherapeutics, Inc.
2054	nanoparticulate paclitaxel	Nanotax(R)	10/6/2015	Treatment of ovarian cancer.	NanOlogy, LLC
2055	naproxcinod	n/a	3/16/2015	Treatment of Duchenne muscular dystrophy.	Nicox SA
2056	Natural human lymphoblastoid interferon-alpha	n/a	8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2057	Natural human lymphoblastoid interferon-alpha	n/a	1/18/2000	Treatment of Behcet's disease	Amarillo Biosciences, Inc.
2058	natural human lymphoblastoid interferon-alpha	n/a	11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.
2059	NDX-peptides	n/a	12/14/2010	Treatment of amyotrophic lateral sclerosis	NeoDiagnostic Research Ltd
2060	Nebacumab	Centoxin	10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc.
2061	necitumumab	n/a	11/20/2015	Treatment of squamous non-small cell lung cancer	Eli Lilly and Company
2062	nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Novartis Pharmaceuticals Corp.
2063	nelarabine	n/a	9/2/1999	Treatment of chronic lymphocytic leukemia.	Novartis Pharmaceuticals Corp.
2064	neostigmine	n/a	3/18/2013	Treatment of acute colonic pseudo-obstruction	Luitpold Pharmaceuticals, Inc.
2065	neostigmine methylsulfate	n/a	2/17/2012	Treatment of Myasthenia Gravis	Luitpold Pharmaceuticals, Inc.
2066	neridronate	n/a	3/25/2013	Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)	Grunenthal USA, Inc.
2067	Neurotrophin-1	n/a	9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2068	Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation
2069	nevirapine	n/a	11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Auritec Pharmaceuticals
2070	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butrylamino)benzamide	n/a	1/13/2012	Treatment of Schwannoma of the central nervous system	Arno Therapeutics, Inc.
2071	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butrylamino)benzamide	n/a	1/13/2012	Treatment of meningioma	Arno Therapeutics, Inc.
2072	Nifedipine	n/a	6/13/1991	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D.
2073	nifurtimox	Lampit	8/5/2010	Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi	Bayer HealthCare Pharmaceuticals, Inc.
2074	nifurtimox	n/a	12/31/2013	Treatment of Chagas disease	MetronomX Therapeutics, LLC
2075	Nikkomycin Z	n/a	2/14/2006	Treatment of coccidioidomycosis	Valley Fever Center for Excellence (1-111 INF)
2076	nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Novartis Pharmaceutical Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2077	nimodipine	Nymalize	9/16/2011	Treatment of subarachnoid hemorrhage.	Arbor Pharmaceuticals, Inc.
2078	Nimotuzumab	n/a	11/17/2004	Treatment of glioma	InnoKeys PTE Ltd.
2079	nimotuzumab	n/a	9/8/2015	Treatment of pancreatic cancer.	InnoCIMab Pte Ltd
2080	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of acute myelogenous leukemia	The Vaccine Company
2081	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	The Vaccine Company
2082	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of chronic myelogenous leukemia.	The Vaccine Company
2083	nintedanib	Ofev	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Boehringer Ingelheim Pharmaceuticals, Inc.
2084	niprisan	Hemoxin	8/15/2003	Treatment of sickle cell disease	Xechem International, Inc.
2085	niraparib	n/a	4/30/2010	Treatment of ovarian cancer	TESARO, Inc.
2086	Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Romark Laboratories, L.C.
2087	nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C.
2088	nitazoxanide	Cryptaz	10/23/2001	Treatment for intestinal amebiasis	Romark Laboratories, L.C.
2089	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB (PUBL)

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2090	Nitisinone	Orfadin	10/19/2001	Treatment of alkaptonuria	Swedish Orphan AB
2091	Nitric oxide	n/a	2/16/2005	Diagnosis of sarcoidosis	SensorMedics Corporation
2092	Nitric oxide	n/a	7/10/1995	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc.
2093	Nitric oxide	n/a	9/11/2013	Treatment of cystic fibrosis	Novoteris, LLC
2094	Nitric oxide	Inomax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc.
2095	Nitric oxide	Inomax	9/27/2004	To reduce the risk of chronic lung disease in premature neonates	INO Therapeutics
2096	nitric oxide	n/a	9/23/2014	Treatment of cystic fibrosis	Advanced Inhalation Therapies Ltd.
2097	nitric oxide	Inomax (R)	9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	INO Therapeutics
2098	nitric oxide	Inomax	12/28/2011	Treatment of pulmonary arterial hypertension	Bellerophon Therapeutics
2099	nitric oxide	n/a	6/18/2012	Treatment of persistent pulmonary hypertension in newborns	GeNO, LLC
2100	Nitroprusside	n/a	2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2101	nivolumab	n/a	8/7/2014	Treatment of Hodgkin lymphoma	Bristol-Myers Squibb Co.
2102	nivolumab	n/a	9/15/2015	Treatment of small cell lung cancer.	Bristol-Myers Squibb Company
2103	nivolumab	Opdivo(R)	9/2/2015	Treatment of hepatocellular carcinoma.	Bristol-Myers Squibb Company
2104	nivolumab	n/a	1/23/2013	Treatment of Stage IIb to IV melanoma	Bristol-Myers Squibb Co.
2105	nivolumab	n/a	8/27/2015	Treatment of glioblastoma	Bristol-Myers Squibb Co
2106	N-Methanocarbathymidine	n/a	10/15/2014	Treatment of neonatal herpes	N & N Pharmaceuticals, Inc.
2107	N-methyl-4-({4-[[{3-methyl(methylsulfonyl)amino]pyrazin-2-yl)methyl]amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride	n/a	7/18/2013	Treatment of mesothelioma	Verastem, Inc.
2108	non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I	n/a	12/15/2014	Treatment of hypoparathyroidism	Chugai Pharma USA, LLC
2109	non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene	At001	12/3/2014	Treatment of x-linked myotubular myopathy	Audentes Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2110	non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase	n/a	12/8/2015	Treatment of Mucopolysaccharidosis Type II	REGENXBIO, Inc.
2111	non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein	n/a	10/20/2014	Treatment of retinitis pigmentosa	RetroSense Therapeutics, LLC
2112	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	12/31/2013	Treatment of leakage from the surgical site following penetrating keratoplasty	US Biotest, Inc.
2113	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	1/31/2014	Treatment of dermal injury due to nuclear/radiation incident	US Biotest, Inc.
2114	noscapine	n/a	12/29/2015	Treatment of amyotrophic lateral sclerosis.	KineMed Inc.
2115	N-t-butylhydroxylamine	n/a	5/12/2015	Treatment of infantile neuronal ceroid lipofuscinosis.	Andrew Lim
2116	N-tert-butyl-3-[(5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/2013	Treatment of polycythemia vera	sanofi-aventis U.S. LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2117	N-tert-butyl-3-[5-methyl-2-{{4-(2-pyridyl-1-ylethoxy)phenyl}amino}pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/2009	Treatment of secondary and primary myelofibrosis	Sanofi-Aventis US, LLC a Sanofi company
2118	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/2009	Treatment of acute myeloid leukemia	Antisoma, Inc.
2119	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/2004	Treatment of pancreatic cancer	Antisoma Research Ltd.
2120	Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/2005	Treatment of renal cell carcinoma	Antisoma Inc.
2121	O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/2013	Treatment of Duchenne Muscular Dystrophy	Vudbenk Life Sciences
2122	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazene-1,1,2-diolate	n/a	12/13/2013	Treatment of multiple myeloma	JSK Therapeutics, Inc.
2123	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1,1,2-diolate	n/a	3/16/2012	Treatment of acute myeloid leukemia	JSK Therapeutics, Inc.
2124	obeticholic acid	n/a	4/9/2008	Treatment of primary biliary cirrhosis	Intercept Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2125	obinutuzumab	Gazyva	4/15/2015	Treatment of follicular lymphoma	Genentech, Inc.
2126	obinutuzumab	Gazyva	6/11/2015	Treatment of splenic marginal zone lymphoma	Genentech, Inc.
2127	obinutuzumab	n/a	2/17/2012	Treatment of diffuse large B cell lymphoma	Genentech, Inc.
2128	obinutuzumab	Gazyva	2/17/2012	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2129	oblimersen	Genasense	8/28/2001	Treatment of acute myelocytic leukemia	Genta, Inc.
2130	oblimersen	Genasense	7/31/2000	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc.
2131	oblimersen	Genasense	8/28/2001	Treatment of chronic lymphocytic leukemia	Genta, Inc.
2132	oblimersen	Genasense	8/28/2001	Treatment of multiple myeloma	Genta, Inc.
2133	Octreotide	Sandostatin Lar	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation
2134	Octreotide	Sandostatin Lar	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation
2135	Octreotide	Sandostatin Lar	8/24/1998	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation
2136	octreotide	Sandostatin Lar	8/5/2010	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
2137	octreotide (oral)	Octreolin(Tm)	6/17/2010	For the oral treatment of acromegaly	Chiasma, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2138	octreotide acetate subcutaneous implant	n/a	12/7/2009	Treatment of acromegaly	Endo Pharmaceuticals Solutions, Inc.
2139	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corp.
2140	Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Allergan, Inc.
2141	ogluflanide disodium	n/a	9/24/2001	Treatment of ovarian cancer	Implicit Bioscience Pty Ltd
2142	olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	AstraZeneca Pharmaceuticals LP
2143	olaptosed pegol	n/a	8/19/2014	Treatment of glioblastoma in conjunction with radiotherapy.	Noxxon Pharma AG
2144	olaratumab	n/a	10/9/2014	Treatment of soft tissue sarcoma	Eli Lilly and Company
2145	oleylphosphocholine	n/a	10/25/2013	Treatment of leishmaniasis	Dafra Pharma International nv
2146	oligodendrocyte progenitor cells	n/a	2/2/2016	Treatment of acute spinal cord injury	Asterias Biotherapeutics
2147	oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	n/a	2/27/2014	Treatment of amyotrophic lateral sclerosis	Genervon Biopharmaceuticals, LLC
2148	olipudase alfa	n/a	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Genzyme Corporation
2149	omacetaine mepesuccinate	n/a	1/12/2009	Treatment of myelodysplastic syndromes	IVAX International GmbH
2150	omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	IVAX International GmbH

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2151	Ombitasvir/Paritaprevir/Ritonavir	Technivie® Tablets	2/24/2016	Treatment of pediatric patients with chronic hepatitis C virus infection	AbbVie Inc.
2152	ombitasvir/paritaprevir/ritonavir and dasabuvir	Viekira Pak	7/16/2015	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	Abbvie, Inc.
2153	ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamide hydrochloride	n/a	3/3/2011	Treatment of soft tissue sarcoma	Sanofi-Aventis U.S., Inc.
2154	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/1995	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals
2155	Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/2000	Treatment of IgA nephropathy.	Pronova Biocare, AS
2156	Omegaven emulsion	Omegaven	2/27/2008	Treatment of parenteral nutrition-associated liver disease	Fresenius Kabi Deutschland GmbH
2157	omeprazole-lansoprazole with buffer	n/a	2/10/2015	Treatment of esophageal ulcers	Effexus Pharmaceuticals, LLC
2158	omigapil	n/a	6/24/2008	Treatment of congenital muscular dystrophy.	Santhera Pharmaceuticals Limited
2159	Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)	n/a	12/22/2014	Treatment of malignant mesothelioma	Oncos Therapeutics

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2160	oncophage	n/a	4/14/2009	Treatment of glioma	Agenus, Inc.
2161	ondansetron inhalation powder	n/a	10/14/2015	Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .	Luxena Pharmaceuticals, Inc.
2162	opioid growth factor	n/a	4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
2163	opium tincture	n/a	12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Valeant Pharmaceuticals International, Inc.
2164	Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc.
2165	oprozomib	n/a	8/25/2014	Treatment of Waldenstrom's macroglobulinemia	Onyx Therapeutics, Inc.
2166	oprozomib	n/a	10/28/2014	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
2167	optically pure phenylalanine derivative	n/a	8/20/2012	Treatment of narcolepsy	Jazz Pharmaceuticals International III Limited
2168	oral unfractionated heparin	n/a	1/29/2004	Treatment of sickle cell disease	TRF Technologies, Inc.
2169	osilodrostat	n/a	9/13/2013	Treatment of Cushing's disease	Novartis Pharmaceuticals corporation
2170	otelixizumab	n/a	2/6/2006	Treatment of new-onset type I diabetes mellitus	GlaxoSmithKline

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2171	OTL38; conjugate of pteroi acid and S0456 near infrared dye	n/a	12/23/2014	Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)	On Target Laboratories, LLC
2172	Oxaliplatin	n/a	10/6/1992	Treatment of ovarian cancer.	Debio Pharm S.A.
2173	oxaloacetate	n/a	7/24/2012	Treatment of gliomas	Terra Biological LLC
2174	Oxaloacetic acid	n/a	11/18/2015	Treatment of amyotrophic lateral sclerosis	Terra Biological LLC
2175	Oxalobacter formigenes	n/a	3/29/2006	Treatment of primary hyperoxaluria	OxThera, Inc.
2176	Oxandrolone	Oxandrin	4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Savient Pharmaceuticals, Inc.
2177	Oxandrolone	Oxandrin	9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp.
2178	oxfendazole	n/a	7/14/2014	Treatment of cysticercosis (including neurocysticercosis)	Robert H. Gilman, MD, DTMH and
2179	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals
2180	Oxymorphone	Numorphan H.P.	3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company
2181	Oxypurinol	n/a	11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp.
2182	oxytocin	n/a	11/24/2014	Treatment of Prader-Willi syndrome	Pr Maithe Tauber

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2183	ozanimod	n/a	12/29/2015	Treatment of pediatric (0 through 16 years of age) ulcerative colitis	Receptos, Inc.
2184	p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt	n/a	3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc.
2185	P140K MGMT transduced human CD34 cells	n/a	1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Lentigen Corporation
2186	p38 mitogen-activated kinase inhibitor	n/a	5/27/2014	Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations	Array BioPharma, Inc.
2187	Paclitaxel	Paxene	4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc.
2188	Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
2189	paclitaxel	n/a	5/1/2009	Treatment of pancreatic cancer	MediGene AG
2190	paclitaxel aqueous gel	Oncogel(TM)	2/1/2008	Treatment of esophageal cancer	BTG International, Inc.
2191	paclitaxel aqueous gel	Oncogel (Tm)	12/23/2008	Treatment of brain cancer.	BTG International Inc.
2192	paclitaxel nanoparticles	n/a	1/2/2013	Treatment of pancreatic cancer	CIRJ Co., Ltd.
2193	paclitaxel poliglumex	Opaxio	9/20/2012	Treatment of glioblastoma multiforme	CTI BioPharma Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2194	paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Abraxis BioScience, LLC
2195	paclitaxel, micellar	Paclical	4/3/2009	Treatment of ovarian cancer	Oasmia Pharmaceutical AB
2196	paclitaxel-coated buttress	n/a	7/15/2014	For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.	AcuityBio, Inc.
2197	pacritinib	n/a	3/13/2008	Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF	CTI BioPharma Corporation
2198	Pafuramidine maleate	n/a	8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Immtech Pharmaceuticals, Inc.
2199	Pafuramidine maleate	n/a	5/14/2007	Treatment of malaria	Immtech Pharmaceuticals, Inc.
2200	pafuramidine maleate	n/a	11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Immtech Pharmaceuticals, Inc.
2201	palovarotene	n/a	7/21/2014	Treatment of fibrodysplasia ossificans progressiva	Clementia Pharmaceuticals, Inc.
2202	panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Novartis Pharmaceuticals Corporation
2203	pantothenate phosphate	n/a	5/4/2015	Treatment of pantothenate kinase associated neurodegeneration (PKAN).	Retrophin, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2204	Papain, trypsin, and chymotrypsin	Wobe-Mugos	12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc.
2205	paquinimod	n/a	1/17/2014	Treatment of systemic sclerosis	Active Biotech AB
2206	parathyroid hormone	Natpara	8/31/2007	Treatment of hypoparathyroidism	NPS Pharmaceuticals, Inc.
2207	paricalcitol	Zemlar	10/27/2015	Treatment of pediatric hyperparathyroidism	Abbvie, inc.
2208	paromomycin	n/a	2/11/2015	Treatment of cutaneous leishmaniasis (Old World and New World)	The Surgeon General, Dept. of the Army
2209	paromomycin sulfate/gentamicin sulfate	n/a	1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Office of the Surgeon General
2210	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc.
2211	pasireotide	n/a	8/25/2009	Treatment of acromegaly	Novartis Pharmaceuticals Corporation
2212	pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Novartis Pharmaceuticals Corporation
2213	pazopanib	n/a	5/6/2013	Treatment of ovarian cancer.	Novartis Pharmaceuticals Corp.
2214	pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	Novartis Pharmaceuticals Corp.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2215	Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Sigma-tau Pharmaceuticals, Inc.
2216	pegargiminase	n/a	7/21/2014	Treatment of mesothelioma.	Polaris Group
2217	Pegaspargase	Oncaspar	10/20/1989	Treatment of acute lymphocytic leukemia.	Baxalta US, Inc.
2218	PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)	n/a	4/2/2015	Treatment of angiosarcoma	Co-D Therapeutics, Inc.
2219	Pegfilgrastim	Neulasta	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
2220	PEG-glucocerebrosidase	Lysodase	12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, NIH
2221	Peginterferon alfa-2a	Pegasys	9/30/1999	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc.
2222	Peginterferon alfa-2a	Pegasys	7/13/1998	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc.
2223	peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Schering-Plough Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2224	PEG-interleukin-2	n/a	2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation
2225	pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Horizon Pharma Rheumatology, LLC
2226	pegsitacase	Uricase-Peg 20	12/3/2009	Treatment of Lesch-Nyhan syndrome.	EnzymeRx, LLC
2227	Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Sensus Corporation
2228	Pegylated arginine deiminase	Melanocid	4/12/1999	Treatment of invasive malignant melanoma.	Polaris Pharmaceuticals, Inc.
2229	pegylated arginine deiminase	Hepacid	3/26/1999	Treatment of hepatocellular carcinoma	Polaris Pharmaceuticals, Inc.
2230	pegylated carboxyhemoglobin	n/a	10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Sangart, Inc.
2231	pegylated carboxyhemoglobin bovine	Sanguinate	1/15/2015	Treatment of the comorbidities associated with Sickle Cell Disease	Prolong Pharmaceuticals, LLC
2232	pegylated granulocyte colony stimulating factor	n/a	4/30/2014	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	PharmaEssentia

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2233	pegylated human recombinant arginase I	n/a	3/16/2015	Treatment of arginase I deficiency (hyperargininemia).	AERase, Inc.
2234	pegylated proline interferon alpha-2b	n/a	4/10/2014	Treatment of myelofibrosis	PharmaEssentia, Corporation
2235	pegylated proline interferon alpha-2b	n/a	4/11/2014	Treatment of essential thrombocythemia	PharmaEssentia, Corporation
2236	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/2012	Treatment of polycythemia vera	PharmaEssentia Corporation
2237	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	KaloBios Pharmaceuticals, Inc.
2238	PEGylated recombinant human hyaluronidase PH20	n/a	10/1/2014	Treatment of pancreatic cancer	Halozyme Therapeutics, Inc.
2239	pelareorep	Reolysin(R)	2/10/2015	Treatment of ovarian cancer	Oncolytics Biotech, Inc.
2240	pelareorep	Reolysin(R)	2/11/2015	Treatment of pancreatic cancer	Oncolytics Biotech, Inc.
2241	pelareorep	Reolysin	4/15/2015	Treatment of malignant glioma	Oncolytics Biotech, Inc.
2242	pelareorep	Reolysin	5/4/2015	Treatment of gastric cancer	Oncolytics Biotech, Inc.
2243	pelareorep	Reolysin	2/24/2015	Treatment of fallopian tube cancer	Oncolytics Biotech, Inc.
2244	pelareorep	Reolysin(R)	2/24/2015	Treatment of primary peritoneal cancer	Oncolytics Biotech, Inc.
2245	Peldesine	n/a	10/5/1993	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2246	pembrolizumab	Keytruda	6/16/2015	Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma	Merck, Sharp & Dohme
2247	pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
2248	pembrolizumab	Ketruda	1/14/2016	Treatment of primary mediastinal B cell lymphoma.	Merck, Sharp & Dohme Corp.
2249	pembrolizumab	Keytruda	2/17/2016	Treatment of multiple myeloma.	Merck, Sharp & Dohme Corp.
2250	pembrolizumab	Keytruda	12/30/2015	Treatment of Hodgkin lymphoma.	Merck, Sharp & Dohme Corp.
2251	pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Eli Lilly and Company
2252	pentagastrin	n/a	5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Medical Defense Technologies, LLC
2253	Pentamidine isethionate	n/a	10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C.
2254	Pentamidine isethionate	Nebupent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc.
2255	Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc.
2256	Pentamidine isethionate (inhalation)	Pneumopent	10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease	Fisons Corporation
2257	pentapeptide with sequence Ac-VSRRR-NH2	n/a	1/13/2015	Treatment of intracerebral hemorrhage	CereNOva, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2258	Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit	Cylexin	7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation
2259	Pentastarch	Pentaspán	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	DuPont Pharmaceuticals
2260	pentetate trisodium	Diethylenetriaminepentacetate	4/12/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
2261	pentetrazol	n/a	9/9/2015	Treatment of idiopathic hypersomnia.	Balance Therapeutics, Inc.
2262	Pentosan polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Alza Corporation
2263	pentosan polysulfate sodium	Lysosan (Tm)	1/5/2015	Treatment of mucopolysaccharidosis (MPS) type VI	Plexcera Therapeutics, LLC
2264	pentosan polysulfate sodium	n/a	11/21/2008	Treatment of sickle cell disease.	TRF Pharma, Inc.
2265	pentosan polysulfate sodium	n/a	9/16/2011	Treatment of sickle cell disease.	Vanguard Therapeutics, Inc.
2266	Pentostatin	Nipent	11/24/1999	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2267	Pentostatin	Nipent	3/27/1998	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc.
2268	Pentostatin	Nipent	1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc.
2269	Pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia.	SuperGen, Inc.
2270	pentoxifylline	n/a	6/14/2012	Treatment of Behcet's disease	Keck Graduate Institute of Applied Life Sciences
2271	Peptide 144 TGF beta-1 inhibitor	n/a	4/27/2006	Treatment of systemic sclerosis	Digna Biotech, S.L.
2272	Peptide 144 TGF beta-1-inhibitor	n/a	4/26/2006	Treatment of localized scleroderma	Digna Biotech, S.L.
2273	Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Rose Pharmaceuticals
2274	peptide YY	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Mondobiotech Laboratories AG
2275	peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	VAXON-Biotech

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2276	peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)	n/a	9/3/2009	Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).	Sarepta Therapeutics, Inc.
2277	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/2011	Treatment of myasthenia gravis	CuraVac Europe SPRL
2278	Peptidomimetic analog of hexarelin	n/a	5/14/2007	Diagnosis of growth hormone deficiency	Aeterna Zentaris GmbH
2279	perampanel	Fycompa	12/7/2012	Treatment of Lennox-Gastaut Syndrome	Eisai, Inc.
2280	peretinoin	n/a	9/23/2011	Treatment of hepatocellular carcinoma.	Kowa Pharmaceutical Europe Co. Ltd.
2281	Perflubron	Liquivent(Tm)	4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	PFC Development/New Alliance Pharmaceutical
2282	perhexiline maleate	n/a	6/14/2012	Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy	Heart Metabolics, Limited.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2283	perifosine	n/a	7/9/2010	Treatment of neuroblastoma	Aeterna Zentaris GmbH
2284	perillyl alcohol	n/a	4/18/2011	Treatment of glioma	NeOnc Technologies, Inc.
2285	pertuzumab	n/a	6/8/2009	Treatment of ovarian cancer	Genentech, Inc.
2286	pertuzumab	n/a	7/12/2013	Treatment of gastric cancer	Genentech, Inc.
2287	pexastimogene devacirepvec	n/a	5/6/2013	Treatment of hepatocellular carcinoma	SillaJen Biotherapeutics, Inc.
2288	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/2012	Treatment of idiopathic thrombocytopenic purpura	PhytoHealth Corporation
2289	PGC-C12E-terlipressin	n/a	12/27/2012	Treatment of ascites due to all etiologies except for cancer	PharmaIN Corporation
2290	phenobarbital sodium injection	n/a	10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent seizures in neonates	Fera Pharmaceuticals, LLC
2291	phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethylethyl) monohydrochloride	n/a	3/16/2015	Treatment of Huntington's disease.	Ipsen Biopharmaceuticals, Inc.
2292	Phenylacetate	n/a	3/6/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
2293	Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/1995	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2294	Phenylbutyrate	n/a	1/19/2000	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc.
2295	phenylephrine	n/a	2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma
2296	phenylephrine	n/a	1/31/2012	Treatment of Tetralogy of Fallot	Luitpold Pharmaceuticals, Inc.
2297	Phosphatidylinositol 3-Kinase "PI3K" Inhibitor	n/a	11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Semafore Pharmaceuticals
2298	phosphorothioate antisense oligonucleotide against EWS-Fli-1	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
2299	phoxilium	n/a	2/14/2014	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Gambro Renal Products, Inc.
2300	picibanil	n/a	5/15/2009	Treatment of patients with lymphatic malformations	Royds Pharmaceuticals, Inc.
2301	picibanil	n/a	3/17/2011	Treatment of lymphatic malformations	Richard Smith, M.D.
2302	Picoplatin	n/a	11/2/2005	Treatment of small cell lung cancer	Poniard Pharmaceuticals
2303	Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc.
2304	Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc.
2305	pirfenidone	Esbriet	3/5/2004	Treatment of idiopathic pulmonary fibrosis	Genentech

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2306	pirfenidone	n/a	11/19/2013	Treatment of systemic sclerosis (including the associated interstitial lung disease)	Genentech, Inc.
2307	pirfenidone	n/a	7/31/2014	Treatment of idiopathic pulmonary fibrosis	Genoa Pharmaceuticals, Inc.
2308	plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent	n/a	6/30/2014	Treatment of cystic fibrosis	Imperial Innovations Limited
2309	Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/2005	Treatment of cystic fibrosis	Copernicus Therapeutics, Inc.
2310	plasmin (human)	n/a	3/30/2009	Treatment of acute peripheral arterial occlusion	Grifols Therapeutics, Inc.
2311	plasminogen (human)	n/a	3/5/2013	Treatment of hypoplasminogenemia, or type I plasminogen deficiency	ProMetic Biotherapeutics, Inc.
2312	pleconaril	n/a	12/22/2014	Treatment of symptomatic entoviral infection in the neonate	AntiVirus Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2313	plerixafor	Mozobil (R)	7/10/2003	For use to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Genzyme Corporation
2314	Plitidepsin	Aplidin	9/30/2004	Treatment of multiple myeloma	PharmaMar USA, Inc.
2315	polidocanol	n/a	2/19/2015	Treatment of congenital venous malformations	Provensis Ltd
2316	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
2317	Poloxamer 188	Florcor	2/22/1990	Treatment of severe burns requiring hospitalization.	CytRx Corporation
2318	Poloxamer 188	n/a	8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation
2319	poloxamer 188	n/a	11/8/2013	Treatment of Acute Limb Ischemia	Mast Therapeutics Inc.
2320	poloxamer 188 (purified)	n/a	6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Mast Therapeutics Inc.
2321	Poloxamer 331	Protox	3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2322	poloxamer-188 NF	n/a	1/19/2010	Treatment of Duchenne muscular dystrophy	Phrixus Pharmaceuticals, Inc.
2323	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc.
2324	Poly I: poly C12U	Ampligen	5/20/1991	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc.
2325	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc.
2326	poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/2013	Treatment of acute encephalitis syndrome	Cour Pharmaceutical Development Company, Inc.
2327	poly-CD-PEG-camptothecin	n/a	5/21/2015	Treatment of ovarian cancer.	Cerulean Pharma, Inc.
2328	polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase	n/a	3/17/2015	Treatment of homocystinuria	Orphan Technologies Limited
2329	Polyethylene glycol-modified uricase	n/a	6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	EnzymeRx, LLC
2330	Polyethylene glycol-modified uricase	Zurase	9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	EnzymeRx, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2331	Polyethylene glycol-modified uricase	Zurase	12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	EnzymeRx, LLC
2332	Poly-ICLC	Hiltonol	3/17/1997	Treatment of primary brain tumors.	Oncovir
2333	polyinosinic-polycytidilic acid	Poly-Iclc	3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir
2334	polyinosinic-polycytidilic acid	Poly-Iclc	8/2/2002	As an adjuvant to smallpox vaccination	Oncovir
2335	polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/2002	Treatment for orthopox virus infections	Oncovir
2336	Polymeric oxygen	n/a	3/25/1992	Treatment of sickle cell anemia.	Capmed USA
2337	polyphenon E	n/a	7/17/2008	Treatment of chronic lymphocytic leukemia	Mitsui Norin Co., Ltd
2338	Polyribonucleotide; Polyribo- inosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/1988	Treatment of AIDS.	Hemispherx Biopharma, Inc.
2339	Polyvalent, shed-antigen melanoma vaccine	n/a	6/9/2006	Treatment of stage IIb to stage IV melanoma	Polynoma LLC
2340	pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Celgene Corporation
2341	pomalidomide	n/a	9/21/2010	Treatment of persons with myeloproliferative neoplasm- associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	Celgene Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2342	ponatinib	Iclusig(R)	3/12/2015	Treatment of gastrointestinal stromal tumors (GIST).	ARIAD Pharmaceuticals, Inc.
2343	ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	ARIAD Pharmaceuticals Inc.
2344	ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ARIAD Pharmaceuticals Inc.
2345	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
2346	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
2347	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2348	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
2349	porcine GM1 ganglioside	n/a	12/3/2012	Treatment of acute spinal cord injury	TRB Chemedica International S.A.
2350	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc.
2351	porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc.
2352	Porfimer sodium	Photofrin	11/18/2004	Treatment of cholangiocarcinoma	Concordia Laboratories, Inc.
2353	Porfimer sodium	Photofrin	11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc.
2354	Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2355	Porfiromycin	Promycin	9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
2356	Porfiromycin	Promycin	3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
2357	Posaconazole	Posoril	7/16/2004	Treatment of zygomycosis	Schering-Plough Corporation
2358	Potassium citrate	Urocit-K	11/1/1984	1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas
2359	Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas
2360	Potassium Iodide Oral Solution	Thyroshield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radioactive iodine	Fleming & Company, Pharmaceuticals
2361	potassium sodium aluminosilicate	n/a	1/8/2007	For treatment of poisoning by or exposure to cesium.	Framework Therapeutics, LLC
2362	pracinostat	n/a	2/27/2014	Treatment of acute myeloid leulemia	MEI Pharma Inc.
2363	pralatrexate	n/a	10/20/2008	Treatment of diffuse large B-cell lymphoma	Allos Therapeutics, Inc.
2364	pralatrexate	Folotyn	7/20/2006	Treatment of T-cell lymphoma	Allos Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2365	pralatrexate	n/a	5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Allos Therapeutics, Inc.
2366	pralatrexate	n/a	10/20/2008	Treatment of follicular lymphoma	Allos Therapeutics, Inc.
2367	pralmorelin hydrochloride	n/a	10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Sella Pharmaceuticals, Inc.
2368	pramipexole	Mirapex	1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Boehringer-Ingelheim Pharmaceuticals, Inc.
2369	prasugrel hydrochloride	Effient	5/26/2015	Treatment of sickle cell disease	Eli Lilly
2370	Primaquine phosphate	n/a	7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc.
2371	pritumumab	n/a	10/28/2014	Treatment of glioma	Nascent Biotech, Inc.
2372	Procarbazine HCl	Matulane	8/8/2006	Treatment of malignant glioma	Sigma-Tau Pharmaceuticals, Inc.
2373	procaspase-activating compound 1	n/a	7/23/2015	Treatment of malignant glioma	Vanquish Oncology, Inc.
2374	profimer sodium	Photofrin(R)	12/2/2011	Treatment of malignant mesothelioma	Concordia Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2375	progesterone	n/a	12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc.
2376	prolactin receptor antagonist	Prolanta	4/15/2013	Treatment of ovarian cancer	Oncolix, Inc.
2377	propagermanium and irbesartan	n/a	12/9/2015	Treatment of focal segmental glomerulosclerosis.	Dimerix Bioscience Ltd.
2378	propranolol	Hemangeol	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Pierre Fabre Dermatologie
2379	propranolol and etodolac	n/a	4/27/2015	Treatment of pancreatic cancer.	Vicus Therapeutics, LLC
2380	propranolol and etodolac	n/a	7/8/2015	Treatment of malignant glioma.	Vicus Therapeutics, LLC
2381	propranolol hydrochloride and etodolac	n/a	2/24/2015	Treatment of hepatocellular carcinoma	Vicus Therapeutics, LLC
2382	Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	LTT Baio-Pharma Co., Ltd
2383	Protaxel	n/a	5/21/2003	Treatment of ovarian cancer	Biophysica, Inc.
2384	Protein C concentrate	Ceprotrin	6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxalta US, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2385	Protein C concentrate	Protein C Concentrate (Human) Vapor Heated, Immuno	6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp.
2386	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
2387	Pulmonary surfactant replacement, porcine	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Chiesi USA, Inc.
2388	purified autologous type 1 regulatory T lymphocytes specific for human type II collagen	n/a	9/1/2015	Treatment of chronic non-infectious uveitis	TxCell SA
2389	purified bovine type collagen	n/a	4/27/2009	Treatment of idiopathic pulmonary fibrosis	ImmuneWorks, Inc.
2390	Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Able Laboratories, Inc.
2391	Purified type II collagen	Colloral	2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2392	PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCA TT 3'	lmt504	11/24/2014	Treatment of rabies virus infections	Mid-Atlantic BioTherapeutics, Inc.
2393	pyridoxine; vitamin B6	n/a	3/3/2011	Treatment of pyridoxine dependent seizures.	NBI Pharmaceuticals, Inc.
2394	pyrimethamine	n/a	8/16/2011	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	ExSAR Corporation
2395	Pyruvate	n/a	2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc
2396	pyrvinium	n/a	1/5/2015	Treatment of familial adenomatous polyposis	StemSynergy Therapeutics, Inc.
2397	quinacrine	n/a	9/28/2012	Treatment of hepatocellular carcinoma	Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur
2398	quinine Sulfate	n/a	6/3/2004	Treatment of malaria	AR Holding Company, Inc.
2399	quinine sulfate	n/a	12/2/2008	Treatment of malaria excluding Plasmodium faliparum	Zydus Pharmaceuticals, Inc.
2400	R-(-)-gossypol	n/a	10/24/2006	Treatment of chronic lymphocytic leukemia.	Ascenta Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2401	R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepine-3-yl]-3-(3-methylaminophenyl)urea	n/a	9/10/2009	Treatment of gastric carcinoids	Trio Medicines Ltd.
2402	R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/2008	Treatment of the behavioral abnormalities associated with fragile X syndrome	Seaside Therapeutics, Inc.
2403	rAAV2-CB-hRPE65	n/a	2/11/2005	Treatment of type II Leber's Congenital Amaurosis	Applied Genetic Technologies Corp.
2404	Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosuppression in pediatric liver transplant recipients	Children's Hospital of Pittsburgh
2405	radiolabeled somastatin analog	Galiomedix(Tm)	12/31/2013	Diagnostic for the management of neuroendocrine tumors	RadioMedix, Inc.
2406	raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Eli Lilly and Company
2407	raloxifene hydrochloride	Evista	8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Consejo Superior de Investigaciones Cientificas
2408	ramucirumab	Cyramza	2/16/2012	Treatment of gastric cancer	Eli Lilly and Company
2409	ramucirumab	n/a	11/4/2011	Treatment of hepatocellular carcinoma	Eli Lilly and Company
2410	ranagenglitucel-L	Glionix(Tm)	5/29/2009	Treatment of astrocytic tumors	NovaRx Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2411	ranprinase	Onconase	1/25/2007	Treatment of malignant mesothelioma	Alfacell Corporation
2412	Rapamycin	n/a	3/20/2007	Treatment of tuberous sclerosis complex	OncoImmune, Inc.
2413	rapamycin	n/a	2/24/2016	Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).	DSLIP
2414	rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2415	raxibacumab	Abthraxtm	11/12/2003	Treatment of anthrax	Human Genome Sciences, Inc.
2416	Re188 P2045 somatostatin analog	n/a	2/6/2014	Treatment of small cell lung cancer	Andarix Pharmaceuticals
2417	Re188 P2045 somatostatin peptide analogue	n/a	6/19/2014	Treatment of pancreatic cancer.	Andarix Pharmaceuticals, Inc.
2418	recilisib sodium	Ex-Rad(R)	9/4/2012	Treatment of acute radiation syndrome	Onconova Therapeutics, Inc.
2419	recilisib sodium	Ex-Rad(R)	6/1/2012	Prevention of acute radiation syndrome	Onconova Therapeutics, Inc.
2420	Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase	n/a	4/30/2014	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Abeona Therapeutics LLC
2421	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	n/a	4/29/2014	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	Abeona Therapeutics
2422	recombinant activated Factor X variant	n/a	3/3/2015	Treatment of intracerebral hemorrhage	Pfizer, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2423	recombinant adeno-associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/2013	For the treatment of Sandhoff disease	Nat'l Tay-Sachs & Allied Diseases Association
2424	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/2009	Treatment of Leber's congenital amaurosis	AmpliPhi Biosciences Corporation
2425	recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp.
2426	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/2009	Treatment of Huntington's disease.	Neurologix, Inc.
2427	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Spark Therapeutics, Inc.
2428	recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP	n/a	10/29/2015	Treatment of Angelman Syndrome.	Agilis Biotherapeutics, LLC
2429	recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase	n/a	12/29/2015	Treatment of ornithine transcarbamylase deficiency	Dimension Therapeutics

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2430	recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAINac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter	n/a	6/16/2015	Treatment of Duchenne muscular dystrophy	Nationwide Children's Hospital
2431	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3)	n/a	11/16/2015	Treatment of achromatopsia caused by mutations in the CNGA3 gene	Applied Genetic Technologies Corp.
2432	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Applied Genetic Technologies Corporation
2433	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/2013	Treatment of Tay-Sachs disease	Na't Tay-Sachs & Allied Diseases Association
2434	Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/2009	Treatment of Hodgkin lymphoma	Affimed Therapeutics AG
2435	recombinant chimeric monoclonal antibody to anthrax	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Elusys Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2436	Recombinant coagulation factor VIIa	n/a	4/26/2006	Treatment of diffuse alveolar hemorrhage	PharmaOrigin ApS
2437	recombinant derivative of C3 transferase	Cethrin	11/18/2005	Treatment of acute spinal cord injury	Vertex Pharmaceuticals, Inc.
2438	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Prevention of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic and secondary forms.	Baxter Healthcare Corporation
2439	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Treatment of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic, and secondary forms.	Baxter Healthcare Corporation
2440	recombinant DNA plasmid	n/a	1/31/2014	Treatment of stage IIb, IIc, III and IV melanoma.	Scancell Ltd.
2441	recombinant elafin	n/a	3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Proteo Biotech AG
2442	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Henogen S.A.
2443	Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/2006	Treatment of anthrax infection	PharmAthene, Inc.
2444	Recombinant Fusion Protein	n/a	7/24/2012	Treatment of Myelodysplastic Syndrome	Apogenix GmbH

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2445	recombinant fusion protein comprising exenatide and XTEN	n/a	10/7/2015	Treatment of short bowel syndrome.	NAIA Pharmaceuticals, Inc.
2446	recombinant fusion protein consisting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/2013	Treatment of myelodysplastic syndrome	Celgene Corporation
2447	recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/2013	Treatment of B-thalassemia	Celgene Corporation
2448	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	n/a	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	CSL Behring, LLC
2449	recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL Behring
2450	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. is now Nventa

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2451	recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Viventia Biotech, Inc.
2452	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/2009	Treatment of glioblastoma multiforme	Apogenix GmbH
2453	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/2010	Treatment of Pompe disease.	BioMarin Pharmaceutical, Inc.
2454	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
2455	recombinant human acid ceramidase	Plexcerase(TM)	12/24/2013	Treatment of Faber disease	Plexcera Therapeutics, LLC
2456	recombinant human alkaline phosphatase	n/a	5/13/2015	Treatment of hypophosphatasia.	AM-Pharma BV
2457	Recombinant human alpha 1-antitrypsin	n/a	4/28/2005	Prevention of bronchopulmonary dysplasia	Arriva Pharmaceuticals, Inc.
2458	recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/2001	Treatment of cystic fibrosis	AiroMedica LLC
2459	recombinant human alpha-1 antitrypsin	n/a	3/6/1998	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2460	recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	AiroMedica LLC
2461	Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/2001	Treatment of myasthenia gravis	Alpha Cancer Technologies, Inc.
2462	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/2013	Treatment of Pompe Disease	Genzyme, a Sanofi Company
2463	Recombinant human alpha-mannosidase	n/a	2/2/2006	Treatment of alpha-mannosidosis	Zymenex A/S
2464	recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Alexion Pharmaceuticals
2465	recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Pfizer, Inc.
2466	recombinant human antithrombin	Atryn	12/7/2007	Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures	GTC Biotherapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2467	Recombinant human antithrombin III	n/a	4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC
2468	recombinant human beta-glucuronidase	n/a	2/16/2012	Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)	Ultragenyx Pharmaceutical, Inc.
2469	Recombinant human C1 inhibitor	n/a	6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Pharming Group N.V.
2470	Recombinant human C1 inhibitor	n/a	6/9/2006	Treatment of capillary leakage syndrome	Pharming Technologies B.V.
2471	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming Group N.V.
2472	recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain)	n/a	6/9/2015	Prevention of graft-versus-host disease	Oncolmmune, Inc.
2473	Recombinant human CD4 immunoglobulin G	n/a	8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc.
2474	Recombinant human Clara Cell 10kDa protein	n/a	7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Therabron Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2475	recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	n/a	3/17/2014	Treatment of dystrophic epidermolysis bullosa	Shire Human Genetic Therapies, Inc.
2476	recombinant human deoxyribonuclease I	n/a	8/18/2014	Treatment of graft-vs-host disease	SciVac Ltd.
2477	recombinant human deoxyribonuclease I (DNase I)	n/a	8/18/2014	Prevention of graft-vs-host disease	SciVac Ltd.
2478	Recombinant human endostatin protein	n/a	8/13/2001	Treatment of neuroendocrine tumors	EntreMed, Inc.
2479	recombinant human endostatin protein	n/a	2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc.
2480	recombinant human erythropoietin (rHuEPO)	n/a	5/26/2011	Treatment of mutliple myeloma	XTL Biopharmaceuticals, Ltd
2481	Recombinant Human Factor VIIa Variant	n/a	11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Pfizer, Inc.
2482	Recombinant human fibrinogen	n/a	10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Pharming Technologies B.V.
2483	recombinant human fucosyltransferase VI [FTVI] + GDP-fucose	n/a	1/27/2015	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	TargaZyme, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2484	recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	ACE BioSciences A/S
2485	Recombinant human gelsolin	n/a	3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	BioAgeis, Therapeutics, Inc.
2486	Recombinant human gelsolin	n/a	1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	BioAegis Therapeutics, Inc.
2487	Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/2010	Treatment of Type I diabetes with residual beta cell function	Diamyd Therapeutics AB
2488	recombinant human GM-CSF, molgramostim	n/a	10/31/2012	Treatment of pulmonary alveolar proteinosis	Serendex ApS
2489	recombinant human growth hormone in an ocular delivery system	n/a	12/3/2012	Treatment of persistent corneal epithelial defects	Jade Therapeutics LLC
2490	Recombinant human granulocyte colony stimulating factor	n/a	7/24/2006	Prevention of implantation failure and unexplained recurrent miscarriage	Nora Therapeutics, Inc.
2491	Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc.
2492	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc.
2493	recombinant human histidyl tRNA synthetase	n/a	4/22/2015	Treatment of facioscapulohumeral muscular dystrophy	aTyr Pharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2494	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/2008	Treatment of acute myeloid leukemia	Xenetic Biosciences Plc
2495	recombinant human IgG1 monoclonal antibody	n/a	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Ultragenyx Pharmaceutical, Inc.
2496	Recombinant human insulin-like growth factor-I	Pv802	2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd.
2497	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/1999	Treatment of major burns that require hospitalization.	Insmmed, Inc.
2498	Recombinant human interleukin-12	n/a	10/20/1997	Treatment of renal cell carcinoma.	Genetics Institute, Inc.
2499	Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/2005	Treatment of stage II (T4), III or IV malignant melanoma.	Zymo Genetics, Inc
2500	Recombinant human keratinocyte growth factor	n/a	12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Swedish Orphan Biovitrum AB (publ) (SOBI)
2501	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/2010	Treatment of LCAT deficiency syndromes	AlphaCore Pharma, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2502	Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	EMD Serono, Inc.
2503	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestrase	7/14/2005	Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease	Lysosomal Acid Lipase, LLC
2504	Recombinant human microplasmin	n/a	1/23/2006	Treatment of peripheral arterial occlusion	ThromboGenics Ltd
2505	recombinant human minibody against complement component	Mubodina(R)	6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Adienne S.A
2506	recombinant human minibody against complement component C5	Mubodina	2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Adienne S.A.
2507	recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Adienne S.A.
2508	recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/2012	Treatment of inclusion body myositis	Novartis Pharmaceuticals Corp.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2509	recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	n/a	8/19/2014	Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath	Novartis Pharmaceuticals Corp
2510	recombinant human monoclonal antibody to hsp90	Mycograb	9/16/2002	Treatment of invasive candidiasis	Novartis Pharmaceuticals Corp.
2511	recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (anti-PD-L1)	n/a	9/21/2015	Treatment of merkel cell carcinoma.	EMD Serono, Inc.
2512	recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/2013	Treatment of multiple myeloma	Patrys Ltd.
2513	recombinant human Naglu-insulin-like growth factor II	n/a	3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Shire Human Genetic Therapies, Inc.
2514	Recombinant human nerve growth factor	n/a	4/16/1999	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc.
2515	recombinant human nerve growth factor	n/a	8/8/2013	Treatment of retinitis pigmentosa	Dompe s.p.a.
2516	recombinant human nerve growth factor	n/a	6/23/2014	Treatment of neurotrophic keratitis	Dompe s.p.a.
2517	recombinant human neutrophil inhibitor (hNE)	n/a	12/9/2003	Treatment of cystic fibrosis	Dyax Corporation
2518	recombinant human Pentraxin-2	n/a	8/26/2014	Treatment of myelofibrosis	Promedior, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2519	recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Promedior, Inc.
2520	Recombinant human platelet derived growth factor BB	n/a	2/1/2007	Treatment of osteonecrosis of the jaws	Luitpold Pharmaceuticals, Inc.
2521	recombinant human platelet derived growth factor-BB	n/a	8/6/2010	Treatment of osteochondritis dissecans	Biomimetic Therapeutics, Inc.
2522	recombinant human porphobilinogen deaminase	Porphozyme	9/9/2002	Treatment of acute intermittent porphyria attacks	Zymenex A/S
2523	recombinant human porphobilinogen deaminase, erythropoetic form	n/a	7/11/2002	Treatment of acute intermittent porphyria preventing attacks	Zymenex A/S
2524	recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/2008	Treatment of retinitis pigmentosa	ProRetina Therapeutics, S.L.
2525	recombinant human serum albumin human growth hormone	n/a	1/13/2016	Treatment of growth hormone deficiency	TEVA Branded Pharmaceutical Products R&D, Inc.
2526	Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/2010	Treatment of idiopathic thrombocytopenic purpura	SuppreMol GmbH
2527	recombinant human surfactant protein D	n/a	6/23/2014	Prevention of bronchopulmonary dysplasia	Airway Therapeutics LLC
2528	Recombinant human thrombopoietin	n/a	9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2529	recombinant human tripeptidyl-peptidase 1 (rhTPP1)	n/a	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	BioMarin Pharmaceutical, Inc.
2530	recombinant human type I pancreatic elastase	n/a	4/3/2009	Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis	Proteon Therapeutics, Inc.
2531	recombinant human type VII collagen	n/a	6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	David T. Woodley, MD and Mei Chen, MD
2532	recombinant human vascular endothelial growth factor	n/a	6/7/2010	Treatment of amyotrophic lateral sclerosis	NeuroNova AB
2533	recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	n/a	2/11/2015	Treatment of eosinophilic esophagitis	Receptos, Inc.
2534	recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4	n/a	7/16/2015	Treatment of gastric cancer	Gilead Sciences, Inc.
2535	recombinant humanized anti-tau antibody	n/a	1/22/2015	Treatment of progressive supranuclear palsy	C2N Diagnostics, LLC
2536	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/2013	Treatment of sickle cell disease	NKT Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2537	recombinant humanized IgG4 monoclonal antibody that binds human colony stimulating factor 1 receptor	n/a	1/11/2016	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Five Prime Therapeutics, Inc.
2538	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc.
2539	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc.
2540	Recombinant humanized MAb 5c8	n/a	10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc.
2541	Recombinant humanized monclonal antibody 5c8	n/a	2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc.
2542	Recombinant humanized monoclonal antibody 5c8	n/a	2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc.
2543	recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	n/a	5/14/2014	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Genentech, Inc.
2544	recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/2011	Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).	Shire Human Genetics Therapies

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2545	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of malignant mesothelioma	National Institutes of Health
2546	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of epithelial ovarian cancer	National Institutes of Health
2547	recombinant kallikrein inhibitor	n/a	11/23/2010	Treatment of Netherton Syndrome.	Dermadis SA
2548	recombinant lens epithelium derived growth factor 1-326	n/a	5/19/2014	Treatment of retinitis pigmentosa	Ocugen, Inc.
2549	Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc.
2550	recombinant monoclonal antibody to human serum amyloid P component	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline
2551	recombinant multimerized human IgG1 Fc	n/a	7/14/2015	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).	Pfizer, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2552	recombinant nematode anticoagulant protein c2 (rNAPc2)	n/a	12/8/2014	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	ARCA Biopharma, Inc.
2553	recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S	n/a	11/17/2014	Treatment of patients with carbon monoxide poisoning	University of Pittsburgh
2554	recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A	n/a	1/6/2016	Treatment of soft tissue sarcoma.	Immune Design Corp.
2555	recombinant ovine interferon tau	Tauferon	1/25/2005	Treatment of pediatric multiple sclerosis	PEPGEN Corporation
2556	Recombinant P-Selectin glycoprotein ligand	n/a	3/29/2006	Prevention of delayed graft function in renal transplant patients	Y's Therapeutics, Inc.
2557	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Y's Therapeutics, Inc.
2558	Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/1999	Treatment of primary ovarian cancer.	Schering Corporation
2559	Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc.
2560	Recombinant secretory leucocyte protease inhibitor	n/a	3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2561	Recombinant soluble human CD4 (rCD4)	n/a	3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc.
2562	Recombinant T-cell receptor ligand	n/a	5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Artielle ImmunoTherapeutics, Inc.
2563	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathy due to thymidine phosphorylase deficiency.	St. George's University of London
2564	Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/2005	Treatment of cystic fibrosis	Aerovance, Inc.
2565	Recombinant urate oxidase	n/a	10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2566	recombinant von Willebrand factor (rhVWF)	n/a	11/23/2010	Treatment of von Willebrand disease.	Baxalta, Inc.
2567	Reduced L-glutathione	Cachexon	2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation
2568	reduced oxidized N-acetyl heparin	n/a	3/19/2015	Treatment of multiple myeloma	Sigma-Tau Research Switserland S.A.
2569	refanalin	n/a	5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Angion Biomedica Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2570	regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Bayer HealthCare Pharmaceuticals, Inc.
2571	regorafenib	Stivarga	6/4/2015	Treatment of hepatocellular carcinoma.	Bayer HealthCare Pharmaceuticals, Inc.
2572	REMUNE HIV 1	n/a	2/14/2014	Treatment of pediatric HIV/AIDS (age through 16 years)	Immune Response BioPharma, Inc.
2573	reparixin	n/a	9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Dompe S.p.A.
2574	reparixin	n/a	1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe S.p.A.
2575	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, Inc.
2576	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	John A. Chiorini, PhD
2577	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/2010	Treatment of acute myeloid leukemia	Aduro BioTech, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2578	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/2010	Treatment of chronic myeloid leukemia	Aduro BioTech, Inc.
2579	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/2010	Treatment of pancreatic cancer.	Aduro BioTech, Inc.
2580	repository corticotropin injection	H.P. Acthar Gel	6/28/2013	Treatment of amyotrophic lateral sclerosis	Questor Pharmaceuticals, Inc.
2581	repository corticotropin or adrenocorticotropin hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc.
2582	resiniferatoxin	n/a	5/13/2003	Treatment of intractable pain at end-stage disease	Sorrento Therapeutics, Inc.
2583	reslizumab	Cinquil	1/12/2011	Treatment of hypereosinophilic syndrome	Teva Pharmaceuticals, Inc.
2584	reslizumab	n/a	12/19/2007	Treatment of children with eosinophilic esophagitis	TEVA
2585	resminostat	n/a	6/29/2011	Treatment of hepatocellular carcinoma	4SC AG
2586	resminostat	n/a	9/16/2011	Treatment of Hodgkin's lymphoma.	4SC AG
2587	Respiratory Syncytial Virus Immune Globulin (human)	Hyperimmune Rsv	9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2588	Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachusetts Public Health Biologics Labs.
2589	retroviral gamma-c cDNA containing vector	n/a	4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc.
2590	Reversal agent linked to chloroquine-like moiety	n/a	3/26/2010	Treatment of malaria	DesignMedix
2591	Revimmune	n/a	2/18/2011	Treatment of autoimmune hemolytic anemia.	Accentia Biopharmaceuticals
2592	Reviparin sodium	Clivarine	6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Abbott
2593	Reviparin sodium	Clivarine	6/18/2001	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Abbott
2594	revusiran	n/a	5/18/2015	Treatment of transthyretin amyloidosis	Alnylam Pharmaceuticals, Inc.
2595	rhIGF-I/rhIGFBP-3	Somatokine	12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmmed, Inc.
2596	rh-microplasmin, ocriplasmin	Jetrea	3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	ThromboGenics Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2597	Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/1993	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc.
2598	ribavirin	Rebetol	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation
2599	ribavirin	Virazole	4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Valeant Pharmaceuticals International
2600	ribavirin elaidate	n/a	9/2/2011	Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer	Translational Therapeutics, Inc.
2601	riboflavin ophthalmic solution & ultraviolet A	n/a	9/2/2011	Treatment of keratoconus	Avedro, Inc.
2602	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	n/a	12/2/2011	Treatment of corneal ectasia following refractive surgery	Avedro, Inc.
2603	ricin vaccine	Rivax(R)	1/7/2011	Prevention of ricin intoxication.	Soligenix, Inc.
2604	Rifabutin	n/a	12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Pfizer Inc.
2605	Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc.
2606	Rifalazil	n/a	4/13/1999	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2607	Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel
2608	Rifampin, isoniazid, pyrazinamide	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel
2609	Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel
2610	Rifapentine	Priftin	3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc.
2611	Rifapentine	Priftin	6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc.
2612	rifaximin	Normix	2/10/1998	Treatment of hepatic encephalopathy	Salix Pharmaceuticals, Inc.
2613	rigosertib	n/a	3/16/2012	Treatment of ovarian cancer	Onconova Therapeutics, Inc.
2614	rigosertib	n/a	3/18/2011	Treatment of pancreatic cancer.	Onconova Therapeutics, Inc
2615	rigosertib	n/a	9/3/2009	Treatment of myelodysplastic syndromes	Onconova Therapeutics, Inc.
2616	R11 retinamide	n/a	5/6/1993	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc.
2617	Riloncept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Regeneron Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2618	rilonacept	Arcalyst	1/9/2013	Treatment of familial Mediterranean fever	Philip J Hashkes, MD, MSc.
2619	rilotumumab	n/a	6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Amgen, Inc.
2620	Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2621	Riluzole	Rilutek	10/15/1996	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2622	riluzole	n/a	2/23/2016	Treatment of spinoceleballar ataxia.	Biohaven Pharmaceutical Holding Company, Ltd.
2623	rindopepimut	n/a	11/19/2007	Treatment of EGFRvIII-expressing glioblastoma multiforme	Celldex Therapeutics, Inc.
2624	riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Bayer HealthCare Pharmaceuticals, Inc.
2625	riociguat	Adempas	7/24/2014	Treatment of systemic sclerosis	Bayer HealthCare Pharmaceuticals
2626	riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Bayer HealthCare Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2627	rituximab	Rituxan	2/14/2006	Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)	Genentech, Inc.
2628	rituximab	Rituxan	3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc.
2629	rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2630	rituximab	Rituxan(R); Mabthera(R)	2/23/2015	Treatment of pemphigus vulgaris.	Genentech, Inc.
2631	rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Genentech, Inc.
2632	rociletinib	n/a	5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Clovis Oncology, Inc.
2633	rofecoxib	Vioxx	3/16/2004	Treatment of juvenile rheumatoid arthritis	MERCK & Co., Inc.
2634	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation
2635	romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Amgen, Inc.
2636	romiplostim	n/a	10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Amgen Inc.
2637	Rose Bengal Disodium	n/a	12/21/2006	Treatment of metastatic melanoma	Provectus Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2638	Roseburia hominis	Rosburix	8/4/2014	Treatment of ulcerative colitis in pediatric patients age 0 through 16 years	4D Pharma Research Ltd
2639	rosuvastatin	Crestor	2/14/2014	For the treatment of pediatric homozygous familial hypercholesterolemia	AstraZeneca Pharmaceuticals LP
2640	rovalpituzumab tesirine	n/a	12/22/2015	Treatment of small cell lung cancer	Stemcentrx, Inc.
2641	rozrolimupab	n/a	9/13/2010	Treatment of primary immune thrombocytopenia.	Symphogen A/S
2642	rsATP7A cDNA	n/a	1/10/2014	Treatment of Menkes disease	Stephen G. Kaler, MD
2643	rSP-C lung surfactant	Venticute	4/3/2000	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals
2644	rSP-C surfactant	Venticute	9/18/2006	For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment	Altana Pharma
2645	rt-PA	Activase	10/20/2014	Treatment of plastic bronchitis	Kathleen A Stringer, PharmD, FCCP - Professor
2646	rubitecan	n/a	7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc.
2647	rucaparib	n/a	7/31/2012	Treatment of ovarian cancer	Clovis Oncology, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2648	rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Eisai, Inc.
2649	ruxolitinib	Jakafi	8/16/2013	Treatment of pancreatic cancer	Incyte Corporation
2650	ruxolitinib	Jakafi	3/26/2010	Treatment of polycythemia vera	Incyte Corporation
2651	ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Incyte Corporation
2652	ruxolitinib phosphate	Jakafi	3/22/2010	Treatment of essential thrombocythemia	Incyte Corporation
2653	rVIIa-FP	n/a	12/22/2011	Treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	CSL Behring
2654	S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated
2655	S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDENISFKEK	n/a	10/20/2009	Treatment of pancreatic cancer	MBiotec GmbH
2656	S3,S13-cyclo(D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminy-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide	n/a	11/16/2015	Treatment of C3 glomerulopathy.	Amyndas Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2657	S3,S13-cyclo(D-tyrosyl-L- isoleucyl-L-cysteinyl-L-valyl-1- methyl-L-tryptophyl-L- glutaminy-L-aspartyl-L- tryptophyl-N-methyl-L-glycyl-L- alanyl-L-histidyl-L-arginyl-L- cysteinyl-N-methyl-L- isoleucinamide)	n/a	10/9/2014	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Amyndas Pharmaceuticals
2658	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Intercept Blood System For	2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Cerus Corporation
2659	sacituzumab govitecan	n/a	11/27/2013	Treatment of small cell lung cancer	Immunomedics, Inc.
2660	sacituzumab govitecan	n/a	5/29/2014	Treatment of pancreatic cancer.	Immunomedics, Inc.
2661	Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase- isomaltase deficiency	QOL Medical, LLC
2662	S-adenosylmethionine	n/a	4/30/1998	Treatment of AIDS-myelopathy.	Genopia USA, Inc.
2663	salicylic acid 6%	n/a	2/17/2012	Treatment of rare congenital ichthyoses.	Orenova Group, LLC
2664	salirasib	n/a	12/18/2006	Treatment of pancreatic cancer.	Kadmon Corporation, LLC
2665	salmeterol xinafoate/fluticasone propionate	n/a	10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease	Lithera, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2666	saposin C	n/a	2/3/2015	Treatment of glioblastoma multiforme	Bexion Pharmaceuticals, LLC
2667	sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical, Inc.
2668	Sar9, Met(O2)11-Substance P	Homspera	3/16/2011	Treatment of idiopathic pulmonary fibrosis	ImmuneRegen BioSciences, Inc.
2669	sarcosine	n/a	10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Guochuan Emil Tsai, MD, PhD
2670	Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation
2671	Sargramostim	Leukine	5/3/1990	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation
2672	sarizotan	n/a	7/7/2015	Treatment of Rett syndrome.	Newron Pharmaceuticals US, Inc.
2673	Satumomab pendetide	Oncoscint Cr/Ov	9/25/1989	Detection of ovarian carcinoma.	Cytogen Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2674	SC-1 monoclonal antibody	n/a	11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Patrys Limited
2675	SDF-1 (108) Lysine Dimer	n/a	7/7/2005	Treatment of osteogenic sarcoma	Chemokine Therapeutics Corporation
2676	sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2677	sebelipase alfa	n/a	7/1/2010	Treatment of lysosomal acid lipase deficiency	Alexion Pharmaceuticals
2678	Secalciferol	Osteo-D	7/26/1993	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA
2679	Secretory leukocyte protease inhibitor	n/a	6/30/1992	Treatment of bronchopulmonary dysplasia.	Synergen, Inc.
2680	selective antagonist of the chemokine receptor type 4	n/a	9/5/2013	Treatment of acute myeloid leukemia	BioLineRx, Ltd.
2681	selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/2011	Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome	Novartis Pharmaceuticals Corporation
2682	selective inhibitor of fungal lanosterol demethylase	n/a	8/19/2014	Treatment of cryptococcal meningitis	Viamet Pharmaceuticals, Inc.
2683	Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2684	Selegiline HCl	Eldepryl	11/7/1984	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc.
2685	selexipag	Uptravi	4/30/2010	Treatment of pulmonary arterial hypertension	Actelion Ltd
2686	self-complimentary adeno-associated virus vector, serotype 9, packaging the full length GAN gene in the viral capsid	n/a	9/27/2013	Treatment of Giant Axonal Neuropathy	Hannah's Hope Fund
2687	selinexor	n/a	1/5/2015	Treatment of multiple myeloma	Karyopharm Therapeutics, Inc.
2688	Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of acute myeloid leukemia	Karyopharm Therapeutics, Inc.
2689	selisistat	n/a	12/7/2009	Treatment of Huntington's disease	Siena Biotech SpA
2690	Seneca Valley virus	n/a	8/22/2008	Treatment of neuroendocrine tumors	Neotropix, Inc.
2691	Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
2692	Serratia marcescens extract (polyribosomes)	Imuvert	9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2693	setmelanotide	n/a	9/21/2015	Treatment of Prader-Willi Syndrome.	Rhythm Metabolics, Inc.
2694	sevuparin	n/a	3/17/2015	Treatment of sickle cell disease	Dilaforette AB
2695	Short chain fatty acid enema	Colomed	8/19/1997	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D.
2696	Short chain fatty acid solution	Colomed	5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer
2697	sialic acid	n/a	9/23/2011	Treatment of hereditary inclusion body myopathy.	Ultragenyx Pharmaceutical, Inc.
2698	sildenafil	Revatio	7/28/2011	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Pfizer, Inc.
2699	Silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon Sil	2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Meda AB
2700	silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon(R) Sil	9/11/2014	Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure	Meda Pharmaceuticals, Inc.
2701	siltuximab	Sylvant	5/26/2006	Treatment of Castleman's disease	Janssen Biotech, Inc.
2702	Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/1999	Treatment of patients with severe dermal burns	Sinclair Pharmaceuticals Ltd

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2703	simtuzumab	n/a	1/5/2015	Treatment of primary sclerosing cholangitis	Gilead Sciences, Inc.
2704	single chain urokinase plasminogen activator	n/a	9/11/2014	Treatment of empyema (pleural)	Lung Therapeutics, Inc.
2705	single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21	n/a	7/17/2014	Treatment of Alport syndrome	Regulus Therapeutics, Inc.
2706	Siponimod	n/a	11/26/2013	Treatment of polymyositis	Novartis Pharmaceuticals Corporation
2707	siponimod	n/a	7/10/2014	Treatment of dermatomyositis	Novartis Pharmaceuticals Corporation
2708	sirolimus	Rapamune	10/31/2012	Treatment of lymphangioleiomyomatosis	Pfizer, Inc.
2709	sirolimus	n/a	6/25/2014	Treatment of lymphangioleiomyomatosis	LAM Therapeutics, Inc.
2710	sirolimus	n/a	3/18/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2711	sirolimus	n/a	11/17/2011	Treatment of lymphangioleiomyomatosis	Cote Orphan Consulting, LLC
2712	sirolimus	n/a	11/4/2011	Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).	Santen Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2713	sirolimus in an implantable collagen matrix	Coll-R, Sirogen	5/10/2012	Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis	Vascular Therapies, LLC
2714	Sitaxsentan Sodium	n/a	11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Pfizer Global Research and Development
2715	sitimagene ceradenovec	Cerepro	7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Finvector Vision Therapies Ltd
2716	skin tissue	Stratagraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Stratatech Corporation
2717	small molecule FGFR4 inhibitor	n/a	9/14/2015	Treatment of hepatocellular cancer (HCC).	Blueprint Medicines Corporation
2718	Small Molecule Inhibitor of Exon 17 mutant KIT	n/a	1/6/2016	Treatment of gastrointestinal stromal tumors (GIST).	Blueprint Medicines Corporation
2719	small molecule inhibitor of Exon 17 Mutant KIT	n/a	1/21/2016	Treatment of mastocytosis	Blueprint Medicines Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2720	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/15/2013	Treatment of Acute Myeloid Leukemia	Epizyme Inc.
2721	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Epizyme Inc.
2722	small molecule inhibitor of phosphodiesterase 10	n/a	9/26/2013	Treatment of Huntington's disease	Omeros Corporation
2723	small molecule normalizing the p53 function	n/a	6/12/2014	Treatment of ovarian cancer	Critical Outcome Technologies, Inc.
2724	smilagenin	Cogane	7/21/2011	Treatment of amyotrophic lateral sclerosis	Junaxo, Inc.
2725	S-nitrosoglutathione	n/a	5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	N30 PHARMAceuticals, LLC
2726	S-nitrosoglutathione	n/a	12/28/2012	Treatment of severe preeclampsia	Salupont Consulting Ltd
2727	sobetirome	n/a	4/29/2011	Treatment of X-linked adrenoleukodystrophy	NeuroVia, Inc.
2728	sodium 2, 2 dimethylbutyrate	n/a	7/25/2008	Treatment of sickle cell disease.	HemaQuest Pharmaceuticals, Inc.
2729	sodium 2-hydroxylinoleate	n/a	8/25/2015	Treatment of neuroblastoma.	Ability Pharmaceuticals, SL

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2730	sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate	n/a	4/3/2009	Treatment of ovarian cancer	Millennium Pharmaceuticals, Inc.
2731	sodium 4-phenylbutyrate	n/a	10/18/2011	Treatment of spinal muscular atrophy	GMP-Orphan SAS
2732	sodium alginate oligosaccharide	n/a	2/24/2016	Treatment of cystic fibrosis.	AlgiPharma AS
2733	Sodium aluminosilicate	n/a	3/4/2005	Treatment of chronic hepatic encephalopathy	Framework Therapeutics, LLc
2734	Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	IC-MedTech Corporation
2735	sodium ascorbate and menadione sodium bisulfite	Apatone(R)	4/15/2013	Treatment of autosomal dominant polycystic liver disease	IC-Medtech Corporation
2736	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
2737	sodium ascorbate and menadione sodium bisulfite	Apatone	4/9/2015	Treatment of noninfected painful total joint without mechanical complication	IC-MedTech Corporation
2738	sodium benzoate and clozapine	n/a	12/22/2011	Treatment of treatment-resistant schizophrenia	Guochuan Emil Tsai, MD, PhD
2739	sodium chlorite	n/a	8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Neuraltus Pharmaceuticals, Inc.
2740	Sodium dichloroacetate	n/a	6/11/1990	Treatment of congenital lactic acidosis	Stacpoole, Peter W. M.D., Ph.D.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2741	Sodium dichloroacetate	n/a	6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D.
2742	Sodium dichloroacetate	n/a	11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D.
2743	sodium dichloroacetate	n/a	7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group
2744	sodium dichloroacetate	n/a	11/29/2010	For pulmonary arterial hypertension.	Peter W. Stackpoole, PhD, MD
2745	sodium fusidate	n/a	10/23/2013	Treatment of patients with prosthetic joint infections	Cempra Pharmaceuticals, Inc.
2746	Sodium Monomercaptoundecahydro-closo-dodecaborate	Borocell	4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner
2747	Sodium nitrite	n/a	4/18/2007	Treatment of cyanide poisoning	Hope Pharmaceuticals
2748	Sodium nitrite	n/a	1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Hope Pharmaceuticals
2749	Sodium nitrite	n/a	4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Hope Pharmaceuticals
2750	sodium nitrite	n/a	9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Hope Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2751	sodium nitrite	n/a	7/8/2008	Treatment of pulmonary arterial hypertension	Airess Pharmaceuticals, Inc.
2752	sodium nitrite	n/a	1/9/2012	Treatment of chlorine gas poisoning	Hope Pharmaceuticals
2753	sodium nitrite and EDTA	n/a	11/10/2015	Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis	Arch Biopartners, Inc.
2754	sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Hope Pharmaceuticals
2755	Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/2007	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
2756	Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Ucyclyd Pharma, Inc.
2757	Sodium phenylbutyrate	n/a	3/20/2007	Treatment of spinal muscular atrophy	Tikvah Therapeutics, Inc.
2758	Sodium phenylbutyrate	n/a	4/24/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
2759	Sodium phenylbutyrate	Buphenyl	1/25/2007	Treatment of spinal muscular atrophy	OrphaMed, Inc.
2760	sodium phenylbutyrate	n/a	8/19/2014	Treatment of maple syrup urine disease	Acer Therapeutics, Inc.
2761	sodium phenylbutyrate	n/a	1/19/2010	Treatment of urea cycle disorder.	Navinta LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2762	sodium phenylbutyrate	n/a	7/2/1992	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp.
2763	sodium phenylbutyrate	Buphenyl	11/22/1993	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp.
2764	sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Lucane Pharma SA
2765	Sodium pyruvate	n/a	3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc
2766	Sodium stibogluconate	n/a	6/16/2006	Treatment of cutaneous leishmaniasis	VioQuest Pharmaceuticals, Inc.
2767	sodium stibogluconate	n/a	10/28/2009	Treatment of cutaneous leishmaniasis	Surgeon General of the US Army
2768	sodium sulfate, potassium sulfate, and magnesium sulfate	Suprep	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Braintree Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2769	sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride	Suclear	9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Braintree Laboratories, Inc.
2770	Sodium tetradecyl sulfate	Sotradecol	6/10/1986	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc.
2771	Sodium Thiosulfate	n/a	2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Luitpold Pharmaceuticals, Inc.
2772	Sodium thiosulfate	n/a	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Fennec Pharmaceuticals, Inc.
2773	sodium thiosulfate	n/a	3/3/2011	Treatment of sulfur mustard poisoning	Hope Pharmaceuticals
2774	sodium thiosulfate	n/a	10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Hope Pharmaceuticals
2775	sodium thiosulfate	n/a	12/2/2010	Treatment of extravasation of meclizethamine hydrochloride into subcutaneous tissues.	Hope Pharmaceuticals
2776	sodium thiosulfate	n/a	11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Hope Pharmaceuticals
2777	sodium thiosulfate	n/a	10/28/2014	Treatment of dermatomyositis	Hope Pharmaceuticals
2778	sodium thiosulfate	n/a	11/19/2012	Treatment of calciphylaxis	Edinburg BioQuarter
2779	Sodium thiosulfate and sodium nitrite	n/a	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2780	Sodium thiosulfate, sodium nitrite, amyl nitrite	Cyanide Antidote Package	6/16/2006	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
2781	sodium valproate	n/a	8/5/2015	Treatment of Wolfram syndrome	The University of Birmingham
2782	Solasonine and solamargine	Coramsine	2/6/2006	Treatment of high risk stage II, stage III and stage IV melanoma	Solbec Pharmaceuticals Limited
2783	Solasonine and solamargine	Coramsine	11/2/2005	Treatment of renal cell carcinoma	Solbec Pharmaceuticals Limited
2784	solnatide	n/a	2/8/2016	Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB)	Apeptico Forschung und Entwicklung GmbH
2785	solnatide	n/a	2/4/2016	Treatment of primary graft dysfunction following lung transplantation	Apeptico Forschung und Entwicklung GmbH
2786	Soluble complement receptor type 1	n/a	3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc.
2787	Soluble recombinant human complement receptor type 1	n/a	11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc.
2788	solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Octapharma USA, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2789	somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.	n/a	2/4/2016	Prevention of organ rejection in living donor kidney transplant recipients	Novartis Pharmaceuticals Corporation
2790	somatorelin	Somatrel	8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc.
2791	Somatostatin	n/a	12/22/1994	Treatment of bleeding esophageal varices.	Eumedita Pharmaceuticals A.G. (Schweiz)
2792	Somatostatin	Zecnil	6/20/1988	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc.
2793	Somatrem for injection	Protropin	12/9/1985	1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000).	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2794	Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2795	Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn
2796	Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company
2797	Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Novo Nordisk Inc.
2798	Somatropin	Serostim	3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	EMD Serono, Inc.
2799	Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Eli Lilly and Company
2800	Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
2801	Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2802	Somatropin (rDNA origin) injection	Norditropin	7/10/1987	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Novo Nordisk Pharmaceuticals
2803	Somatropin (rDNA)	Saizen	5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	EMD Serono, Inc.
2804	Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	EMD Serono, Inc.
2805	Somatropin (r-DNA) for injection	Serostim	3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	EMD Serono, Inc.
2806	Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn
2807	somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company
2808	Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
2809	Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	EMD Serono, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2810	Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc.
2811	Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc.
2812	Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company
2813	sonidegib	n/a	3/23/2015	Treatment of medulloblastoma	Novartis Pharmaceuticals Corp.
2814	Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Bayer Pharmaceuticals Corporation
2815	Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Bayer Pharmaceutical Corporation
2816	sorafenib	Nexavar	12/12/2011	Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer	Bayer HealthCare Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2817	sotalol (IV)	So-Aqueous	7/25/2008	For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.	Academic Pharmaceuticals
2818	Sotalol HCl	Betapace	9/23/1988	1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treating ventricular tachyarrhythmias	Berlex Laboratories, Inc.
2819	sotalol hydrochloride	n/a	2/10/2014	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Arbor Pharmaceuticals, LLC
2820	sotatercept	n/a	12/5/2013	Treatment of beta-thalassemia intermedia and major	Celgene Corporation
2821	sotatercept	n/a	4/28/2014	Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.	Celgene Corporation
2822	sparsentan	n/a	1/5/2015	Treatment of Focal Segmental Glomerulosclerosis	Retrophin, LLC
2823	spherical carbon adsorbent	n/a	12/19/2007	Treatment of chronic pouchitis	Ocera Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2824	spironolactone	Aldactone	5/22/2014	Use in pediatric patients with primary hyperaldosteronism	CMP Pharma, Inc.
2825	squalamine lactate	n/a	5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation
2826	staphylococcal aureus protein A	n/a	6/10/2015	Treatment of immune thrombocytopenic purpura	Protalex, Inc.
2827	Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Biotest Pharmaceuticals Corporation
2828	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of acute lymphoblastic leukemia.	Gamida Cell Ltd.
2829	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of Hodgkin lymphoma.	Gamida Cell Ltd.
2830	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of myelodysplastic syndrome.	Gamida Cell Ltd.
2831	stemchymal	n/a	12/16/2015	Treatment of polyglutamine spinocerebellar ataxia	Stement Biotherapeutics, Inc.
2832	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemodialysis Solution	Accusol	5/29/2009	For use as a replacement solution in adults and children during Continous Renal Replacement Therapy	Nikkiso America, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2833	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemodialysis Solution	Accusol	11/17/2014	For use as a replacement solution in adults and children during Continous Renal Replacement Therapy	Emergent Virology, LLC
2834	Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax.	Novatech SA
2835	Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion.	Novatech SA
2836	Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Bryan Corporation
2837	stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Biocodex
2838	Substituted imidazopyridine amide	n/a	12/22/2015	Treatment of active tuberculosis (TB).	Qurient Co., Ltd.
2839	Succimer	Chemet	11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc.
2840	Succimer	Chemet	3/22/1991	Treatment of mercury intoxication.	Sanofi Winthrop, Inc.
2841	Succimer	Chemet Capsules	5/9/1984	Treatment of lead poisoning in children.	Bock Pharmacal Company
2842	Sucralfate suspension	n/a	3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc.
2843	Sucralfate suspension	n/a	3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2844	Sulfadiazine	n/a	3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc.
2845	sulfamidase	n/a	5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Shire Human Genetic Therapies, Inc.
2846	Sulfapyridine	n/a	9/10/1990	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company
2847	sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Medigen Biotechnology Corporation
2848	sulthiame	n/a	7/25/2013	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Marathon Pharmaceuticals, LLC
2849	Superoxide dismutase (human)	n/a	3/6/1985	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership
2850	superoxide dismutase, gliadin	Etr019	4/30/2010	Treatment of amyotrophic lateral sclerosis	Verius Limited

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2851	Suramin	Metaret	5/6/1997	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company
2852	Synsorb Pk	n/a	7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc.
2853	Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH	n/a	2/4/2016	Treatment of ovarian cancer.	Soricimed Biopharma Inc.
2854	synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA	n/a	6/4/2014	Prevention of scarring post glaucoma filtration surgery	Isarna Therapeutics GmbH
2855	Synthetic 47 amino acid-long N-terminally myristoylated, HBV-L-protein derived lipopeptide	n/a	3/31/2015	Treatment of hepatitis D virus infection.	MYR GmbH
2856	Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid	Drepanol	10/24/1991	Prophylactic treatment of sickle cell disease.	Omex International, Inc.
2857	synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene	n/a	4/22/2015	Treatment of primary hyperoxaluria type 1	Dicerna Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2858	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/2013	Treatment of hemophilia A	Alnylam Pharmaceuticals
2859	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/2013	Treatment of hemophilia B	Alnylam Pharmaceuticals
2860	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/2012	Treatment of ischemic optic neuropathy	Quark Pharmaceuticals, Inc.
2861	synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Quark Pharmaceuticals, Inc.
2862	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/2012	Treatment of familial amyloidotic polyneuropathy	Alnylam Pharmaceuticals, Inc.
2863	synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA	n/a	2/8/2016	Treatment of primary hyperoxaluria type 1	Alnylam Pharmaceuticals, Inc.
2864	Synthetic human secretin	n/a	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2865	Synthetic human secretin	n/a	9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Innovate Biopharmaceuticals, Inc.
2866	Synthetic human secretin	Chiostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
2867	Synthetic human secretin	n/a	6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
2868	Synthetic human secretin	n/a	6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
2869	synthetic oligomer of 16 nucleotides	n/a	1/13/2015	Treatment of myotonic dystrophy Type I	Isis Pharmaceuticals, Inc.
2870	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Atox Bio, Inc.
2871	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/16/2013	Treatment of high altitude pulmonary edema	Apeptico Forschung und Entwicklung GmbH

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2872	Synthetic porcine secretin	Secreflo	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
2873	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
2874	Synthetic porcine secretin	n/a	6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
2875	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
2876	synthetic signal peptide of human mucin-1 (amino acids 1-21)	n/a	6/16/2015	Treatment of multiple myeloma.	Vaxil Bio Therapeutics Ltd.
2877	synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue	n/a	3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Chiesi USA, Inc.
2878	T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine	Neurovax	2/6/2014	Treatment of Pediatric Multiple Sclerosis	Immune Response BioPharma, Inc.
2879	T4 endonuclease V, liposome encapsulated	n/a	6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2880	taberminogene vadenovec	Trinam	10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Finvector Vision Therapies, Ltd.
2881	Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Astellas Pharma US, Inc.
2882	Tacrolimus	Prograf	4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc.
2883	tacrolimus	n/a	5/4/2015	Treatment of pulmonary arterial hypertension	Stanford University School of Medicine
2884	tacrolimus	Envarsus Xr	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Veloxis Pharmaceuticals, Inc.
2885	tacrolimus	n/a	3/16/2015	Treatment of pulmonary arterial hypertension.	Selten Pharma, Inc.
2886	tacrolimus	n/a	7/6/2012	Treatment of hemorrhagic cystitis	Lipella Pharmaceuticals Inc.
2887	tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Eli Lilly and Company
2888	tadalafil	Cialis(R); Adcirca(R)	5/4/2015	Treatment of Duchenne Muscular Dystrophy (DMD)	Eli Lilly and Company
2889	tafamidis	n/a	5/23/2006	Treatment of familial amyloid polyneuropathy	Pfizer, Inc.
2890	tafamidis meglumine	n/a	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Pfizer, Inc.
2891	tafenoquine	n/a	1/15/2013	Treatment of malaria	Glaxo Group Limited, England

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2892	talactoferrin alfa	n/a	8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc.
2893	talactoferrin alfa	n/a	8/20/2003	For the treatment of graft versus host disease	Agennix, Inc.
2894	Taliglucerase alfa	Elelyso For Injection	9/3/2009	Treatment of Gaucher's disease	Pfizer, Inc.
2895	talimogene laherparepvec	Imlygic	3/14/2011	Treatment of stage IIb-stage IV melanoma	BioVex, Inc. (subsidiary of Amgen)
2896	Tamibarotene	n/a	10/11/2007	Treatment of acute promyelocytic leukemia (APL).	CytRx Corporation
2897	Tanespimycin	n/a	9/9/2004	Treatment of multiple myeloma	Bristol-Myers Squibb
2898	tarextumab	n/a	1/26/2015	Treatment of small cell lung cancer	OncoMed Pharmaceuticals, Inc.
2899	tarextumab	n/a	1/26/2015	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
2900	Targeted Gastrin 17 Complexed Peptide	n/a	5/14/2014	Treatment of pancreatic cancer	Tyg Oncology Ltd
2901	tasimelteon	Hetlioz	1/19/2010	Non-24-hour sleepwake disorder in blind individuals without light perception	Vanda Pharmaceuticals, Inc.
2902	tasimelteon	n/a	4/30/2010	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Vanda Pharmaceuticals, Inc.
2903	taurine	n/a	3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Johan L. Van Hove, MD, PhD

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2904	tazemetostat	n/a	2/4/2016	Treatment of malignant rhabdoid tumors (MRTs)	Epizyme Inc.
2905	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc.
2906	TD-K6a.513a.12	Reveker	6/15/2006	Treatment of pachyonychia congenita	TransDerm, Inc.
2907	technetium Tc 99m tilmanocept	Lymphoseek	9/17/2014	Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck	Navidea Biopharmaceuticals
2908	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Immunomedics, Inc.
2909	Technetium Tc99m rh-Annexin V	Apomate	11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation
2910	Technetium Tc99m sulfur colloid injection, lyophilized	Technetium Tc99m Sulfur Colloi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma.	Pharmalucence, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2911	tecovirimat	n/a	12/18/2006	post exposure prophylaxis against smallpox	SIGA Technologies, Inc.
2912	tecovirimat	n/a	12/27/2006	Treatment of smallpox.	SIGA Technologies, Inc.
2913	tecovirimat	n/a	9/29/2010	Treatment of orthopoxvirus infections.	SIGA Technologies, Inc.
2914	teduglutide [rDNA origin]	Gattex	6/29/2000	Treatment of short bowel syndrome.	NPS Pharmaceuticals, Inc.
2915	Tegafur/gimeracil/oteracil	n/a	7/20/2006	Treatment of gastric cancer	Taiho Pharma USA, Inc.
2916	telatinib	n/a	5/17/2010	Treatment of gastric cancer	ACT Biotech Inc.
2917	temocillin sodium	Negaban	4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Belpharma S.A.
2918	Temoporfin	Foscan	10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Biolitec Pharma Ireland Ltd.
2919	Temozolomide	Temodal	10/18/2004	Treatment of newly diagnosed high grade glioma	Schering-Plough Research Institute
2920	Temozolomide	Temodal	10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute
2921	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute
2922	temozolomide	n/a	11/25/2015	Treatment glioblastoma multiforme in pediatric patients	AmpliPharm Pharmaceuticals, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2923	Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Wyeth Pharmaceuticals, Inc.
2924	Teniposide	Vumon For Injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
2925	tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Gilead Sciences, Inc.
2926	teprotumumab	n/a	5/6/2013	Treatment of active (dynamic) phase Grave's orbitopathy	River Vision, Inc.
2927	terguride	Mysalfon, Teluron	5/17/2013	Treatment of systemic sclerosis	Serodapharm UG
2928	Teriparatide	Parathar	10/28/1999	Treatment of idiopathic osteoporosis.	Biomeasure, Inc.
2929	Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2930	teriparatide	Forteo	4/18/2014	Treatment of hypoparathyroidism	Entera Bio, Ltd.
2931	Terlipressin	Glypressin	3/6/1986	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc.
2932	terlipressin	n/a	10/29/2004	Treatment of Hepatorenal Syndrome	Ikaria (INO Therapeutics)
2933	tesetaxel	n/a	12/22/2008	Treatment of gastric cancer	Genta Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2934	tesetaxel	n/a	11/21/2008	Treatment of stages IIB, IIC, III, and stage IV melanoma	Genta, Inc.
2935	Testosterone	Theraderm Testosterone Transdermal System	9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories
2936	Testosterone propionate ointment 2%	n/a	7/31/1991	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc.
2937	testosterone undecanoate (oral)	n/a	2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	SOV Therapeutics, Inc.
2938	tetra substituted prophyrin derivative containing manganese (III)	n/a	1/17/2014	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Aeolus Pharmaceuticals, Inc.
2939	Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Prestwick Pharmaceuticals, Inc
2940	Tetrabenazine	n/a	5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Prestwick Pharmaceuticals, Inc.
2941	tetrabenazine	n/a	7/1/2009	Treatment of Tourette's Syndrome in school-age children, ages 5-16	Valeant International (Barbados) SRL
2942	tetracosactide hexaacetate (beta 1-24-corticotrophin)	Synacthen Depot, S. Retard	10/31/2012	Treatment of infantile spasms	Cerium Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2943	Tetraiodothyroacetic acid	n/a	5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot
2944	tetra-substituted porphyrin derivative containing manganese (III)	n/a	3/16/2015	Treatment of idiopathic pulmonary fibrosis	Aeolus Pharmaceuticals
2945	Tezacitabine	n/a	1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Sanofi-Aventis US, Inc.
2946	Thalidomide	n/a	5/1/1995	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation
2947	Thalidomide	n/a	5/15/1995	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation
2948	Thalidomide	Thalomid	4/6/1999	Treatment of Crohn's disease.	Celgene Corporation
2949	Thalidomide	n/a	7/29/1998	Treatment of Kaposi's sarcoma.	Celgene Corporation
2950	Thalidomide	Thalomid	10/14/1998	Treatment of multiple myeloma	Celgene Corporation

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2951	Thalidomide	n/a	1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation
2952	Thalidomide	Synovir	3/11/1996	Treatment of HIV-associated wasting syndrome.	Celgene Corporation
2953	Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Celgene Corporation
2954	Thalidomide	n/a	2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation
2955	Thalidomide	n/a	3/5/1990	Treatment of graft versus host disease.	Andrulis Research Corporation
2956	Thalidomide	n/a	11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc.
2957	Thalidomide	n/a	3/5/1990	Prevention of graft versus host disease.	Andrulis Research Corporation
2958	Thalidomide	Thalomid	9/27/2004	Treatment of myelodysplastic syndrome	Celgene Corporation
2959	thalidomide	n/a	9/19/1988	1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation	Pediatric Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2960	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/2008	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Aldagen, Inc.
2961	Theranost 68 Ga RGD	n/a	10/1/2014	A Diagnostic for the management of Moyamoya disease (MMD)	Advanced Imaging Projects, LLC (AIP)
2962	Theranost 68Ga RGD	n/a	1/26/2015	Diagnostic for the clinical management of patients with tuberculosis	Advanced Imaging Projects, LLC
2963	theranost 68Ga-RGD	n/a	12/8/2014	Diagnostic for clinical management of patients with neuroblastoma	Advanced Imaging Projects, LLC
2964	Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Adienne S.A.
2965	thioureidobutyronitrile	Kevetrin	1/20/2016	Treatment of pancreatic cancer.	Cellceutix Corporation
2966	thioureidobutyronitrile	Kevetrin	11/17/2015	Treatment of retinoblastoma.	Cellceutix Corporation
2967	thioureidobutyronitrile	Kevetrin	7/14/2015	Treatment of ovarian cancer	Cellceutix Corporation
2968	Thymalfasin	Zadaxin	5/3/1991	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc.
2969	Thymalfasin	Zadaxin	3/6/2000	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2970	Thymalfasin	Zadaxin	3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	SciClone Pharmaceuticals, Inc.
2971	Thymalfasin	Zadaxin	1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc.
2972	thymopentin	n/a	2/4/2011	Treatment of sarcoidosis.	Mondobiotech Laboratories AG
2973	Thymosin beta 4	n/a	5/28/2004	Treatment of epidermolysis bullosa.	RegeneRx Biopharmaceuticals, Inc.
2974	thymosin beta 4	n/a	12/31/2013	Treatment of patients with neurotrophic keratopathy	ReGenTree, LLC
2975	Thyrotropin alfa	Thyrogen	8/3/2001	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation
2976	Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation
2977	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/2000	Chronic myelogenous leukemia (CML)	Valeant Pharmaceuticals North America
2978	tigecycline	n/a	10/23/2013	Treatment of acute myeloid leukemia.	Trillium Therapeutics, Inc.
2979	Tilarginine acetate	n/a	4/11/2005	Treatment of cardiogenic shock	Arginox Pharmaceuticals, Inc.
2980	tin ethyl etiopurpurin	n/a	11/4/2003	Prevention of access graft disease in hemodialysis patients	Miravant Medical Technologies

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2981	Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Presutti Laboratories, Inc.
2982	tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc.
2983	Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D.
2984	Tiotropium bromide	Spiriva	1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc.
2985	tipelukast	n/a	10/20/2014	Treatment of idiopathic pulmonary fibrosis	MediciNova, Inc.
2986	Tipifarnib	Zarnestra	7/6/2004	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev.
2987	tiprelestat	Elafin	12/28/2012	Treatment of pulmonary arterial hypertension	Proteo Biotech AG
2988	tiptorelin pamoate	n/a	8/20/2012	Treatment of central precocious puberty	Debiopharm
2989	tirapazamine	n/a	11/30/2015	Treatment of hepatocellular carcinoma	Teclison Limited
2990	tirapazamine	n/a	10/23/2002	Treatment of head and neck cancer	Sanofi-Aventis US, Inc.
2991	tirasemtiv	n/a	3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Cytokinetics Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2992	Tiratricol	Triacana	8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires
2993	tisagenlecleucel-T	n/a	2/3/2015	Treatment of diffuse large B-cell lymphoma	Novartis Pharmaceuticals Corporation
2994	Tissue Plasminogen activator	n/a	4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Catherine Amliel-Lefond, MD
2995	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/2006	Treatment of osteonecrosis.	Aastrom Biosciences, Inc.
2996	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/2007	Treatment of dilated cardiomyopathy	Vericel Corporation.
2997	tivantinib	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Daiichi Sankyo Pharma Development
2998	Tizanidine HCl	Zanaflex	1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc.

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2999	Tobramycin	Tobi	6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Novartis Pharmaceuticals Corp.
3000	Tobramycin for inhalation	Tobi	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Novartis Pharmaceuticals Corp
3001	tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Genentech, Inc.
3002	tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Genentech, Inc.
3003	Tolcapone	n/a	12/24/2013	Treatment of transthyretin amyloidosis	SOM Innovation Biotech SL (SOM Biotech)
3004	tolerogen	n/a	2/5/2015	Treatment of myasthenia gravis	Toleranzia AB
3005	tolvaptan	Samsca	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Otsuka Pharmaceuticals Co., Ltd.
3006	Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Johnson & Johnson Pharmaceutical R & D, LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3007	topiramate injection	n/a	7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	CURx Pharmaceuticals, Inc.
3008	Toremifene	n/a	8/17/1993	Treatment of desmoid tumors.	Orion Corporation
3009	Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation
3010	Tosedostat	n/a	12/10/2008	Treatment of acute myeloid leukemia	CTI BioPharma Corporation
3011	Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	GlaxoSmithKline LLC
3012	trabectedin	Yondelis	3/29/2005	Treatment of patients with ovarian cancer	Janssen Research & Development, LLC
3013	trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma	Janssen Research & Development, LLC
3014	trabedersen	n/a	8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Isarna Therapeutics GmbH
3015	trabedersen	n/a	7/21/2009	Treatment of pancreatic cancer.	Isarna Therapeutics GmbH

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3016	trabedersen	Oncomun	6/5/2002	Treatment of malignant glioma	Isarna Therapeutics GmbH
3017	tralokinumab	n/a	7/24/2012	Treatment of idiopathic pulmonary fibrosis	MedImmune Ltd.
3018	Tramadol hydrochloride	n/a	4/26/2005	Management of postherpetic neuralgia	TheraQuest Biosciences, LLC
3019	Tramadol hydrochloride	n/a	1/28/2005	Treatment of painful HIV-associated neuropathy	TheraQuest Biosciences, LLC
3020	trametinib	Mekinist	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	Novartis Pharmaceuticals Corp.
3021	trametinib and dabrafenib	Mekinist And Tafinlar	9/20/2012	Treatment of Stage IIb through IV melanoma.	Novartis Pharmaceuticals Corp.
3022	Tranilast	Rizaben	12/2/2003	For the treatment of malignant glioma	Angiogen Pharmaceuticals, Pty. Ltd.
3023	tranilast	Rizaben	12/23/2010	Prevention of scarring following glaucoma filtration surgery	Altacor Ltd
3024	trans sodium crocetinate	n/a	12/3/2012	Treatment of brain metastasis	Diffusion Pharmaceuticals, LLC
3025	trans sodium crocetinate	n/a	7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Diffusion Pharmaceuticals, LLC
3026	Transforming growth factor-beta 2	n/a	12/18/1992	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3027	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/2013	Treatment of glioma	Eli Lilly and Company
3028	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/2013	Treatment of hepatocellular carcinoma	Eli Lilly and Company
3029	Transgenic human alpha 1 antitrypsin	n/a	5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited
3030	trastuzumab	Herceptin	10/13/2009	Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction	Genentech, Inc.
3031	trastuzumab	Herceptin	12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc.
3032	trastuzumab emtansine	Kadcyla	10/25/2013	For the treatment of gastric cancer including gastroesophageal junction cancer.	Genethex, Inc.
3033	trebananib	n/a	8/30/2013	Treatment of ovarian cancer	Amgen, Inc.
3034	trehalose	n/a	11/17/2014	Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease)	BioBlast Pharma Ltd
3035	tremelimumab	n/a	3/18/2015	Treatment of malignant mesothelioma	MedImmune, LLC
3036	tremelimumab	n/a	9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	MedImmune
3037	Treosulfan	Ovastat	5/16/1994	Treatment of ovarian cancer.	Medac GmbH

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3038	treosulfan	n/a	4/8/2015	Conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases in adults and pediatric patients.	Medac GmbH
3039	treprostinil	Remodulin	6/4/1997	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp.
3040	treprostinil (inhalational)	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	LungRx, Inc.
3041	treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump	n/a	12/29/2015	Treatment of pulmonary arterial hypertension	SteadyMed Therapeutics
3042	Tretinoin	Atra-iv	1/14/1993	Treatment of acute and chronic leukemia.	Antigenics, Inc.
3043	Tretinoin	Atra-iv	4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
3044	Tretinoin	n/a	4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc
3045	Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc.
3046	tri-antennary glycotriptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/2001	Treatment for hepatocellular carcinoma	Cell Works Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3047	tricitiribine	n/a	2/1/2008	Treatment of multiple myeloma	VioQuest Pharmaceuticals, Inc.
3048	Trientine HCl	Syprine	12/24/1984	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research
3049	trientine hydrochloride	Syprine(R)	11/2/2010	Treatment of manganism.	Cerberus Princeton, LLC
3050	trifarotene	n/a	6/6/2014	Treatment of congenital ichthyosis	Galderma R&D, LLC
3051	Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Baylor Research Institute
3052	Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/2006	Treatment of fatty acid disorders	Baylor Research Institute
3053	triheptanoin	n/a	10/21/2014	Treatment of glucose transporter type-1 deficiency syndrome	Ultragenyx Pharmaceutical, Inc.
3054	triheptanoin	n/a	4/15/2015	Treatment of fatty acid oxidation disorders	Ultragenyx Pharmaceutical, Inc.
3055	Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc.
3056	Trisaccharides A and B	Biosynject	4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3057	Trisaccharides A and B	Biosynject	4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd.
3058	Trisaccharides A and B	Biosynject	4/20/1987	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd.
3059	Trisodium citrate concentration	Hemocitrate	6/15/1995	For use in leukapheresis procedures.	Hemotec Medical Products, Inc.
3060	Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.	CustomCare Pharmacy
3061	triterpenoid saponin	n/a	7/23/2014	Treatment of mantle cell lymphoma	Avicin Therapeutics, Ltd.
3062	Trypan blue	Membraneblue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Dutch Ophthalmic Research Center Int'l BV
3063	tryptophan hydroxylase (TPH) inhibitor	n/a	3/9/2012	Management of symptoms of carcinoid syndrome associated with carcinoid tumor	Lexicon Pharmaceuticals, Inc.
3064	Tumor necrosis factor-binding protein 1	n/a	1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm ³ .	EMD Serono, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3065	Tumor necrosis factor-binding protein II	n/a	1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
3066	tumor-infiltrating lymphocytes; LN-144	n/a	6/9/2015	Treatment of malignant melanoma Stages IIb to IV	Lion Biotechnologies, Inc.
3067	TXA127	n/a	10/25/2013	Treatment of acute radiation syndrome	US Biotest, Inc.
3068	Tyloxapol	Supervent	3/8/1995	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
3069	Type 1 native bovine skin collagen	n/a	2/1/2008	Treatment of diffuse systemic sclerosis	arGentis Pharmaceuticals, LLC
3070	ubenimex	n/a	11/19/2015	Treatment of pulmonary arterial hypertension.	Eiger BioPharmaceuticals, Inc.
3071	ubiquinol	Ubi-Q-Nol, Li-Q-Nol	4/12/2004	Treatment of Huntington's Disease	Gel-Tec, Division of Tishcon Corp.
3072	Ubiquinol, coenzyme Q10, ubiquinone	Ubi-Q-Nol	4/12/2004	Treatment of pediatric congestive heart failure	Gel-Tec, Division of Tishcon Corporation
3073	Ubiquinone	Ubi-Q-Gel	12/14/1999	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp.
3074	ublituximab	n/a	9/5/2013	Treatment of Nodal marginal zone lymphoma	TG Therapeutics, Inc.
3075	ublituximab	n/a	9/5/2013	Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)	TG Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3076	ublituximab	n/a	8/6/2010	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.
3077	udenafil	n/a	8/31/2015	Treatment of single ventricle congenital heart disease with Fontan physiology	Mezzion Pharma Co. Ltd.
3078	ulocuplumab	n/a	1/12/2015	Treatment of acute myeloid leukemia	Bristol-Myers Squibb Company
3079	Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	3/22/2001	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
3080	unoprostone isopropyl	Rescula	9/16/2010	Treatment of retinitis pigmentosa	R-Tech Ueno, Ltd.
3081	urea	n/a	11/7/2011	Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosiform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).	Orenova Group, LLC
3082	Urea for intravitreal injection	Neurosolve	12/14/2005	Treatment of retinitis pigmentosa	Vitreo Retinal Technologies, Inc

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3083	uridine triacetate	n/a	5/1/2009	An antidote in the treatment of 5-fluorouracil or capecitabine poisoning	Wellstat Therapeutics Corp.
3084	uridine triacetate	n/a	9/3/2009	Treatment of mitochondrial disease	Wellstat Therapeutics Corporation
3085	uridine triacetate	n/a	8/9/2013	Treatment of hereditary orotic aciduria	Wellstat Therapeutics, Inc.
3086	Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	EMD Serono, Inc.
3087	Urogastrone	n/a	11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision
3088	Ursodiol	Urso 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Aptalis Pharma US, Inc.
3089	ursodiol	Ursofalk Suspension	10/23/2007	Treatment of cystic fibrosis liver disease	Asklepion Pharmaceuticals, LLC
3090	ustekinumab	Stelara	11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Johnson & Johnson Pharmaceutical & Development LLC
3091	Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/2004	Treatment of severe complications from the smallpox vaccine	DynPort Vaccine Company LLC

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3092	Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/2004	Treatment of complications of vaccinia vaccination	Cangene Corporation
3093	vadastuximab talirine	n/a	11/10/2015	Treatment of acute myeloid leukemia.	Seattle Genetics, Inc.
3094	Valine, isoleucine and leucine	Vil	1/5/1996	Treatment of hyperphenylalaninemia	Leas Research Products
3095	valine-valine-ganciclovir	n/a	5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Verenta Pharmaceuticals, Inc.
3096	Valproate	n/a	5/5/2008	Treatment of fragile X syndrome	Neuropharm Ltd,
3097	Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc.
3098	valsartan oral solution	n/a	10/28/2015	Treatment of hypertension in pediatric patients 0 through 16 years of age	Carmel Biosciences
3099	vancomycin	n/a	12/27/2012	Treatment of endophthalmitis	Fera Pharmaceuticals, LLC
3100	vancomycin hydrochloride (inhalational)	n/a	9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Savara Pharmaceuticals, Inc.
3101	vandetanib	Caprelsa(R)	10/21/2005	Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma	AstraZeneca Pharmaceutical LP

Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3102	Vapreotide	Sanvar	4/6/2004	Treatment of symptomatic carcinoid tumors	H3 Pharma, Inc.
3103	vapreotide	Octastatin	1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A.
3104	vapreotide	Octastatin	3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A.
3105	vapreotide	Sanvar	1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiovision, Inc.
3106	vapreotide	Sanvar	11/4/2003	Treatment of acromegaly	H3 Pharma, Inc.
3107	Varbulin	Azixa	11/5/2009	Treatment of glioblastoma multiforme.	Myrexix, Inc.
3108	Varicella Zoster Immune Globulin (Human)	Varizig	11/7/2006	Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella	Cangene bioPharma, Inc.
3109	Varlitinib	n/a	8/5/2015	Treatment of cholangiocarcinoma.	ASLAN Pharmaceuticals
3110	vascular endothelial growth factor 165b	n/a	6/24/2008	Treatment of advanced melanoma stages IIb through IV.	PhiloGene, Inc.
3111	Vasoactive intestinal peptide	n/a	3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	mondoBIOTECH
3112	vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	n/a	5/13/2014	Treatment of pulmonary arterial hypertension, WHO Group 1	PhaseBio Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3113	Vasoactive intestinal polypeptide	n/a	6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals
3114	Vasomera	n/a	11/19/2015	Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), and X-linked dilated cardiomyopathy (XL-dCMP).	PhaseBio Pharmaceuticals, Inc.
3115	vatiquinone	Vincerinone	11/17/2014	Treatment of Rett syndrome	Edison pharmaceuticals, Inc.
3116	vatiquinone	Vincerinone	6/4/2014	Treatment of Leigh Syndrome	Edison Pharmaceuticals, Inc.
3117	vatiquinone	Vincerinone	1/31/2014	Treatment of Friedreich's ataxia	Edison pharmaceuticals, Inc.
3118	velaglucerase-alfa	Vpriv	6/8/2009	Treatment of Gaucher disease	Shire Human Genetics Therapies, Inc.
3119	veliparib	n/a	9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	AbbVie, Inc.
3120	veliparib	n/a	12/17/2014	Treatment of brain metastases when used in combination with DNA-damaging agents	AbbVie Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3121	veliparib	n/a	5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	AbbVie, Inc.
3122	veliparib	n/a	11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	AbbVie, Inc.
3123	veltuzumab	n/a	11/17/2014	Treatment of pemphigus	Immunomedics, Inc.
3124	veltuzumab	n/a	7/28/2015	Treatment of immune thrombocytopenic purpura.	Immunomedics, Inc.
3125	veltuzumab	n/a	8/28/2008	Treatment of chronic lymphocytic leukemia	Immunomedics, Inc.
3126	vemurafenib	Zelboraf	11/26/2013	Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation	Genentech, Inc.
3127	vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Hoffmann-La Roche, Inc.
3128	vemurafenib	Zelboraf	9/8/2014	Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600E mutation	Genentech, Inc.
3129	vemurafenib	Zelboraf	8/26/2014	Treatment of hairy cell leukemia (HCL).	Genentech, Inc.
3130	venetoclax	n/a	2/4/2016	Treatment of acute myeloid leukemia.	AbbVie Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3131	verteporfin	Visudyne(R)	3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Valeant Pharmaceuticals North America LLC
3132	vibriolysin	Vibrilase	6/16/2006	Debridement of severe, deep dermal burns in hospitalized patients	BioMarin Pharmaceutical Inc.
3133	vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	H. Lundbeck A/S
3134	vinCRISTine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Talon Therapeutics, Inc.
3135	vincristine sulfate liposomes	Marqibo	6/24/2008	Treatment of metastatic uveal melanoma.	Talon Therapeutics
3136	vintafolide	n/a	12/16/2013	Treatment of ovarian cancer	Endocyte, Inc.
3137	Virulizin	Virulizin	2/1/2001	Treatment of pancreatic cancer.	ZOR Pharmaceuticals, LLC
3138	vitamin A palmitate	n/a	7/14/2015	Prevention of bronchopulmonary dysplasia.	Advent Therapeutics, Inc.
3139	volanesorsen sodium, apolipoprotein C-III antisense oligonucleotide	n/a	6/23/2015	treatment of familial chylomicronemia syndrome	Ixis Pharmaceuticals, Inc.
3140	volasertib	n/a	4/14/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
3141	von Willebrand Factor Human Concentrate	Wilfactin	5/29/2014	Treatment of Von Willebrand Disease	rEVO Biologics, Inc.
3142	vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Merck & Co., Inc.

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3143	vosaroxin	n/a	10/28/2009	Treatment of acute myeloid leukemia	Sunesis Pharmaceuticals, Inc.
3144	Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/2010	Prevention of bronchopulmonary dysplasia.	Fox Pharma, Inc.
3145	Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc.
3146	xenon gas	n/a	12/3/2014	Treatment of hypoxic ischemic encephalopathy	Neuroprotexon
3147	xenon gas	n/a	5/18/2015	To improve neurological outcome in hospitalized cardiac arrest patients.	Neuroprotexon
3148	Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/2006	Treatment of Hodgkin's disease.	Alissa Pharma, LLC
3149	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/2012	Treatment of soft tissue sarcoma	OncoTherapy Science, Inc.
3150	Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody	Cea-Cide	8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc.
3151	Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Hoffmann-La Roche, Inc.
3152	Zalcitabine	n/a	12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT
3153	zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Glaxo Wellcome Inc.
3154	Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Lemmon Company

**Orphan Drug Designations and Approvals List as of 03-01-2016
Governs April 1, 2016 - June 30, 2016**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3155	Zoledronate	Zometa, Zabel	8/18/2000	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp.
3156	zoledronate D,L-lysine monohydrate (ZLM)	n/a	4/15/2015	Treatment of complex regional pain syndrome (CRPS)	Thar Pharmaceuticals
3157	zoledronic acid	Zometa, Reclast, Aclasta	5/6/2013	Treatment of complex regional pain syndrome (CRPS).	Axsome Therapeutics, Inc.
3158	Zosuquidar trihydrochloride	n/a	12/15/2005	Treatment of acute myeloid leukemia	Kanisa Pharmaceuticals, Inc.
3159		Dysport(R)	12/5/1991	Treatment of essential blepharospasm.	Ipsen Biopharmaceuticals, Inc.
3160		Nicord	4/28/2014	For the treatment of acute myeloid leukemia	Gamida Cell Ltd
3161		Biothrax	4/11/2014	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Emergent Product Development Gaithersburg, Inc.